Clinical and Biological Features Associated With Epider Mutations in Lung Cancers

Journal of the National Cancer Institute

97, 339-346

DOI: 10.1093/jnci/dji055

Citation Report

#	Article	IF	Citations
1	Molecular Markers Help Characterize Neuroendocrine Lung Tumors. Annals of Thoracic Surgery, 1996, 62, 798-810.	0.7	118
2	Aberrant methylation: common in thymic carcinomas, rare in thymomas. Oncology Reports, 2005, 14, 1621.	1.2	10
3	Program for the Assessment of Clinical Cancer Tests (PACCT): assisting the development of tailored cancer therapy. Personalized Medicine, 2005, 2, 363-369.	0.8	1
4	Detection of Oncogenic Mutations in the EGFR Gene in Lung Adenocarcinoma with Differential Sensitivity to EGFR Tyrosine Kinase Inhibitors. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 73-81.	2.0	37
5	EGFR Tyrosine Kinase Domain Mutations Are Detected in Histologically Normal Respiratory Epithelium in Lung Cancer Patients. Cancer Research, 2005, 65, 7568-7572.	0.4	259
6	What is the best way to manage patients treated with gefitinib for non-small-cell lung cancer?. Nature Clinical Practice Oncology, 2005, 2, 290-291.	4.3	0
7	Identification of EGFR kinase domain mutations among lung cancer patients in China: implication for targeted cancer therapy. Cell Research, 2005, 15, 212-217.	5.7	58
8	Targeted therapies for non-small cell lung cancer. International Journal of Clinical Practice, 2005, 59, 1055-1062.	0.8	14
9	Current Management of Advanced Non-Small Cell Lung Cancer: Targeted Therapy. Seminars in Oncology, 2005, 32, 315-328.	0.8	43
10	Ongoing First-Line Studies of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Select Patient Populations. Seminars in Oncology, 2005, 32, 9-15.	0.8	72
11	Integrative analysis of multiple gene expression profiles with quality-adjusted effect size models. BMC Bioinformatics, 2005, 6, 128.	1.2	45
12	Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors. Journal of Molecular Medicine, 2005, 83, 976-983.	1.7	27
14	Epidermal Growth Factor Receptor Mutations in Patients with Nonâ€“Small Cell Lung Cancer. Cancer Research, 2005, 65, 7525-7529.	0.4	143
15	Inhibition of EGFR Signaling: All Mutations Are Not Created Equal. PLoS Medicine, 2005, 2, e377.	3.9	38
16	Selecting Patients for Epidermal Growth Factor Receptor Inhibitor Treatment: A FISH Story or a Tale of Mutations?. Journal of Clinical Oncology, 2005, 23, 6813-6816.	0.8	56
17	Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants. PLoS Medicine, 2005, 2, e313.	3.9	603
18	A Curious Link Between Epidermal Growth Factor Receptor Amplification and Survival: Effect of â€œAllele Dilutionâ€•on Gefitinib Sensitivity?. Journal of the National Cancer Institute, 2005, 97, 621-623.	3.0	22
19	High Expression of ErbB Family Members and Their Ligands in Lung Adenocarcinomas That Are Sensitive to Inhibition of Epidermal Growth Factor Receptor. Cancer Research, 2005, 65, 11478-11485.	0.4	135

#	Article	IF	Citations
20	Gefitinib Versus Cetuximab in Lung Cancer: Round One. Journal of the National Cancer Institute, 2005, 97, 1168-1169.	3.0	16
21	Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR. Clinical Cancer Research, 2005, 11, 8105-8108.	3.2	125
22	Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva Â®) and Gefitinib (Iressa Â®). Oncologist, 2005, 10, 579-589.	1.9	107
23	Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Annals of Oncology, 2005, 16, 1906-1914.	0.6	59
24	Targeting HER1/EGFR in cancer therapy: experience with erlotinib. Future Oncology, 2005, 1, 449-460.	1.1	26
25	Stable RNA Interferenceâ€“Mediated Suppression of Cyclophilin A Diminishes Nonâ€“Small-Cell Lung Tumor Growth In vivo. Cancer Research, 2005, 65, 8853-8860.	0.4	89
26	Methyl-CpG Binding Domain 1 Gene Polymorphisms and Risk of Primary Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2474-2480.	1.1	21
27	Factors Predicting Response to EGFR Tyrosine Kinase Inhibitors. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 314-322.	0.8	24
28	Bronchioloalveolar carcinoma: A Review of the Epidemiology, Pathology, and Treatment. Seminars in Respiratory and Critical Care Medicine, 2005, 26, 342-352.	0.8	21
29	Erlotinib hydrochloride. Nature Reviews Drug Discovery, 2005, 4, S14-S15.	21.5	22
30	Erlotinib in the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy, 2005, 5, 767-775.	1.1	21
31	Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma. British Journal of Cancer, 2005, 93, 355-363.	2.9	152
32	EGFR inhibitors: what have we learned from the treatment of lung cancer?. Nature Clinical Practice Oncology, 2005, 2, 554-561.	4.3	77
33	TP53 and KRAS Mutation Load and Types in Lung Cancers in Relation to Tobacco Smoke: Distinct Patterns in Never, Former, and Current Smokers. Cancer Research, 2005, 65, 5076-5083.	0.4	237
34	Differential Effects of Gefitinib and Cetuximab on Nonâ€“small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations. Journal of the National Cancer Institute, 2005, 97, 1185-1194.	3.0	294
35	The ALPI Trial: The Italian/European Experience with Adjuvant Chemotherapy in Resectable Non-Small Lung Cancer. Clinical Cancer Research, 2005, 11, 5011s-5016s.	3.2	58
36	Predicting the Future From Trials of the Past: Epidermal Growth Factor Receptor Expression and Outcome of Fractionated Radiation Therapy Trials. Journal of Clinical Oncology, 2005, 23, 5437-5439.	0.8	2
37	Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic Features. Clinical Cancer Research, 2005, 11, 6177-6185.	3.2	103

#	Article	IF	Citations
38	Activated Epidermal Growth Factor Receptorâ€“Stat-3 Signaling Promotes Tumor Survival In vivo in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2005, 11, 8288-8294.	3.2	217
39	EGFR Gene Mutations: A Call for Global x Global Views of Cancer. Journal of the National Cancer Institute, 2005, 97, 326-328.	3.0	27
40	Molecular targeted therapy for lung cancer. Lancet, The, 2005, 366, 1507-1508.	6.3	8
41	Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa) Tj ETQq1 1 0.784314 rg BT /Overl	6.3	2,057
42	Epidermal Growth Factor Receptor Mutations and Gene Amplification in Nonâ€“Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. Journal of Clinical Oncology, 2005, 23, 8081-8092.	0.8	608
43	Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2005, 23, 6829-6837.	0.8	701
44	Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptorâ€“Positive Nonâ€“Small-Cell Lung Cancer Patients. Journal of Clinical Oncology, 2005, 23, 5007-5018.	0.8	367
45	Erlotinib in Lung Cancer â€” Molecular and Clinical Predictors of Outcome. New England Journal of Medicine, 2005, 353, 133-144.	13.9	1,787
47	Genomics and the second golden era of cancer drug development. Molecular BioSystems, 2005, 1, 17.	2.9	48
48	EGFR Pharmacogenomics. Molecular Diagnosis and Therapy, 2005, 5, 137-139.	3.3	1
49	Cancer Diagnostics. Molecular Diagnosis and Therapy, 2005, 5, 357-364.	3.3	28
50	The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development. Clinical Cancer Research, 2005, 11, 7967-7985.	3.2	219
51	Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Human Pathology, 2005, 36, 1127-1134.	1.1	53
52	Erlotinib: Small-molecule targeted therapy in the treatmentof non-small-cell lung cancer. Clinical Therapeutics, 2005, 27, 1513-1534.	1.1	98
53	Mechanisms of lung cancer. Drug Discovery Today Disease Mechanisms, 2005, 2, 213-223.	0.8	16
54	Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer, 2005, 50, 1-8.	0.9	112
55	Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation. Lung Cancer, 2005, 50, 259-263.	0.9	9
56	Pathogenesis of Lung Cancer. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 216-223.	1.4	120

#	Article	IF	Citations
57	LUNG CANCER PRENEOPLASIA. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 331-348.	9.6	191
58	Aberrant Promoter Methylation of p16 and MGMT Genes in Lung Tumors from Smoking and Never-Smoking Lung Cancer Patients. Neoplasia, 2006, 8, 46-51.	2.3	121
59	The place of targeted therapies in the management of non-small cell bronchial carcinoma. Revue Des Maladies Respiratoires, 2006, 23, 137-147.	1.7	2
60	Should every lung cancer patient be tested for EGFR mutation?. Expert Opinion on Therapeutic Targets, 2006, 10, 789-791.	1.5	1
61	Is EGFR expression important in non-small cell lung cancer?. Thorax, 2006, 61, 98-99.	2.7	35
62	Cancer therapies targeted to the epidermal growth factor receptor and its family members. Expert Opinion on Therapeutic Patents, 2006, 16, 147-164.	2.4	3
63	Mutational and Epigenetic Evidence for Independent Pathways for Lung Adenocarcinomas Arising in Smokers and Never Smokers. Cancer Research, 2006, 66, 1371-1375.	0.4	147
64	Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 5034-5042.	0.8	701
65	Prospective Phase II Study of Gefitinib for Chemotherapy-NaÃ¯ve Patients With Advanced Nonâ€“Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations. Journal of Clinical Oncology, 2006, 24, 3340-3346.	0.8	490
66	Epidermal Growth Factor Receptor Mutations and Response to Chemotherapy in Patients with Non-Small-Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2006, 36, 344-350.	0.6	29
67	Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer, 2006, 52, 225-233.	0.9	31
68	Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas. Journal of Clinical Oncology, 2006, 24, 1700-1704.	0.8	202
69	Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. Lung Cancer, 2006, 52, 47-52.	0.9	44
70	Uncommon V599E BRAF Mutations in Japanese Patients with Lung Cancer. Journal of Surgical Research, 2006, 133, 203-206.	0.8	64
71	Lung Adenocarcinoma Harboring Mutations in the ERBB2 Kinase Domain. Journal of Molecular Diagnostics, 2006, 8, 351-356.	1.2	34
72	Novel Therapies Targeting Signaling Pathways in Lung Cancer. Thoracic Surgery Clinics, 2006, 16, 379-396.	0.4	12
73	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer: Impact of Primary or Secondary Mutations. Clinical Lung Cancer, 2006, 7, S138-S144.	1.1	76
74	Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Journal of Clinical Oncology, 2006, 24, 2158-2163.	0.8	143

#	Article	IF	Citations
75	A review of erlotinib and its clinical use. Expert Opinion on Pharmacotherapy, 2006, 7, 177-193.	0.9	74
76	Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer, 2006, 51, 89-96.	0.9	55
77	Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial. Lung Cancer, 2006, 52, 93-97.	0.9	96
78	Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer, 2006, 53, 117-121.	0.9	56
79	L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer. Lung Cancer, 2006, 54, 103-108.	0.9	29
80	Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer, 2006, 53, 311-322.	0.9	74
81	Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. Lung Cancer, 2006, 54, 25-33.	0.9	57
82	Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer, 2006, 54, 193-199.	0.9	35
83	Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer, 2006, 54, 387-398.	0.9	92
84	Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. Lung Cancer, 2006, 54, 419-422.	0.9	56
85	Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Nonâ€“Small-Cell Lung Cancer Patients Treated With Gefitinib. Journal of Clinical Oncology, 2006, 24, 2549-2556.	0.8	348
86	Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas. Clinical Cancer Research, 2006, 12, 4283-4287.	3.2	154
87	Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. Annals of Diagnostic Pathology, 2006, 10, 306-315.	0.6	36
88	An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor. Cell, 2006, 125, 1137-1149.	13.5	1,358
89	Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 2006, 366, 2-16.	1.0	1,744
90	Predicting the outcome of chemotherapy for lung cancer. Current Opinion in Pharmacology, 2006, 6, 323-331.	1.7	68
91	Mutations of the epidermal growth factor receptor in non-small cell lung cancer â€“ Search and destroy. European Journal of Cancer, 2006, 42, 17-23.	1.3	153
92	High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Human Pathology, 2006, 37, 453-457.	1.1	21

#	Article	IF	Citations
93	BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Human Pathology, 2006, 37, 520-527.	1.1	90
94	Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. Human Pathology, 2006, 37, 755-763.	1.1	62
95	Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. Journal of Thoracic Oncology, 2006, 1, 847-855.	0.5	108
96	Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Basic Science Discovery with Immediate Clinical Impact. American Journal of the Medical Sciences, 2006, 331, 139-149.	0.4	11
97	EGFR: A Prognostic and/or a Predictive Marker?. Journal of Thoracic Oncology, 2006, 1, 395-397.	0.5	4
98	The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases. Journal of Thoracic Oncology, 2006, 1, 344-359.	0.5	33
99	Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 520-525.	0.5	22
100	Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma. Journal of Thoracic Oncology, 2006, 1, S8-S12.	0.5	6
101	Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines. Oncology Reports, 2006, 15, 1205.	1.2	3
102	EGFR Mutation of Tumor and Serum in Gefitinib-Treated Patients with Chemotherapy-Naive Nonâ€“small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 260-267.	0.5	64
103	Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma. Journal of Thoracic Oncology, 2006, 1, 787-795.	0.5	14
104	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Nonâ€“Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. Journal of Thoracic Oncology, 2006, 1, 52-60.	0.5	6
105	Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. Journal of Thoracic Oncology, 2006, 1, 847-855.	0.5	157
106	The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases. Journal of Thoracic Oncology, 2006, 1, 344-359.	0.5	80
107	Signal Transduction Therapy for Cancer - Whither Now?. Current Signal Transduction Therapy, 2006, 1, 1-12.	0.3	14
108	Clinicopathologic Characteristics of the EGFR Gene Mutation in Nonâ€“small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 231-239.	0.5	121
109	EGFR: A Prognostic and/or a Predictive Marker?. Journal of Thoracic Oncology, 2006, 1, 395-397.	0.5	7
110	Predictive Factors of Gefitinib Antitumor Activity in East Asian Advanced Non-small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 520-525.	0.5	32

#	Article	IF	Citations
111	A Simple and Sensitive Method for Detecting Major Mutations Within the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Gene in Non???small-cell Lung Carcinoma. Diagnostic Molecular Pathology, 2006, 15, 101-108.	2.1	31
112	Rapid Screening for EGFR Mutations. Cancer Journal (Sudbury, Mass), 2006, 12, 17-18.	1.0	0
113	Molecular Biology, Genomics, and Proteomics in Bronchioloalveolar Carcinoma. Journal of Thoracic Oncology, 2006, 1, S8-S12.	0.5	14
114	Epidermal Growth Factor Receptor (EGFR) Targeted Therapies in Non- Small Cell Lung Cancer (NSCLC). Reviews on Recent Clinical Trials, 2006, 1, 1-13.	0.4	44
116	Clinical experience with erlotinib in non-small-cell lung cancer (NSCLC). Drugs of Today, 2006, 42, 147.	0.7	17
117	Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma. Respirology, 2006, 11, 287-291.	1.3	6
118	Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer. Respirology, 2006, 11, 687-692.	1.3	32
119	Worldwide trends in lung cancer pathology. Respirology, 2006, 11, 533-538.	1.3	124
120	Targeted cancer therapy: The prime time show in oncology. Asia-Pacific Journal of Clinical Oncology, 2006, 2, 1-2.	0.7	0
121	Targeting epidermal growth factor receptor in lung cancer: Perspective from the Asia-Pacific region. Asia-Pacific Journal of Clinical Oncology, 2006, 2, 22-31.	0.7	2
122	Molecular diagnostics of non-small cell lung cancer using mediastinal lymph nodes sampled by endoscopic ultrasound-guided needle aspiration. Cytopathology, 2006, 17, 3-9.	0.4	10
123	Recent trends in the treatment of advanced lung cancer. Cancer Science, 2006, 97, 448-452.	1.7	16
124	High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Science, 2006, 97, 642-648.	1.7	138
125	EGFR point mutation in non-small cell lung cancer is occasionally accompanied by a second mutation or amplification. Cancer Science, 2006, 97, 753-759.	1.7	73
126	A critical appraisal of prognostic and predictive factors for common lung cancers. Histopathology, 2006, 48, 779-786.	1.6	21
127	Comparing antibody and small-molecule therapies for cancer. Nature Reviews Cancer, 2006, 6, 714-727.	12.8	661
128	Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. British Journal of Cancer, 2006, 94, 896-903.	2.9	132
129	Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Modern Pathology, 2006, 19, 541-547.	2.9	38

#	Article	IF	Citations
130	Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. Modern Pathology, 2006, 19, 986-998.	2.9	17
131	Epidermal growth factor receptor directed therapy in head and neck cancer. Critical Reviews in Oncology/Hematology, 2006, 57, 25-43.	2.0	46
132	Clinical experience with gefitinib: An update. Critical Reviews in Oncology/Hematology, 2006, 58, 31-45.	2.0	50
134	Carcinogen Exposure and Epigenetic Silencing in Bladder Cancer. Annals of the New York Academy of Sciences, 2006, 1076, 810-821.	1.8	49
135	Biological and clinical implications of EGFR mutations in lung cancer. International Journal of Clinical Oncology, 2006, 11, 190-198.	1.0	194
136	Resistance to gefitinib. International Journal of Clinical Oncology, 2006, 11, 487-491.	1.0	31
137	Defining clinically relevant molecular subsets of lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 11-15.	1.1	17
138	Molecular classification of tumors with special reference to EGFR mutation in lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 17-23.	1.1	6
139	The impact and role of EGFR gene mutation on non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 25-31.	1.1	7
141	The future of epidemiology. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2006, 49, 622-627.	7.2	5
142	From the bench to the bed: individualizing treatment in non-small-cell lung cancer. Clinical and Translational Oncology, 2006, 8, 71-76.	1.2	17
143	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell, 2006, 9, 485-495.	7.7	427
144	EGF receptor mutations in lung cancer: From humans to mice and maybe back to humans. Cancer Cell, 2006, 9, 421-423.	7.7	47
145	2006 Highlights From: The European Society for Medical Oncology Congress Istanbul, Turkey; Sept. 29-Oct. 3, 2006 International Association for the Study of Lung Cancer Early Invasive Lung Cancer Workshop Turin, Italy; Sept. 25â€“26, 2006. Clinical Lung Cancer, 2006, 8, 170-178.	1.1	0
146	Geographic Variation in the Second-Line Treatment of Nonâ€“Small Cell Lung Cancer. Seminars in Oncology, 2006, 33, 39-44.	0.8	6
147	Optimizing Therapy in Previously Treated Nonâ€“Small Cell Lung Cancer. Seminars in Oncology, 2006, 33, 25-31.	0.8	7
148	Epidermal Growth Factor Receptor Targeting in Cancer. Seminars in Oncology, 2006, 33, 369-385.	0.8	645
149	K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review. Clinical Lung Cancer, 2006, 8, 30-38.	1.1	212

#	Article	IF	Citations
150	The Way Forward: New Drugs and New Therapeutic Strategies in Lung Cancer Therapy. Clinical Lung Cancer, 2006, 7, S109-S110.	1.1	0
151	Exclusive mutation in epidermal growth factor receptor gene, HER-2, and KRAS, and synchronous methylation of nonsmall cell lung cancer. Cancer, 2006, 106, 2200-2207.	2.0	132
152	A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer, 2006, 107, 1034-1041.	2.0	72
153	Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer. Cancer, 2006, 107, 1866-1872.	2.0	3
154	Nuclear factor-Î¹B (nf-Î¹B) is frequently expressed in lung cancer and preneoplastic lesions. Cancer, 2006, 107, 2637-2646.	2.0	179
155	Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer. Cancer, 2006, 107, 2858-2865.	2.0	59
156	EGFR and erbB2 mutation status in Japanese lung cancer patients. International Journal of Cancer, 2006, 118, 180-184.	2.3	157
157	Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. International Journal of Cancer, 2006, 118, 963-969.	2.3	151
158	Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. International Journal of Cancer, 2006, 118, 257-262.	2.3	601
159	FrequentEGFR mutations in noninvasive bronchioloalveolar carcinoma. International Journal of Cancer, 2006, 118, 2498-2504.	2.3	43
160	Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer. International Journal of Cancer, 2006, 119, 727-734.	2.3	20
161	Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. International Journal of Cancer, 2006, 119, 741-744.	2.3	128
162	FrequentEGFR mutations in brain metastases of lung adenocarcinoma. International Journal of Cancer, 2006, 119, 1491-1494.	2.3	183
163	Mutational analysis of theHER2 gene in lung tumors from Caucasian patients: Mutations are mainly present in adenocarcinomas with bronchioloalveolar features. International Journal of Cancer, 2006, 119, 2586-2591.	2.3	170
164	Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. International Journal of Cancer, 2006, 119, 2353-2358.	2.3	102
165	The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers. Journal of Surgical Oncology, 2006, 93, 44-46.	0.8	12
166	EGFR Targeted Therapy: View from Biological Standpoint. Cell Cycle, 2006, 5, 2072-2076.	1.3	32
167	Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling. Cancer Research, 2006, 66, 11389-11398.	0.4	112

#	Article	IF	Citations
168	Overexpression of Glycosylphosphatidylinositol (GPI) Transamidase Subunits Phosphatidylinositol Glycan Class T and/or GPI Anchor Attachment 1 Induces Tumorigenesis and Contributes to Invasion in Human Breast Cancer. Cancer Research, 2006, 66, 9829-9836.	0.4	62
169	Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Annals of Oncology, 2006, 17, 981-985.	0.6	118
170	Wnt/Î²-Catenin Signaling Mediates Antineoplastic Effects of Imatinib Mesylate (Gleevec) in Anaplastic Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 159-168.	1.8	38
171	EUS-FNA and biomarkers for the staging of non-small cell lung cancer. Endoscopy, 2006, 38, 114-117.	1.0	9
172	Reporting of ethnicity in research on chronic disease: update. Postgraduate Medical Journal, 2006, 82, 737-742.	0.9	9
173	Erlotinib for Frontline Treatment of Advanced Nonâ€“Small Cell Lung Cancer: a Phase II Study. Clinical Cancer Research, 2006, 12, 6049-6055.	3.2	197
174	Re: Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. Journal of the National Cancer Institute, 2006, 98, 362-363.	3.0	8
175	Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 2038-2043.	0.8	620
176	Molecular Context of the EGFR Mutations: Evidence for the Activation of mTOR/S6K Signaling. Clinical Cancer Research, 2006, 12, 710-717.	3.2	116
177	Joint effect of asthma/atopy and an IL-6 gene polymorphism on lung cancer risk among lifetime non-smoking Chinese women. Carcinogenesis, 2006, 27, 1240-1244.	1.3	47
178	Baseline Gene Expression Predicts Sensitivity to Gefitinib in Nonâ€“Small Cell Lung Cancer Cell Lines. Molecular Cancer Research, 2006, 4, 521-528.	1.5	129
179	RESPONSE: Re: Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. Journal of the National Cancer Institute, 2006, 98, 363-364.	3.0	1
180	Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 3078-3084.	3.2	97
181	Multiple Oncogenic Changes (K-RASV12, p53 Knockdown, Mutant EGFRs, p16 Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial Cells. Cancer Research, 2006, 66, 2116-2128.	0.4	247
182	Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway. Clinical Cancer Research, 2006, 12, 7222-7231.	3.2	84
183	Update on Epidermal Growth Factor Receptor Mutations in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 7232-7241.	3.2	357
184	A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening. Clinical Cancer Research, 2006, 12, 751-758.	3.2	212
185	EGFRMutations in Small-Cell Lung Cancers in Patients Who Have Never Smoked. New England Journal of Medicine, 2006, 355, 213-215.	13.9	241

#	Article	IF	Citations
186	Detection of EGFR Gene Mutation in Lung Cancer by Mutant-Enriched Polymerase Chain Reaction Assay. Clinical Cancer Research, 2006, 12, 43-48.	3.2	191
187	Detection ofEGFRMutations in Archived Cytologic Specimens of Nonâ€“Small Cell Lung Cancer Using High-Resolution Melting Analysis. American Journal of Clinical Pathology, 2006, 126, 608-615.	0.4	138
188	Exercise induced bronchoconstriction in elite athletes: measuring the fall. Thorax, 2006, 61, 94-96.	2.7	24
189	Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer. Journal of Medical Genetics, 2006, 44, 166-172.	1.5	47
190	Clinical Course of Patients with Nonâ€“Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib. Clinical Cancer Research, 2006, 12, 839-844.	3.2	688
191	Mutations Within the Kinase Domain and Truncations of the Epidermal Growth Factor Receptor Are Rare Events in Bladder Cancer: Implications for Therapy. Clinical Cancer Research, 2006, 12, 4671-4677.	3.2	59
192	Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma. Clinical Cancer Research, 2006, 12, 1680-1685.	3.2	151
193	Erlotinib: Optimizing Therapy with Predictors of Response?. Clinical Cancer Research, 2006, 12, 2961-2963.	3.2	20
194	Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes and Development, 2006, 20, 1496-1510.	2.7	426
195	Effect of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutations on the Outcome of Patients with Nonâ€“Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2006, 12, 4416s-4420s.	3.2	127
196	A Blood-Based Test for Epidermal Growth Factor Receptor Mutations in Lung Cancer: Fig. 1.. Clinical Cancer Research, 2006, 12, 3875-3877.	3.2	11
197	Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Nonâ€“Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features. Clinical Cancer Research, 2006, 12, 1647-1653.	3.2	402
198	Gefitinib for Epidermal Growth Factor Receptor Mutant Lung Cancers: Searching for a Weapon of Mass Destruction. Journal of Clinical Oncology, 2006, 24, 3319-3321.	0.8	7
199	Expression Profileâ€“Defined Classification of Lung Adenocarcinoma Shows Close Relationship With Underlying Major Genetic Changes and Clinicopathologic Behaviors. Journal of Clinical Oncology, 2006, 24, 1679-1688.	0.8	296
200	Selecting Lung Cancer Patients for Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by Immunohistochemistry and Fluorescence In situ Hybridizationâ€”Why, When, and How?. Clinical Cancer Research, 2006, 12, 4409s-4415s.	3.2	52
201	Targeted Therapies in Combination with Chemotherapy in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 4451s-4457s.	3.2	20
203	Lung cancer in never-smokers. Journal of Clinical Pathology, 2006, 60, 337-340.	1.0	39
204	Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib. Cancer Research, 2006, 66, 8163-8171.	0.4	388

#	Article	IF	Citations
205	Biological Markers for Nonâ€“Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. Clinical Cancer Research, 2006, 12, 3652-3656.	3.2	62
206	Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Nonâ€“Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Clinical Cancer Research, 2006, 12, 3908-3914.	3.2	550
207	Glu346Lys Polymorphism in the Methyl-CpG Binding Domain 4 Gene and the Risk of Primary Lung Cancer. Japanese Journal of Clinical Oncology, 2006, 36, 483-488.	0.6	20
208	Optimization of Patient Selection for Gefitinib in Nonâ€“Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation. Clinical Cancer Research, 2006, 12, 2538-2544.	3.2	245
209	Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity. Journal of Clinical Oncology, 2006, 24, 2245-2251.	0.8	334
210	Genomic Approaches to Lung Cancer: Fig. 1.. Clinical Cancer Research, 2006, 12, 4384s-4391s.	3.2	49
211	Lung cancer genetics and pharmacogenomics. Cytogenetic and Genome Research, 2006, 115, 298-302.	0.6	2
212	Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. Annals of Oncology, 2006, 17, ii42-ii45.	0.6	28
213	Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer. Critical Reviews in Clinical Laboratory Sciences, 2006, 43, 291-323.	2.7	15
214	Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations. Journal of Biological Chemistry, 2006, 281, 40183-40192.	1.6	85
215	Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7817-7822.	3.3	248
216	Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Nonâ€“Small-Cell Lung Cancer. Clinical Cancer Research, 2006, 12, 3915-3921.	3.2	312
217	Epidermal Growth Factor Receptor Copy Number Alterations Correlate With Poor Clinical Outcome in Patients With Head and Neck Squamous Cancer. Journal of Clinical Oncology, 2007, 25, 2164-2170.	0.8	356
218	Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives. Expert Review of Molecular Diagnostics, 2007, 7, 821-836.	1.5	12
219	Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. Molecular Cancer Therapeutics, 2007, 6, 2642-2651.	1.9	53
220	The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 5763-5768.	3.2	81
221	Telomere Length and Telomerase Expression in Atypical Adenomatous Hyperplasia and Small Bronchioloalveolar Carcinoma of the Lung. American Journal of Clinical Pathology, 2007, 127, 254-262.	0.4	29
222	International comparisons of survival from lung cancer: pitfalls and warnings. Nature Clinical Practice Oncology, 2007, 4, 570-577.	4.3	73

#	Article	IF	Citations
223	â€˜Classicalâ€™ but not â€˜otherâ€™ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. British Journal of Cancer, 2007, 97, 1560-1566.	2.9	74
224	BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations. PLoS Medicine, 2007, 4, e315.	3.9	444
225	Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor. Current Respiratory Medicine Reviews, 2007, 3, 69-77.	0.1	6
226	Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt. Cancer Research, 2007, 67, 5779-5788.	0.4	107
227	Optimizing Anti-EGFR Strategies in Cancer Treatment. Current Cancer Therapy Reviews, 2007, 3, 267-275.	0.2	0
228	Neutrophils Promote Aerogenous Spread of Lung Adenocarcinoma with Bronchioloalveolar Carcinoma Features. Clinical Cancer Research, 2007, 13, 3518-3527.	3.2	46
229	Genetics of Preneoplasia: Lessons from Lung Cancer. Current Molecular Medicine, 2007, 7, 3-14.	0.6	103
230	Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. Oncologist, 2007, 12, 211-220.	1.9	44
231	Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development. Oncologist, 2007, 12, 840-849.	1.9	100
232	Detection of Epidermal Growth Factor Receptor Variations by Partially Denaturing HPLC. Clinical Chemistry, 2007, 53, 62-70.	1.5	41
233	Detection of Epidermal Growth Factor Receptor Mutation in Transbronchial Needle Aspirates of Non-Small Cell Lung Cancer. Chest, 2007, 131, 1628-1634.	0.4	106
234	A Translational View of the Molecular Pathogenesis of Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 327-343.	0.5	274
235	Molecular Pathogenesis of Early-Stage Non-small Cell Lung Cancer and a Proposal for Tissue Banking to Facilitate Identification of New Biomarkers. Journal of Thoracic Oncology, 2007, 2, S128-S135.	0.5	19
236	EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2007, 2, 423-429.	0.5	84
237	Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies. Pharmacogenomics, 2007, 8, 1211-1220.	0.6	2
238	Expression Profiling and Lung Cancer Development. Proceedings of the American Thoracic Society, 2007, 4, 127-132.	3.5	29
240	Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biology and Therapy, 2007, 6, 661-667.	1.5	83
241	Assessing the roles ofEGFRgene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors. Biomarkers in Medicine, 2007, 1, 203-207.	0.6	2

#	Article	IF	Citations
242	Absence of Activating Mutations in the EGFR Kinase Domain in Spanish Head and Neck Cancer Patients. Tumor Biology, 2007, 28, 273-279.	0.8	34
243	Erlotinib in cancer treatment. Annals of Oncology, 2007, 18, vi35-vi41.	0.6	111
245	Emergence of Epidermal Growth Factor Receptor T790M Mutation during Chronic Exposure to Gefitinib in a Nonâ€“Small Cell Lung Cancer Cell Line. Cancer Research, 2007, 67, 7807-7814.	0.4	170
246	Epidermal Growth Factor Receptors with Tyrosine Kinase Domain Mutations Exhibit Reduced Cbl Association, Poor Ubiquitylation, and Down-regulation but Are Efficiently Internalized. Cancer Research, 2007, 67, 7695-7702.	0.4	39
247	Differential Constitutive Activation of the Epidermal Growth Factor Receptor in Nonâ€“Small Cell Lung Cancer Cells Bearing EGFR Gene Mutation and Amplification. Cancer Research, 2007, 67, 2046-2053.	0.4	166
248	CETUXIMAB (ERBITUXÂ®), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER. , 2007, , 43-67.		0
249	Clonality and Prognostic Implications of p53 and Epidermal Growth Factor Receptor Somatic Aberrations in Multiple Primary Lung Cancers. Clinical Cancer Research, 2007, 13, 52-58.	3.2	98
250	Distinctive Evaluation of Nonmucinous and Mucinous Subtypes of Bronchioloalveolar Carcinomas inEGFRand K-rasGene-Mutation Analyses for Japanese Lung Adenocarcinomas. American Journal of Clinical Pathology, 2007, 128, 100-108.	0.4	121
251	An Alternative Approach to Determining Therapeutic Choices in Advanced Non-small Cell Lung Carcinoma (NSCLC): Maximizing the Diagnostic Procedure and the Use of Low-Volume Lung Biopsies. Journal of Thoracic Oncology, 2007, 2, 387-396.	0.5	17
252	Targeting of Epidermal Growth Factor Receptor in Patients Affected by Biliary Tract Carcinoma. Journal of Clinical Oncology, 2007, 25, 1145-1145.	0.8	6
253	Use of a Cytokine Gene Expression Signature in Lung Adenocarcinoma and the Surrounding Tissue as a Prognostic Classifier. Journal of the National Cancer Institute, 2007, 99, 1257-1269.	3.0	131
254	Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. Clinical Cancer Research, 2007, 13, 3731-3737.	3.2	283
255	HKI-272 in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 4593s-4596s.	3.2	47
256	Targeted therapies in lung cancer. Annals of Oncology, 2007, 18, ix135-ix142.	0.6	35
257	Pulmonary adenocarcinomaâ€“targeted gene therapy by a cancer- and tissue-specific promoter system. Molecular Cancer Therapeutics, 2007, 6, 244-252.	1.9	19
258	Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors. Clinical Cancer Research, 2007, 13, 4606s-4612s.	3.2	51
259	Adenocarcinoma, a molecular perspective. Annals of Oncology, 2007, 18, ix147-ix149.	0.6	19
260	Pharmacogenomics of Non-Small Cell Lung Cancer. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2007, 5, 228-234.	0.3	0

#	Article	IF	Citations
261	Mechanisms of Intrinsic and Acquired Resistance to EGFR Inhibitors. Current Cancer Therapy Reviews, 2007, 3, 276-283.	0.2	0
262	Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment. Current Cancer Therapy Reviews, 2007, 3, 226-235.	0.2	0
263	Smoking and Lung Cancer: Future Research Directions. International Journal of Toxicology, 2007, 26, 353-364.	0.6	21
264	EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung. Oncology Reports, 2007, 17, 1405.	1.2	2
265	Presentation and Stage-Specific Outcomes of Lifelong Never-smokers with Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2007, 2, 827-830.	0.5	56
266	Mutational Analysis in Cytological Specimens of Advanced Lung Adenocarcinoma: A Sensitive Method for Molecular Diagnosis. Journal of Thoracic Oncology, 2007, 2, 1086-1090.	0.5	102
267	Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions. Oncology Reports, 2007, 18, 1507-12.	1.2	4
268	PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncology Reports, 2007, 17, 853.	1.2	26
269	M02-03: Tumor hypoxia and metastasis in non-small cell lung cancers. Journal of Thoracic Oncology, 2007, 2, S154-S155.	0.5	2
270	Clinical Significance of Epidermal Growth Factor Receptor Gene Mutations on Treatment Outcome after First-line Cytotoxic Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 632-637.	0.5	62
271	Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China. Journal of Thoracic Oncology, 2007, 2, 430-439.	0.5	180
273	Combination of Standard Chemotherapy and Targeted Agents. Journal of Thoracic Oncology, 2007, 2, S19-S23.	0.5	2
274	M02-02: Update of EGFR inhibitors and radiation in the management of non-small cell lung cancerâ€¦where do we go next?. Journal of Thoracic Oncology, 2007, 2, S153-S154.	0.5	3
275	Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges. International Journal of Biological Markers, 2007, 22, 10-23.	0.7	5
276	Microsatellite and EGFR, HER2 and K-RAS Analyses in Sclerosing Hemangioma of the Lung. American Journal of Surgical Pathology, 2007, 31, 1512-1520.	2.1	36
277	Apoptosis Induced by Depsipeptide FK228 Coincides with Inhibition of Survival Signaling in Lung Cancer Cells. Cancer Journal (Sudbury, Mass), 2007, 13, 105-113.	1.0	36
278	Targeting the Epidermal Growth Factor Receptor in Colorectal Carcinoma. Cancer Nursing, 2007, 30, S1-S9.	0.7	5
279	Diagnosis and treatment of bronchioloalveolar carcinoma. Current Opinion in Pulmonary Medicine, 2007, 13, 290-296.	1.2	22

#	Article	IF	Citations
280	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 22-28.	0.5	71
281	Small Peripheral Pulmonary Adenocarcinoma. Advances in Anatomic Pathology, 2007, 14, 120-128.	2.4	7
282	EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. European Journal of Cancer, 2007, 43, 520-526.	1.3	71
283	Rational bases for the development of EGFR inhibitors for cancer treatment. International Journal of Biochemistry and Cell Biology, 2007, 39, 1416-1431.	1.2	115
284	Targeting novel and established therapies for non-small cell lung cancer. Cancer Letters, 2007, 250, 9-16.	3.2	10
285	The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends in Molecular Medicine, 2007, 13, 527-534.	3.5	117
286	Transcriptional Profiling of Non-Small Cell Lung Cancer Cells with Activating EGFR Somatic Mutations. PLoS ONE, 2007, 2, e1226.	1.1	31
287	Src-Family Kinases Are Activated in Non-Small Cell Lung Cancer and Promote the Survival of Epidermal Growth Factor Receptor-Dependent Cell Lines. American Journal of Pathology, 2007, 170, 366-376.	1.9	141
288	EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer, 2007, 58, 324-328.	0.9	81
289	Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung. Lung Cancer, 2007, 58, 30-35.	0.9	20
290	Epidermal Growth Factor Receptor Mutation Status and Adjuvant Chemotherapy With Uracil-Tegafur for Adenocarcinoma of the Lung. Journal of Clinical Oncology, 2007, 25, 3952-3957.	0.8	42
291	The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression. Lung Cancer, 2007, 57, 96-102.	0.9	15
292	Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridizationâ€“Positive/Phospho-Aktâ€“Positive or Never Smoker Patients With Advanced Nonâ€“Small-Cell Lung Cancer: The ONCOBELL Trial. Journal of Clinical Oncology, 2007, 25, 2248-2255.	0.8	218
293	Response to Treatment and Survival of Patients with Nonâ€Small Cell Lung Cancer Undergoing Somatic EGFR Mutation Testing. Oncologist, 2007, 12, 90-98.	1.9	156
294	Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Annals of Oncology, 2007, 18, 752-760.	0.6	257
295	Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers. PLoS Medicine, 2007, 4, e125.	3.9	130
296	Phase II Clinical Trial of Chemotherapy-NaÃ¯ve Patients â‰¥ 70 Years of Age Treated With Erlotinib for Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 760-766.	0.8	306
297	EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Annals of Oncology, 2007, 18, 99-103.	0.6	136

#	Article	IF	Citations
298	How could pharmacogenomics help improve patient survival?. Lung Cancer, 2007, 57, S35-S41.	0.9	10
300	KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonâ€“Small-Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 2890-2896.	3.2	597
301	Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features. Journal of Molecular Diagnostics, 2007, 9, 320-326.	1.2	188
302	EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?. Expert Opinion on Medical Diagnostics, 2007, 1, 183-191.	1.6	2
303	Lung Cancer in Never Smokers: A Review. Journal of Clinical Oncology, 2007, 25, 561-570.	0.8	587
304	Personalized Medicine and Proteomics:â€‰ Lessons from Non-Small Cell Lung Cancer. Journal of Proteome Research, 2007, 6, 2925-2935.	1.8	56
305	Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 587-595.	0.8	593
308	Patterns of EGFR, HER2, TP53, and KRAS Mutations of p14arf Expression in Nonâ€“Small Cell Lung Cancers in Relation to Smoking History. Cancer Research, 2007, 67, 5667-5672.	0.4	111
309	Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer, 2007, 56, 383-389.	0.9	131
310	Up-regulation of PTEN at the transcriptional level is an adverse prognostic factor in female lung adenocarcinomas. Lung Cancer, 2007, 57, 201-206.	0.9	18
311	Chromosomal aberrations of malignant pleural effusions of lung adenocarcinoma: Different cytogenetic changes are correlated with genders and smoking habits. Lung Cancer, 2007, 57, 292-301.	0.9	22
312	Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer, 2007, 58, 411-413.	0.9	105
313	Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer, 2007, 58, 95-103.	0.9	154
314	Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer. Drugs, 2007, 67, 1125-1138.	4.9	15
315	Erlotinib in non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 2579-2592.	0.9	11
316	MTP23-01: Salvage therapy for NSCLC. Journal of Thoracic Oncology, 2007, 2, S289-S290.	0.5	0
317	Clinical Features Reflect Exon Sites of EGFR Mutations in Patients with Resected Non-Small-Cell Lung Cancer. Journal of Korean Medical Science, 2007, 22, 393.	1.1	11
318	Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer. Journal of Thoracic Oncology, 2007, 2, S12-S14.	0.5	6

#	Article	IF	Citations
319	Clinical and Preclinical Experience with Gefitinib and Sunitinib. Breast Care, 2007, 2, 68-73.	0.8	2
321	Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Human Mutation, 2007, 28, 760-770.	1.1	51
322	Amplification, mutation and loss of heterozygosity of the EGFR gene in metastatic lung cancer. International Journal of Cancer, 2007, 120, 1828-1831.	2.3	9
323	The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. International Journal of Cancer, 2007, 120, 1239-1247.	2.3	120
324	Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer, 2007, 109, 581-587.	2.0	117
325	Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas. Cancer, 2007, 109, 741-750.	2.0	74
326	Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer. Cancer, 2007, 109, 1836-1844.	2.0	69
327	Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer. Journal of Surgical Oncology, 2007, 95, 63-69.	0.8	30
328	Epidermal Growth Factor Receptor Double Activating Mutations Involving Both Exons 19 and 21 Exist in Chinese Non-small Cell Lung Cancer Patients. Clinical Oncology, 2007, 19, 499-506.	0.6	47
329	Disproportionate representation ofKRAS gene mutation in atypical adenomatous hyperplasia, but even distribution ofEGFR gene mutation from preinvasive to invasive adenocarcinomas. Journal of Pathology, 2007, 212, 287-294.	2.1	120
330	EGFR kinase domain mutations â€“ functional impact and relevance for lung cancer therapy. Oncogene, 2007, 26, 5693-5701.	2.6	76
331	Epidermal growth factor receptor mutations in lung cancer. Nature Reviews Cancer, 2007, 7, 169-181.	12.8	2,741
332	Lung cancer in never smokers â€” a different disease. Nature Reviews Cancer, 2007, 7, 778-790.	12.8	1,276
333	Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?. British Journal of Cancer, 2007, 96, 857-863.	2.9	90
334	Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. British Journal of Cancer, 2007, 96, 1191-1196.	2.9	46
335	Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). British Journal of Cancer, 2007, 97, 778-784.	2.9	198
336	Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition. British Journal of Cancer, 2007, 97, 741-744.	2.9	45
337	Epidermal growth factor receptor gene mutations in atypical adenomatous hyperplasias of the lung. Modern Pathology, 2007, 20, 967-973.	2.9	33

#	Article	IF	Citations
338	Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Modern Pathology, 2007, 20, 1028-1035.	2.9	51
339	Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation, 2007, 75, 788-799.	1.0	72
340	Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Science, 2007, 98, 96-101.	1.7	86
341	Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation. Cancer Science, 2007, 98, 357-363.	1.7	48
342	Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. Cancer Science, 2007, 98, 985-991.	1.7	30
343	Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Science, 2007, 98, 1275-1280.	1.7	238
344	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Science, 2007, 98, 1817-1824.	1.7	554
345	Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. Acta Pharmacologica Sinica, 2007, 28, 1476-1493.	2.8	39
346	Correlation between EGFR gene mutation pattern and Akt phosphorylation in pulmonary adenocarcinomas. Pathology International, 2007, 57, 268-275.	0.6	12
347	Epidermal growth factor receptor mutations in lung cancers. Pathology International, 2007, 57, 233-244.	0.6	72
348	Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. BMC Cancer, 2007, 7, 128.	1.1	36
349	Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers. BMC Cancer, 2007, 7, 74.	1.1	35
350	Sequence variations in DNA repair gene XPCis associated with lung cancer risk in a Chinese population: a case-control study. BMC Cancer, 2007, 7, 81.	1.1	31
351	EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients. Cancer Genetics and Cytogenetics, 2007, 173, 107-113.	1.0	79
352	Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma. Diagnostic Cytopathology, 2007, 35, 257-262.	0.5	14
353	â€œWho Should Receive Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer and When?â€• Current Treatment Options in Oncology, 2007, 8, 28-37.	1.3	18
354	Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer. Medical Oncology, 2007, 24, 388-393.	1.2	21
355	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issues. Internal and Emergency Medicine, 2007, 2, 3-12.	1.0	12

#	Article	IF	Citations
356	Simple method to detect important epidermal growth factor receptor gene mutations with bronchoscopic specimens of lung cancer patients for gefitinib treatment. Targeted Oncology, 2007, 2, 145-151.	1.7	3
357	Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. Cancer and Metastasis Reviews, 2008, 27, 387-402.	2.7	26
358	Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2008, 61, 489-496.	1.1	75
359	EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. Targeted Oncology, 2008, 3, 173-186.	1.7	3
360	Accuracy of epidermal growth factor receptor gene mutation analysis by direct sequencing method based on small biopsy specimens from patients with non-small cell lung cancer: analysis of results in 19 patients. International Journal of Clinical Oncology, 2008, 13, 442-446.	1.0	14
361	Place des thÃ©rapeutiques biologiques ciblÃ©es. Oncologie, 2008, 10, 540-544.	0.2	0
362	EGFR / HER2 / HER3 expression in tumour and gefitinib treatment in Chinese patients with advanced non-small cell lung cancer. Chinese-German Journal of Clinical Oncology, 2008, 7, 440-446.	0.1	1
363	Elevated expression level of laminin 5 may be a negative predictive factor for the response to gefitinib in lung cancer patients. Chinese-German Journal of Clinical Oncology, 2008, 7, 677-681.	0.1	0
364	Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. Journal of Cancer Research and Clinical Oncology, 2008, 134, 569-577.	1.2	64
365	A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1371-1376.	1.2	12
366	Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer. Prostate, 2008, 68, 803-808.	1.2	19
367	Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer. Cancer, 2008, 113, 1396-1403.	2.0	21
368	Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications. Cancer, 2008, 113, 3199-3208.	2.0	84
369	EGFR inhibition in the treatment of nonâ€small cell lung cancer. Drug Development Research, 2008, 69, 359-372.	1.4	51
370	Chronic rhinosinusitis and risk of lung cancer in the Singapore Chinese Health Study. International Journal of Cancer, 2008, 123, 1398-1402.	2.3	20
371	Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Modern Pathology, 2008, 21, 1168-1175.	2.9	79
372	Molecular epidemiology of cancer. Biochemistry (Moscow), 2008, 73, 532-542.	0.7	28
373	Molecular diagnosis in oncology. Molecular Biology, 2008, 42, 687-698.	0.4	3

#	Article	IF	Citations
374	EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids. Oncogene, 2008, 27, 4336-4343.	2.6	72
375	Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). British Journal of Cancer, 2008, 98, 907-914.	2.9	200
376	Emerging ethnic differences in lung cancer therapy. British Journal of Cancer, 2008, 99, 1757-1762.	2.9	122
377	Absence of epidermal growth factor receptor mutations in cervical cancer. International Journal of Gynecological Cancer, 2008, 18, 749-754.	1.2	33
378	Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinibâ€treated patients with lung adenocarcinoma. Cancer Science, 2008, 99, 303-308.	1.7	37
379	Occurrence of mutations in the epidermal growth factor receptor gene in Xâ€rayâ€induced rat lung tumors. Cancer Science, 2008, 99, 241-245.	1.7	15
380	Soy consumption reduces the risk of nonâ€smallâ€cell lung cancers with epidermal growth factor receptor mutations among Japanese. Cancer Science, 2008, 99, 1202-1208.	1.7	28
381	Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Science, 2008, 99, 1589-1594.	1.7	92
382	Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SPâ€C promoter. Cancer Science, 2008, 99, 1747-1753.	1.7	27
383	Clinical significance of pretreatment serum amphiregulin and transforming growth factorâ€α, and an epidermal growth factor receptor somatic mutation in patients with advanced nonâ€squamous, nonâ€small cell lung cancer. Cancer Science, 2008, 99, 2295-2301.	1.7	29
384	Nonâ€solid oncogenes in solid tumors: EML4â€“ALK fusion genes in lung cancer. Cancer Science, 2008, 99, 2349-2355.	1.7	209
385	Tyrosine kinase activating mutations in human malignancies: Implications for diagnostic pathology. Experimental and Molecular Pathology, 2008, 85, 68-75.	0.9	10
386	High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer, 2008, 8, 142.	1.1	184
387	Association of epidermal growth factor receptor (EGFR) gene copy number amplification with neck lymph node metastasis in areca-associated oral carcinomas. Oral Oncology, 2008, 44, 270-276.	0.8	55
388	Stepwise progression from ground-glass opacity towards invasive adenocarcinoma: Long-term follow-up of radiological findings. Lung Cancer, 2008, 60, 298-301.	0.9	30
389	ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer, 2008, 60, 401-407.	0.9	78
390	EGFR FISH versus mutation: Different tests, different end-points. Lung Cancer, 2008, 60, 160-165.	0.9	44
391	Bronchioloalveolar Carcinoma: The Case for Two Diseases. Clinical Lung Cancer, 2008, 9, 24-29.	1.1	70

#	Article	IF	Citations
392	Extensive-Stage Small-Cell Lung Cancer: Evolution of Systemic Therapy and Future Directions. Clinical Lung Cancer, 2008, 9, 262-270.	1.1	15
393	EGFR/KRAS Mutations and Gefitinib Therapy in Chinese NSCLC Patients. Onkologie, 2008, 31, 174-178.	1.1	22
394	Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment. Expert Review of Respiratory Medicine, 2008, 2, 167-178.	1.0	56
395	Signalling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative. , 2008, , 224-244.		1
396	EGFR Signaling Networks in Cancer Therapy. , 2008, , .		11
397	Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-â€“small cell lung cancer. Human Pathology, 2008, 39, 126-136.	1.1	76
398	Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. Human Pathology, 2008, 39, 316-323.	1.1	22
399	EGFR Polymorphism of the Kinase Domain in Japanese Lung Cancer. Journal of Surgical Research, 2008, 148, 260-263.	0.8	16
400	EGFR Mutations and EGFR Tyrosine Kinase Inhibition in Nonâ€“Small Cell Lung Cancer. Seminars in Oncology Nursing, 2008, 24, 27-33.	0.7	11
401	EGFR Antagonists in Cancer Treatment. New England Journal of Medicine, 2008, 358, 1160-1174.	13.9	1,869
402	Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals. Cancer Letters, 2008, 265, 307-317.	3.2	112
403	Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Current Opinion in Genetics and Development, 2008, 18, 73-79.	1.5	269
404	Advances in the treatment of non-small cell lung cancer. Cancer Treatment Reviews, 2008, 34, 521-526.	3.4	6
405	Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors. Lung Cancer, 2008, 60, S10-S18.	0.9	21
406	EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. Lung Cancer, 2008, 60, S23-S30.	0.9	46
407	KRAS mutational testing in the selection of patients for EGFR-targeted therapies. Seminars in Diagnostic Pathology, 2008, 25, 288-294.	1.0	16
408	Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 2008, 26, 4268-4275.	0.8	674
409	First-Line Gefitinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Harboring SomaticEGFRMutations. Journal of Clinical Oncology, 2008, 26, 2442-2449.	0.8	812

#	Article	IF	Citations
410	Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer, 2008, 59, 111-118.	0.9	91
411	Molecular genetics of lung cancer in people who have never smoked. Lancet Oncology, The, 2008, 9, 676-682.	5.1	113
412	Refining the bipartite model of lung cancer. Lancet Oncology, The, 2008, 9, 918-919.	5.1	1
413	Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 2895-2899.	3.2	649
414	Molecular Pathologyâ€”Translating Research into Clinical Practice: An Expanding Frontier in Surgical Oncology. Surgical Oncology Clinics of North America, 2008, 17, 303-321.	0.6	1
415	Combined anti-proliferative and anti-angiogenic strategies for cancer. Expert Opinion on Pharmacotherapy, 2008, 9, 701-715.	0.9	18
416	EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story. Annual Review of Medicine, 2008, 59, 429-442.	5.0	152
417	Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer. Journal of Clinical Oncology, 2008, 26, 1742-1751.	0.8	267
418	A mouse model for EML4-ALK -positive lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19893-19897.	3.3	490
419	EGFR Mutations in Lung Adenocarcinomas. Journal of Molecular Diagnostics, 2008, 10, 242-248.	1.2	180
420	Epidermal Growth Factor Receptor (EGFR) High Gene Copy Number and Activating Mutations in Lung Adenocarcinomas Are Not Consistently Accompanied by Positivity for EGFR Protein by Standard Immunohistochemistry. Journal of Molecular Diagnostics, 2008, 10, 160-168.	1.2	58
421	First- or Second-line Therapy with Gefitinib Produces Equal Survival in Nonâ€“Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 847-853.	2.5	66
422	Genetic Predictors of MEK Dependence in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2008, 68, 9375-9383.	0.4	235
423	Aberrations of chromosome 19 in asbestos-associated lung cancer and in asbestos-induced micronuclei of bronchial epithelial cells in vitro. Carcinogenesis, 2008, 29, 913-917.	1.3	28
424	Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response. Clinical Cancer Research, 2008, 14, 162-168.	3.2	140
425	Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. European Respiratory Journal, 2008, 32, 924-930.	3.1	112
426	Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer. Clinical Cancer Research, 2008, 14, 6092-6096.	3.2	159
427	Trichomegaly of the Eyelashes After Lung Cancer Treatment with the Epidermal Growth Factor Receptor Inhibitor Erlotinib. Journal of Clinical Oncology, 2008, 26, 3460-3462.	0.8	40

#	Article	IF	Citations
428	Detection of epidermal growth factor receptor gene mutations in cytology specimens from patients with non-small cell lung cancer utilising high-resolution melting amplicon analysis. Journal of Clinical Pathology, 2008, 61, 487-493.	1.0	86
429	Epidermal Growth Factor Receptor Gene Amplification Is Acquired in Association with Tumor Progression of EGFR-Mutated Lung Cancer. Cancer Research, 2008, 68, 2106-2111.	0.4	134
430	Identification of Novel Isoforms of theEML4-ALKTransforming Gene in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2008, 68, 4971-4976.	0.4	419
431	Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (EGFR) Mutations with the Classical Mutation Pattern. Oncologist, 2008, 13, 1276-1284.	1.9	70
432	EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers. Journal of Thoracic Oncology, 2008, 3, 13-17.	0.5	441
433	Targeting Growth Factors in Lung Cancer. Chest, 2008, 133, 1209-1216.	0.4	39
434	Establishment of Patient-Derived Nonâ€“Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers. Clinical Cancer Research, 2008, 14, 6456-6468.	3.2	268
435	Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers. British Journal of Cancer, 2008, 98, 154-160.	2.9	100
436	The role of gefitinib in the management of Asian patients with non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2008, 17, 401-411.	1.9	12
437	Mechanisms of Disease: signal transduction in lung carcinogenesisâ€”a comparison of smokers and never-smokers. Nature Clinical Practice Oncology, 2008, 5, 610-618.	4.3	22
438	Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14112-14117.	3.3	113
439	Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers. Clinical Cancer Research, 2008, 14, 6963-6973.	3.2	112
441	Laser Capture Microdissection and Protein Microarray Analysis of Human Non-small Cell Lung Cancer. Molecular and Cellular Proteomics, 2008, 7, 1902-1924.	2.5	103
442	Cyclic AMP Response Element-Binding Protein Overexpression: A Feature Associated with Negative Prognosis in Never Smokers with Nonâ€“Small Cell Lung Cancer. Cancer Research, 2008, 68, 6065-6073.	0.4	92
443	The Potential Role of Pharmacogenomic and Genomic in the Adjuvant Treatment of Early Stage Non Small Cell Lung Cancer. Current Genomics, 2008, 9, 252-262.	0.7	20
444	Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response. Clinical Cancer Research, 2008, 14, 4877-4882.	3.2	294
445	EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. European Respiratory Journal, 2008, 33, 436-440.	3.1	39
446	Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian Perspective. Japanese Journal of Clinical Oncology, 2008, 39, 137-150.	0.6	72

#	Article	IF	Citations
447	A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Nonâ€“Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy. Clinical Cancer Research, 2008, 14, 3867-3874.	3.2	73
448	Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib. Clinical Cancer Research, 2008, 14, 7060-7067.	3.2	156
449	Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas. Cancer Prevention Research, 2008, 1, 192-200.	0.7	84
450	A Subset of Lung Adenocarcinomas and Atypical Adenomatous Hyperplasiaâ€“Associated Foci Are Genotypically Related. American Journal of Clinical Pathology, 2008, 129, 202-210.	0.4	46
451	MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor NaÃ¯ve Cohort. Journal of Thoracic Oncology, 2008, 3, 331-339.	0.5	181
452	EGFR Mutations Predict Survival Benefit From Gefitinib in Patients With Advanced Lung Adenocarcinoma: A Historical Comparison of Patients Treated Before and After Gefitinib Approval in Japan. Journal of Clinical Oncology, 2008, 26, 5589-5595.	0.8	210
453	Increased Prevalence ofEGFR-Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms. Clinical Cancer Research, 2008, 14, 4079-4084.	3.2	71
454	PIK3CA Mutations and Copy Number Gains in Human Lung Cancers. Cancer Research, 2008, 68, 6913-6921.	0.4	399
455	Somatic pharmacogenomics in cancer. Pharmacogenomics Journal, 2008, 8, 305-314.	0.9	22
458	Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion. Cancer Research, 2008, 68, 132-142.	0.4	114
459	Gefitinib First or Gefitinib Second. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 783-785.	2.5	0
460	Biomarkers in oncology drug development: rescuers or troublemakers?. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1391-1402.	1.5	16
461	Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma. Journal of Thoracic Oncology, 2008, 3, 111-116.	0.5	248
462	Detection of EGFR Gene Mutations Using the Wash Fluid of CT-Guided Biopsy Needle in NSCLC Patients. Journal of Thoracic Oncology, 2008, 3, 472-476.	0.5	38
463	Personalizing protein-drug interactions. Pure and Applied Chemistry, 2008, 80, 1811-1820.	0.9	1
464	Wood-Smoke Exposure as a Response and Survival Predictor in Erlotinib-treated Non-small Cell Lung Cancer Patients: An Open Label Phase II Study. Journal of Thoracic Oncology, 2008, 3, 887-893.	0.5	28
465	Clinical Experience with Gefitinib in Indian Patients. Journal of Thoracic Oncology, 2008, 3, 380-385.	0.5	24
466	Sequential Molecular Changes during Multistage Pathogenesis of Small Peripheral Adenocarcinomas of the Lung. Journal of Thoracic Oncology, 2008, 3, 340-347.	0.5	78

#	Article	IF	Citations
467	Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer. Current Signal Transduction Therapy, 2008, 3, 234-243.	0.3	0
468	Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis. American Journal of Surgical Pathology, 2008, 32, 810-827.	2.1	352
469	Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Current Opinion in Oncology, 2008, 20, 162-175.	1.1	46
470	Molecularly Targeted Therapy for Lung Cancer: Recent Topics. Journal of Lung Cancer, 2008, 7, 1.	0.2	2
471	Role of Epidermal Growth Factor Receptor and the HER-2 Gene in Hormone Refractory Prostate Cancer. Korean Journal of Urology, 2008, 49, 24.	0.2	0
472	Molecular Predictors of EGFR-TKI Sensitivity in Advanced Nonâ€“small Cell Lung Cancer. International Journal of Medical Sciences, 2008, 5, 209-217.	1.1	67
473	Targeted therapies in non-small cell lung cancer. Cancer Imaging, 2008, 8, 199-205.	1.2	6
474	Molecular Basis of Pulmonary Disease. , 2009, , 305-364.		4
478	Hormone Replacement Therapy and Outcomes for Women with Non-Small-Cell Lung Cancer: Can An Association be Confirmed?. Current Oncology, 2009, 16, 21-25.	0.9	31
479	Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. Journal of Oncology, 2009, 2009, 1-12.	0.6	53
480	Second Line Treatments in Advanced Platinum-Resistant Non Small Cell Lung Cancer. A Critical Review of Literature. Reviews on Recent Clinical Trials, 2009, 4, 27-33.	0.4	8
481	Characterizing the developmental pathways TTF-1 , NKX2â€“8 , and PAX9 in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5312-5317.	3.3	50
482	First-Line Gefitinib for Patients With Advanced Nonâ€“Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy. Journal of Clinical Oncology, 2009, 27, 1394-1400.	0.8	480
483	Micropapillary Histology. American Journal of Clinical Pathology, 2009, 131, 615-617.	0.4	7
484	The â€œLazarus Responseâ€•in Treatment-NaÃ¯ve, Poor Performance Status Patients With Nonâ€“Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation. Journal of Clinical Oncology, 2009, 27, 1350-1354.	0.8	69
486	Erlotinib: applications in therapy and current status of research. Expert Review of Clinical Pharmacology, 2009, 2, 15-36.	1.3	1
487	Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 2630-2636.	3.2	229
488	Mutations and Response to Epidermal Growth Factor Receptor Inhibitors: Fig. 1.. Clinical Cancer Research, 2009, 15, 1133-1139.	3.2	120

#	Article	IF	Citations
489	Uncovering Disparities in Survival after Nonâ€“Smallâ€“Cell Lung Cancer among Asian/Pacific Islander Ethnic Populations in California. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2248-2255.	1.1	19
490	Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Nonâ€“small cell Lung Cancer Cell Lines withMETAmplification. Clinical Cancer Research, 2009, 15, 907-913.	3.2	47
491	HER Family Receptor Abnormalities in Lung Cancer Brain Metastases and Corresponding Primary Tumors. Clinical Cancer Research, 2009, 15, 4829-4837.	3.2	151
492	EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases. Clinical Cancer Research, 2009, 15, 4554-4560.	3.2	258
493	Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: A population-based prospective study. Oncology Reports, 2009, 22, 683-91.	1.2	25
494	Gefitinib in lung cancer therapy: Clinical results, predictive markers of response and future perspectives. Cancer Biology and Therapy, 2009, 8, 206-212.	1.5	10
495	Second-Line Treatments in Non-small Cell Lung Cancer. Chest, 2009, 135, 1596-1609.	0.4	33
497	Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines. Journal of Thoracic Oncology, 2009, 4, 161-166.	0.5	59
498	Theme: Oncology - Molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates. Biomarkers in Medicine, 2009, 3, 139-151.	0.6	4
499	IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors. Future Oncology, 2009, 5, 305-308.	1.1	9
500	Genomics of Lung Cancer. Proceedings of the American Thoracic Society, 2009, 6, 152-158.	3.5	36
501	Reasons for response differences seen in the V15-32, INTEREST and IPASS trials. Nature Reviews Clinical Oncology, 2009, 6, 287-294.	12.5	21
502	EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis, 2009, 30, 1155-1160.	1.3	46
503	Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines. PLoS ONE, 2009, 4, e4576.	1.1	177
504	Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR Mutation. Clinical Cancer Research, 2009, 15, 5359-5368.	3.2	150
505	MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Annals of Oncology, 2009, 20, 298-304.	0.6	286
506	The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. Oncologist, 2009, 14, 1116-1130.	1.9	57
507	Whole Genome Comparison of Allelic Imbalance between Noninvasive and Invasive Small-Sized Lung Adenocarcinomas. Cancer Research, 2009, 69, 1615-1623.	0.4	33

#	Article	IF	Citations
508	Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 7502-7509.	3.2	136
510	Lung Cancer in Never Smokers: Molecular Profiles and Therapeutic Implications. Clinical Cancer Research, 2009, 15, 5646-5661.	3.2	137
511	EGFR and K-ras Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors. American Journal of Clinical Pathology, 2009, 131, 478-489.	0.4	67
512	Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of Chemotherapy. Clinical Cancer Research, 2009, 15, 4806-4814.	3.2	212
513	Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Annals of Oncology, 2009, 20, 213-226.	0.6	37
514	Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer. Clinical Cancer Research, 2009, 15, 5714-5723.	3.2	174
515	Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Annals of Oncology, 2009, 20, 696-702.	0.6	206
516	Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice. Cancer Research, 2009, 69, 7088-7095.	0.4	23
517	Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Nonâ€“Small Cell Lung Cancer with EGFR Mutations. Clinical Cancer Research, 2009, 15, 4493-4498.	3.2	182
518	Pathogenesis of lung cancer signalling pathways: roadmap for therapies. European Respiratory Journal, 2009, 33, 1485-1497.	3.1	151
519	Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2009, 4, 12-21.	0.5	75
520	ErbBs in lung cancer. Experimental Cell Research, 2009, 315, 557-571.	1.2	61
521	ERBBs in the gastrointestinal tract: Recent progress and new perspectives. Experimental Cell Research, 2009, 315, 583-601.	1.2	46
522	Epidermal growth factor receptor (EGFR) double-activating somatic mutations in exons 19 and 21 in Japanese nonâ€“small cell lung cancer patients. Cancer Genetics and Cytogenetics, 2009, 195, 179-182.	1.0	10
523	Differential Expression of Biomarkers in Men and Women. Seminars in Oncology, 2009, 36, 553-565.	0.8	52
524	EGFR protein overexpression and mutation in areca quidâ€“associated oral cavity squamous cell carcinoma in Taiwan. Head and Neck, 2009, 31, 1068-1077.	0.9	28
525	MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. International Journal of Cancer, 2009, 124, 1778-1784.	2.3	131
526	Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology, 2009, 135, 1483-1493.	1.2	26

#	Article	IF	Citations
527	Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Research and Treatment, 2009, 115, 115-121.	1.1	116
528	Resistance mechanisms of tumour cells to EGFR inhibitors. Clinical and Translational Oncology, 2009, 11, 270-275.	1.2	19
529	Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. Clinical and Translational Oncology, 2009, 11, 428-436.	1.2	4
531	Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with nonâ€smallâ€cell lung cancer for gefitinib treatment. Cancer Science, 2009, 100, 1931-1934.	1.7	15
532	Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung. Modern Pathology, 2009, 22, 668-678.	2.9	134
533	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Modern Pathology, 2009, 22, 508-515.	2.9	429
534	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nature Reviews Clinical Oncology, 2009, 6, 352-366.	12.5	207
535	Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene, 2009, 28, S14-S23.	2.6	179
536	Clinicopathological features and epidermal growth factor receptor mutations associated with epithelialâ€“mesenchymal transition in nonâ€small cell lung cancer. Respirology, 2009, 14, 371-376.	1.3	17
537	Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions. Current Problems in Cancer, 2009, 33, 245-294.	1.0	9
538	American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 6251-6266.	0.8	732
539	Clinical Features and Outcome of Patients With Nonâ€“Small-Cell Lung Cancer Who Harbor EML4-ALK. Journal of Clinical Oncology, 2009, 27, 4247-4253.	0.8	1,775
541	Epidermal Growth Factor Receptor Mutations in Plasma DNA Samples Predict Tumor Response in Chinese Patients With Stages IIIB to IV Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 2653-2659.	0.8	281
542	The Changing Epidemiology of Lung Cancer. Methods in Molecular Biology, 2009, 472, 397-411.	0.4	64
543	Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. Lung Cancer, 2009, 63, 241-246.	0.9	17
544	Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer, 2009, 63, 315-321.	0.9	107
545	NAT2 fast acetylator genotypes are associated with an increased risk for lung cancer with wildtype epidermal growth factor receptors in Taiwan. Lung Cancer, 2009, 64, 9-12.	0.9	12
546	Improved survival from lung cancer in British Columbia compared to Scotlandâ€”Are different treatment rates the whole story?. Lung Cancer, 2009, 64, 358-366.	0.9	13

#	Article	IF	Citations
547	Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. Lung Cancer, 2009, 65, 25-33.	0.9	47
548	Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer, 2009, 65, 198-203.	0.9	131
549	Gefitinib or Carboplatinâ€“Paclitaxel in Pulmonary Adenocarcinoma. New England Journal of Medicine, 2009, 361, 947-957.	13.9	7,606
550	Gefitinib. Drugs, 2009, 69, 2303-2328.	4.9	55
551	Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonâ€“Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway. Clinical Lung Cancer, 2009, 10, 281-289.	1.1	394
552	Gefitinib for the treatment of non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2009, 9, 17-35.	1.1	46
553	Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. Journal of Clinical Pathology, 2009, 62, 886-891.	1.0	46
554	Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. New England Journal of Medicine, 2009, 361, 958-967.	13.9	2,213
555	Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2009, 18, 293-301.	1.9	15
556	Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers. Cancer Research, 2009, 69, 8341-8348.	0.4	114
557	Phase II Study of Preoperative Gefitinib in Clinical Stage I Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 6229-6236.	0.8	93
558	Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer. Lung Cancer, 2009, 66, 107-113.	0.9	20
559	Association Between Estrogen Receptor-Î² Expression and Epidermal Growth Factor Receptor Mutation in the Postoperative Prognosis of Adenocarcinoma of the Lung. Journal of Clinical Oncology, 2009, 27, 411-417.	0.8	158
560	First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncology, The, 2009, 10, 1102-1110.	5.1	28
561	Estrogen and its signaling pathway in non-small cell lung cancer(NSCLC). Journal of Nanjing Medical University, 2009, 23, 217-223.	0.1	3
562	Epidermal Growth Factor Receptor Mutation and Pathologic-Radiologic Correlation Between Multiple Lung Nodules with Ground-Glass Opacity Differentiates Multicentric Origin from Intrapulmonary Spread. Journal of Thoracic Oncology, 2009, 4, 1490-1495.	0.5	103
563	Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma. Journal of Thoracic Oncology, 2009, 4, 22-29.	0.5	222
564	Germ-Line and Somatic Presentations of the EGFR T790M Mutation in Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 139-141.	0.5	41

#	Article	IF	Citations
565	EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort. Journal of Thoracic Oncology, 2009, 4, 318-325.	0.5	52
566	The status of KRAS mutations in patients with non-small cell lung cancers from mainland China. Oncology Reports, 2009, 22, 1013-20.	1.2	27
567	Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 787-791.	0.5	30
568	Erlotinib Combined with Cyclosporine in a Liver-Transplant Recipient with Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 138-139.	0.5	6
569	Recent Developments of Targeted Therapies in the Treatment of Non-Small Cell Lung Cancer. Current Drug Discovery Technologies, 2009, 6, 91-102.	0.6	29
570	Personalized cancer therapy coming of age: clinical highlights in 2009 and future directions. Personalized Medicine, 2010, 7, 121-124.	0.8	2
571	Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations. Journal of Thoracic Oncology, 2010, 5, 1551-1558.	0.5	117
572	Primary Lung Adenocarcinomas in Children and Adolescents Treated for Pediatric Malignancies. Journal of Thoracic Oncology, 2010, 5, 1764-1771.	0.5	22
573	Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop. Journal of Thoracic Oncology, 2010, 5, 1706-1713.	0.5	273
574	The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies. Genes and Cancer, 2010, 1, 1200-1210.	0.6	88
575	Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations. Journal of Thoracic Oncology, 2010, 5, 1048-1053.	0.5	76
576	Gender, Histology, and Time of Diagnosis Are Important Factors for Prognosis: Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan. Journal of Thoracic Oncology, 2010, 5, 1011-1017.	0.5	76
577	Frequency of EGFR and KRAS Mutations in Japanese Patients with Lung Adenocarcinoma with Features of the Mucinous Subtype of Bronchioloalveolar Carcinoma. Journal of Thoracic Oncology, 2010, 5, 1197-1200.	0.5	66
578	High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 305-313.	0.5	206
579	De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 399-400.	0.5	74
580	Molecular Diagnostics Testing for Lung Adenocarcinoma. , 2010, 15, 103-110.		1
581	Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and KRAS Mutations in Patients with Adenocarcinoma of the Lung with Bronchioloalveolar Features?. Journal of Thoracic Oncology, 2010, 5, 344-348.	0.5	68
582	Correlation between Epidermal Growth Factor Receptor Mutations and Expression of Female Hormone Receptors in East-Asian Lung Adenocarcinomas. Journal of Thoracic Oncology, 2010, 5, 17-22.	0.5	35

#	Article	IF	Citations
583	Association Between Age at Diagnosis and the Presence of EGFR Mutations in Female Patients with Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1949-1952.	0.5	36
584	Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1404-1409.	0.5	50
585	Clinicopathological and Therapeutic Significance of CXCL12 Expression in Lung Cancer. International Journal of Immunopathology and Pharmacology, 2010, 23, 153-164.	1.0	28
586	Overexpression of EGFR pathway-related genes in the circulation is highly correlated with EGFR mutations and overexpression in paired cancer tissue from patients with non-small cell lung cancer. Oncology Reports, 2010, 23, .	1.2	8
587	Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas. Journal of Thoracic Oncology, 2010, 5, 1130-1135.	0.5	91
588	Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial. Journal of Thoracic Oncology, 2010, 5, 1382-1390.	0.5	138
589	Japanese Lung Cancer Research Trends and Performance in Science Citation Index. Internal Medicine, 2010, 49, 2219-2228.	0.3	130
590	Correlation Between HLA Alleles and EGFR Mutation in Japanese Patients with Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 2010, 5, 1136-1142.	0.5	12
591	Biomarkers with Predictive and Prognostic Function in Nonâ€“Small Cell Lung Cancer: Ready for Prime Time?. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 822-832.	2.3	36
592	Deregulation of p27 and Cyclin D1/D3 Control Over Mitosis Is Associated with Unfavorable Prognosis in Non-small Cell Lung Cancer, as Determined in 405 Operated Patients. Journal of Thoracic Oncology, 2010, 5, 1325-1336.	0.5	41
593	A Single Institution-Based Retrospective Study of Surgically Treated Bronchioloalveolar Adenocarcinoma of the Lung: Clinicopathologic Analysis, Molecular Features, and Possible Pitfalls in Routine Practice. Journal of Thoracic Oncology, 2010, 5, 830-836.	0.5	76
594	Prognostic Implications of Epidermal Growth Factor Receptor and KRAS Gene Mutations and Epidermal Growth Factor Receptor Gene Copy Numbers in Patients with Surgically Resectable Non-small Cell Lung Cancer in Taiwan. Journal of Thoracic Oncology, 2010, 5, 1175-1184.	0.5	50
595	Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1937-1944.	1.2	29
596	Impact of biomarkers on non-small cell lung cancer treatment. Targeted Oncology, 2010, 5, 5-17.	1.7	17
597	Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. Medical Oncology, 2010, 27, 950-957.	1.2	13
598	Biomarkers in bronchopulmonary cancer. Clinical and Translational Oncology, 2010, 12, 92-99.	1.2	3
599	Low correspondence of EGFR mutations in tumor tissue and paired serum of non-small-cell lung cancer patients. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2010, 22, 27-31.	0.7	5
600	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer and Metastasis Reviews, 2010, 29, 49-60.	2.7	191

#	Article	IF	Citations
601	Stepwise progression of pulmonary adenocarcinomaâ€"clinical and molecular implications. Cancer and Metastasis Reviews, 2010, 29, 15-21.	2.7	109
602	The Emerging Role of Biomarkers in Advanced Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2010, 11, 149-159.	1.1	20
603	Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Nonâ€"Small-Cell Lung Cancer. Clinical Lung Cancer, 2010, 11, 257-263.	1.1	8
604	Relationship between EGFR expression, copy number and mutation in lung adenocarcinomas. BMC Cancer, 2010, 10, 376.	1.1	70
605	Kinases as targets in the treatment of solid tumors. Cellular Signalling, 2010, 22, 984-1002.	1.7	88
606	Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy. FEBS Letters, 2010, 584, 2699-2706.	1.3	141
607	Sex differences in lung cancer susceptibility: A review. Gender Medicine, 2010, 7, 381-401.	1.4	157
608	Mechanisms of resistance to HER family targeting antibodies. Experimental Cell Research, 2010, 316, 1083-1100.	1.2	136
609	Clinical outcomes in nonâ€smallâ€cell lung cancer patients with EGFR mutations: pooled analysis. Journal of Cellular and Molecular Medicine, 2010, 14, 51-69.	1.6	126
610	Epidermal growth factor receptor mutations detected by denaturing highâ€performance liquid chromatography in nonsmall cell lung cancer. Cancer, 2010, 116, 4309-4317.	2.0	20
611	Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data. Critical Reviews in Oncology/Hematology, 2010, 75, 94-109.	2.0	38
612	Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer. Journal of Biomedical Science, 2010, 17, 37.	2.6	9
613	Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. Journal of Pathology, 2010, 220, 446-451.	2.1	311
614	Epidermal growth factor receptor (EGFR) expression in periocular and extraocular sebaceous carcinoma. Journal of Cutaneous Pathology, 2010, 37, 231-238.	0.7	22
615	Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinibâ€resistant nonâ€small cell lung cancer cells with acquired MET amplification. Cancer Science, 2010, 101, 167-172.	1.7	58
616	Predictive advantage of a cell type classification for pulmonary adenocarcinoma coupled with data for p53, Kâ€ras and EGFR alterations. Cancer Science, 2010, 101, 1745-1753.	1.7	3
617	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer, 2010, 10, 760-774.	12.8	943
618	Integrating molecular diagnostics into anticancer drug discovery. Nature Reviews Drug Discovery, 2010, 9, 523-535.	21.5	53

#	Article	IF	Citations
619	Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene. Respirology, 2010, 15, 700-705.	1.3	8
620	Gene Expression Analysis for Tumor Profiling. , 2010, , 225-241.		0
621	Predictive molecular markers for EGFR-TKI in non-small cell lung cancer patients: new insights and critical aspects. Journal of Nucleic Acids Investigation, 2010, 1, 10.	0.5	1
623	Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer. Lung Cancer: Targets and Therapy, 2011, 2, 1.	1.3	2
624	Molecular Biology of Lung Cancer. Japanese Journal of Lung Cancer, 2010, 50, 329-341.	0.0	0
625	EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Frontiers in Bioscience - Landmark, 2010, 15, 65.	3.0	26
626	EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget, 2010, 1, 497-514.	0.8	159
627	Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer. Clinical Cancer Research, 2010, 16, 3349-3355.	3.2	108
628	Molecular Diagnosis of Activating EGFR Mutations in Nonâ€“Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis. Clinical Cancer Research, 2010, 16, 3163-3170.	3.2	108
629	Development of Central Nervous System Metastases in Patients with Advanced Nonâ€“Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib. Clinical Cancer Research, 2010, 16, 5873-5882.	3.2	209
630	cIAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18â€“Infected Lung Cancer. Clinical Cancer Research, 2010, 16, 5200-5210.	3.2	67
631	Primary Oncocytic Adenocarcinomas of the Lung. American Journal of Clinical Pathology, 2010, 133, 133-140.	0.4	12
632	Reproductive Factors, Hormone Use, and Risk for Lung Cancer in Postmenopausal Women, the Nurses' Health Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2525-2533.	1.1	78
633	The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. European Respiratory Review, 2010, 19, 186-196.	3.0	35
634	EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Nonâ€“Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry. American Journal of Clinical Pathology, 2010, 133, 922-934.	0.4	110
635	Good Clinical Response to Gefitinib in a Non-small Cell Lung Cancer Patient Harboring a Rare Somatic Epidermal Growth Factor Gene Point Mutation; Codon 768 AGC > ATC in Exon 20 (S768I). Japanese Journal of Clinical Oncology, 2010, 40, 1105-1109.	0.6	50
636	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer. Current Gerontology and Geriatrics Research, 2010, 2010, 1-8.	1.6	2
637	Power to detect selective allelic amplification in genome-wide scans of tumor data. Bioinformatics, 2010, 26, 518-528.	1.8	9

#	Article	IF	Citations
638	Gene Profiling of Clinical Routine Biopsies and Prediction of Survival in Nonâ€“Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 181-188.	2.5	44
639	A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond. Expert Review of Anticancer Therapy, 2010, 10, 955-965.	1.1	14
640	The Evolving Role of Histology in the Management of Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 5311-5320.	0.8	247
641	Nrf2 and Keap1 Abnormalities in Nonâ€“Small Cell Lung Carcinoma and Association with Clinicopathologic Features. Clinical Cancer Research, 2010, 16, 3743-3753.	3.2	380
642	MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer. Clinical Cancer Research, 2010, 16, 430-441.	3.2	316
643	Second-line treatments of advanced non-small-cell lung cancer: new evidence for clinical practice. Annals of Oncology, 2010, 21, 428-429.	0.6	9
644	Should we continue to use the term non-small-cell lung cancer?. Annals of Oncology, 2010, 21, vii225-vii229.	0.6	35
645	Loss of PTEN Expression by Blocking Nuclear Translocation of EGR1 in Gefitinib-Resistant Lung Cancer Cells Harboring Epidermal Growth Factor Receptorâ€“Activating Mutations. Cancer Research, 2010, 70, 8715-8725.	0.4	142
646	Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer. Experimental Lung Research, 2010, 36, 531-537.	0.5	12
647	Treatment of Brain Metastasis from Lung Cancer. Cancers, 2010, 2, 2100-2137.	1.7	61
648	Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncology, 2010, 12, 1061-1070.	0.6	112
649	Identification of a Novel Biomarker, SEMA5A, for Nonâ€“Small Cell Lung Carcinoma in Nonsmoking Women. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2590-2597.	1.1	270
650	Chromosomal and genomic changes in lung cancer. Cell Adhesion and Migration, 2010, 4, 100-106.	1.1	39
651	Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation. Case Reports in Oncology, 2010, 3, 98-105.	0.3	11
652	Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer. Clinical Cancer Research, 2010, 16, 174-183.	3.2	93
653	Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers. Journal of Thoracic Oncology, 2010, 5, 1734-1740.	0.5	90
655	EGFR Mutation Testing in Non-Small Cell Lung Cancer. Current Respiratory Medicine Reviews, 2010, 6, 310-321.	0.1	2
656	Past, Present and Future of Targeted Therapy in Solid Tumors. Current Cancer Drug Targets, 2010, 10, 433-461.	0.8	30

#	Article	IF	Citations
657	Novel Agents in the Management of Lung Cancer. Current Medicinal Chemistry, 2010, 17, 4291-4325.	1.2	21
658	Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies. Current Cancer Drug Targets, 2010, 10, 799-812.	0.8	28
660	Targeted Therapies in Lung Cancer. Surgical Pathology Clinics, 2010, 3, 71-82.	0.7	33
661	Tumor size matters differently in pulmonary adenocarcinoma and squamous cell carcinoma. Lung Cancer, 2010, 67, 296-300.	0.9	10
662	Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer, 2010, 68, 198-203.	0.9	105
663	Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke. Lung Cancer, 2010, 67, 12-16.	0.9	15
664	Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level?. Lung Cancer, 2010, 68, 1-9.	0.9	39
665	PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer, 2010, 69, 279-283.	0.9	161
666	Lung cancer cell lines: Useless artifacts or invaluable tools for medical science?. Lung Cancer, 2010, 68, 309-318.	0.9	109
667	Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients. Lung Cancer, 2010, 69, 265-271.	0.9	12
668	Comparable rate of EGFR kinase domain mutation in lung adenocarcinomas from Chinese male and female never-smokers. Acta Pharmacologica Sinica, 2010, 31, 647-648.	2.8	12
669	High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma. Onkologie, 2010, 33, 231-238.	1.1	39
670	Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib. Oncology, 2010, 79, 355-362.	0.9	20
671	Small-Cell Carcinoma With an Epidermal Growth Factor Receptor Mutation in a Never-Smoker With Gefitinib-Responsive Adenocarcinoma of the Lung. Clinical Lung Cancer, 2010, 11, E1-E4.	1.1	53
673	A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Human Pathology, 2010, 41, 94-102.	1.1	81
674	The close correlation between 8-hydroxy-2â€²-deoxyguanosine and epidermal growth factor receptor activating mutation in nonâ€“small cell lung cancer. Human Pathology, 2010, 41, 951-959.	1.1	11
675	The biology and treatment of EML4-ALK non-small cell lung cancer. European Journal of Cancer, 2010, 46, 1773-1780.	1.3	516
676	Absence of hotspot mutations in exons 9 and 20 of the PIK3CA gene in human oral squamous cell carcinoma in the Greek population. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2010, 109, e53-e58.	1.6	12

#	Article	IF	Citations
677	Clinical Applications of Kinase Inhibitors in Solid Tumors. , 2010, , 615-631.		1
678	Co-Activation of Epidermal Growth Factor Receptor and c-MET Defines a Distinct Subset of Lung Adenocarcinomas. American Journal of Pathology, 2010, 177, 2191-2204.	1.9	42
679	Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer, 2010, 69, 110-115.	0.9	83
680	Impact of Environmental Tobacco Smoke on the Incidence of Mutations in Epidermal Growth Factor Receptor Gene in Never-Smoker Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 487-492.	0.8	74
681	18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: A single-institution retrospective analysis. Lung Cancer, 2010, 67, 76-80.	0.9	66
682	Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncology, The, 2010, 11, 75-84.	5.1	121
683	Lung cancer in never smokers: a new hot area of research. Lancet Oncology, The, 2010, 11, 304-305.	5.1	21
684	Comparison of Antioxidant Activities in Black Soybean Preparations Fermented with Various Microorganisms. Agricultural Sciences in China, 2010, 9, 1065-1071.	0.6	23
685	Mutation Detection of Epidermal Growth Factor Receptor and KRAS Genes Using the Smart Amplification Process Version 2 from Formalin-Fixed, Paraffin-Embedded Lung Cancer Tissue. Journal of Molecular Diagnostics, 2010, 12, 257-264.	1.2	38
686	The Gender-Specific Aspects of Lung Cancer. , 2010, , 260-269.		0
687	Genomics in the Diagnosis and Management of Lung Cancer. , 2010, , 432-445.		0
688	American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Nonâ€“Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. Journal of Clinical Oncology, 2011, 29, 2121-2127.	0.8	476
689	A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Nonâ€“Small-Cell Lung Cancer. Journal of Molecular Diagnostics, 2011, 13, 74-84.	1.2	160
690	EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. British Journal of Cancer, 2011, 105, 420-427.	2.9	62
691	Evaluation and Treatment of Patients with Nonâ€“Small Cell Lung Cancer. Medical Clinics of North America, 2011, 95, 1041-1054.	1.1	24
692	A Decade of Advances in Treatment for Advanced Nonâ€“Small Cell Lung Cancer. Clinics in Chest Medicine, 2011, 32, 839-851.	0.8	58
693	Molecular Biology of Lung Cancer: Clinical Implications. Clinics in Chest Medicine, 2011, 32, 703-740.	0.8	194
694	Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. European Respiratory Journal, 2011, 37, 624-631.	3.1	304

#	Article	IF	Citations
695	Lung cancer in never smokers: Change of a mindset in the molecular era. Lung Cancer, 2011, 72, 9-15.	0.9	78
697	Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung. Lung Cancer, 2011, 73, 379-380.	0.9	21
698	Late breast metastasis from resected lung cancer diagnosed by epidermal growth factor receptor gene mutation. Lung Cancer, 2011, 74, 352-353.	0.9	10
699	Personalized medicine in lung cancer: what we need to know. Nature Reviews Clinical Oncology, 2011, 8, 661-668.	12.5	145
700	INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer, 2011, 11, 430.	1.1	74
701	Lung Cancer: Epidemiology, Etiology, and Prevention. Clinics in Chest Medicine, 2011, 32, 605-644.	0.8	1,444
702	The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncology, 2011, 7, 519-541.	1.1	47
703	Standardization of Epidermal Growth Factor Receptor (EGFR) Measurement by Quantitative Immunofluorescence and Impact on Antibody-Based Mutation Detection in Nonâ€“Small Cell Lung Cancer. American Journal of Pathology, 2011, 179, 580-589.	1.9	21
704	Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?. Cancer Treatment Reviews, 2011, 37, 533-542.	3.4	31
705	Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer. European Respiratory Journal, 2011, 38, 903-910.	3.1	28
706	2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment â€" First-line therapy. European Journal of Cancer, 2011, 47, S248-S257.	1.3	5
707	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, The, 2011, 12, 735-742.	5.1	3,758
708	Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncology, The, 2011, 12, 795-805.	5.1	199
709	Imaging of Lung Cancer in the Era of Molecular Medicine. Academic Radiology, 2011, 18, 424-436.	1.3	37
710	Nonfilter and filter cigarette consumption and the incidence of lung cancer by histological type in Japan and the United States: Analysis of 30â€year data from populationâ€based cancer registries. International Journal of Cancer, 2011, 128, 1918-1928.	2.3	59
711	Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. Cancer Discovery, 2011, 1, 78-89.	7.7	455
712	Epidermal growth factor receptor mutationâ€guided treatment for lung cancers: Where are we now?. Thoracic Cancer, 2011, 2, 1-6.	0.8	5
713	Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. Breast Cancer Research, 2011, 13, R133.	2.2	37

#	Article	IF	Citations
714	Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFRâ€“TKI for adenocarcinoma of the lung. Lung Cancer, 2011, 71, 350-355.	0.9	39
715	The different clinical significance of EGFR mutations in exon 19 and 21 in non-small cell lung cancer patients of China. Neoplasma, 2011, 58, 74-81.	0.7	31
716	Detection of EGFR and K-ras mutations for diagnosis of multiple lung adenocarcinomas. Frontiers in Bioscience - Landmark, 2011, 16, 2961.	3.0	2
717	Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy. Frontiers in Bioscience - Landmark, 2011, 16, 1714.	3.0	8
718	Utilization of Unlabeled Probes for the Detection of Fibroblast Growth Factor Receptor 2 Exons 7 and 12 Mutations in Endometrial Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 341-346.	0.6	4
719	Gefitinib Therapy in Patients With Advanced Non-Small Cell Lung Cancer With or Without Testing for Epidermal Growth Factor Receptor (EGFR) Mutations. Medicine (United States), 2011, 90, 159-167.	0.4	30
720	C-KIT and PDGFRA Zygosity in Gastrointestinal Stromal Tumors. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 21-27.	0.6	6
721	Tyrosine Kinase Inhibitors and Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer. Medicine (United States), 2011, 90, 168-170.	0.4	6
722	Novel Therapeutic Targets in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 1601-1612.	0.5	127
723	Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncology Reports, 2011, 25, 921-8.	1.2	73
724	Association of Keap1 and Nrf2 Genetic Mutations and Polymorphisms With Endometrioid Endometrial Adenocarcinoma Survival. International Journal of Gynecological Cancer, 2011, 21, 1428-1435.	1.2	33
725	Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes. Current Opinion in Oncology, 2011, 23, 88-92.	1.1	41
726	Whatâ€™s new in non-small cell lung cancer for pathologists the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 2011, 43, 103-115.	0.3	54
727	Genotyping Non-small Cell Lung Cancer (NSCLC) in Latin America. Journal of Thoracic Oncology, 2011, 6, 1955-1959.	0.5	113
728	Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Multicenter Study. Journal of Thoracic Oncology, 2011, 6, 148-155.	0.5	26
729	Frequency and Type of Epidermal Growth Factor Receptor Mutations in African Americans with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 627-630.	0.5	70
731	Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Experimental and Therapeutic Medicine, 2011, 2, 685-693.	0.8	33
732	A Phase II Randomized Trial of Gefitinib Alone or with Tegafur/Uracil Treatment in Patients with Pulmonary Adenocarcinoma Who had Failed Previous Chemotherapy. Journal of Thoracic Oncology, 2011, 6, 1110-1116.	0.5	28

#	Article	IF	Citations
733	Comprehensive Analysis of Epidermal Growth Factor Receptor Gene Status in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 1016-1021.	0.5	18
734	Evaluation of Kras Gene Mutation and Copy Number Gain in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, 15-20.	0.5	48
735	NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, S-1-S-32.	2.3	227
736	Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. Ecological Management and Restoration, 2011, 24, 374-380.	0.2	24
737	Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepitheliomaâ€like carcinomas. Cancer Science, 2011, 102, 282-287.	1.7	63
738	Pulmonary adenocarcinoma with a micropapillary pattern: a clinicopathological, immunophenotypic and molecular analysis. Histopathology, 2011, 59, 1204-1214.	1.6	40
739	Detection of low-level EGFR T790M mutation in lung cancer tissues. Apmis, 2011, 119, 403-411.	0.9	27
740	Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. Oncogene, 2011, 30, 1744-1752.	2.6	35
741	Clinicopathologic Factors Affecting the Progression-Free Survival of Patients With Advanced Nonâ€“Small-Cell Lung Cancer After Gefitinib Therapy. Clinical Lung Cancer, 2011, 12, 56-61.	1.1	7
742	Monoclonal antibodies against EGFR in non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2011, 80, 1-9.	2.0	42
743	Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells. Biochemical Pharmacology, 2011, 81, 1263-1270.	2.0	51
744	EGFR Mutations and Lung Cancer. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 49-69.	9.6	644
745	Gender aspects in haematology and oncology: Overview and own observations in lung cancer. Memo - Magazine of European Medical Oncology, 2011, 4, 209-216.	0.3	0
746	A histology-based algorithm in the molecular diagnosis of mutations of the epidermal growth factor receptor (EGFR)â€“in non-small-cell lung cancer (NSCLC)*. Memo - Magazine of European Medical Oncology, 2011, 4, 248-253.	0.3	1
747	Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer. European Respiratory Journal, 2011, 37, 183-193.	3.1	37
748	Comparison of p53 and Epidermal Growth Factor Receptor Gene Status Between Primary Tumors and Lymph Node Metastases in Non-Small Cell Lung Cancers. Annals of Surgical Oncology, 2011, 18, 543-550.	0.7	48
749	EGFR and p53 Status of Pulmonary Pleomorphic Carcinoma: Implications for EGFR Tyrosine Kinase Inhibitors Therapy of an Aggressive Lung Malignancy. Annals of Surgical Oncology, 2011, 18, 2952-2960.	0.7	51
750	Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Modern Pathology, 2011, 24, 1348-1359.	2.9	299

#	Article	IF	Citations
752	EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of bronchial epithelium: an immunohistochemical and genetic study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 571-581.	1.4	10
753	The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology, 2011, 137, 687-694.	1.2	34
754	Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2011, 67, 331-338.	1.1	16
755	The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Medical Oncology, 2011, 28, 697-702.	1.2	42
756	Molecular oncology of lung cancer. General Thoracic and Cardiovascular Surgery, 2011, 59, 527-537.	0.4	60
757	The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain. BMC Medical Genetics, 2011, 12, 144.	2.1	41
758	Clinical pharmacogenomic testing of KRAS, BRAF and EGFRmutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer, 2011, 11, 406.	1.1	83
759	Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of earlyâ€stage nonsmall cell lung cancers. Cancer, 2011, 117, 606-617.	2.0	59
760	Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma. Cancer, 2011, 117, 819-825.	2.0	61
761	Activation of the Signal Transducer and Activator of Transcription 3 Pathway Up-Regulates Estrogen Receptor-Î² Expression in Lung Adenocarcinoma Cells. Molecular Endocrinology, 2011, 25, 1145-1158.	3.7	16
762	Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung Cancer. Current Drug Targets, 2011, 12, 922-933.	1.0	25
763	Targeted Therapies for Lung Cancer. Cancer Journal (Sudbury, Mass), 2011, 17, 512-527.	1.0	91
764	EGFRL858R Mutation and Polymorphisms of Genes Related to Estrogen Biosynthesis and Metabolism in Never-Smoking Female Lung Adenocarcinoma Patients. Clinical Cancer Research, 2011, 17, 2149-2158.	3.2	28
765	Clinical Features and Outcome of Patients With Nonâ€“Small-Cell Lung Cancer Harboring BRAF Mutations. Journal of Clinical Oncology, 2011, 29, 3574-3579.	0.8	500
766	Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Therapeutic Advances in Medical Oncology, 2011, 3, 113-125.	1.4	96
767	Long Exposure of Environmental Tobacco Smoke Associated with Activating EGFR Mutations in Never-Smokers with Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2011, 17, 39-45.	3.2	27
768	Tumor Epidermal Growth Factor Receptor Genotype and Depression in Stage IV Nonâ€Small Cell Lung Cancer. Oncologist, 2011, 16, 1299-1306.	1.9	12
769	Soy intake is associated with lower lung cancer risk: results from a meta-analysis of epidemiologic studies. American Journal of Clinical Nutrition, 2011, 94, 1575-1583.	2.2	71

#	Article	IF	Citations
770	Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17761-17766.	3.3	405
771	Emerging Concepts in the Pathology and Molecular Biology of Advanced Nonâ€“Small Cell Lung Cancer. American Journal of Clinical Pathology, 2011, 136, 228-238.	0.4	43
772	Association of Epidermal Growth Factor Receptor Mutations with Metastatic Presentations in Non-Small Cell Lung Cancer. ISRN Oncology, 2011, 2011, 1-6.	2.1	10
773	Clustered Genomic Alterations in Chromosome 7p Dictate Outcomes and Targeted Treatment Responses of Lung Adenocarcinoma WithEGFR-Activating Mutations. Journal of Clinical Oncology, 2011, 29, 3435-3442.	0.8	33
774	Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors. Clinical Cancer Research, 2011, 17, 1131-1139.	3.2	172
775	Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects. Oncologist, 2011, 16, 1006-1020.	1.9	13
776	Genetic and epigenetic changes in lung carcinoma and their clinical implications. Modern Pathology, 2011, 24, 932-943.	2.9	64
777	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology, 2011, 6, 244-285.	0.5	4,127
778	Polymorphisms in inflammatory pathway genes, host factors and lung cancer risk in Chinese female never-smokers. Carcinogenesis, 2011, 32, 522-529.	1.3	66
779	Adenosquamous Carcinoma of the Lung. American Journal of Clinical Pathology, 2011, 135, 783-789.	0.4	82
780	Functional EGFR Germline Polymorphisms May Confer Risk for EGFR Somatic Mutations in Nonâ€“Small Cell Lung Cancer, with a Predominant Effect on Exon 19 Microdeletions. Cancer Research, 2011, 71, 2423-2427.	0.4	44
781	Epidermal Growth Factor Receptor Mutation Status in Stage I Lung Adenocarcinoma with Different Image Patterns. Journal of Thoracic Oncology, 2011, 6, 1066-1072.	0.5	45
782	Role and Relevance of TrkB Mutations and Expression in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2011, 17, 2638-2645.	3.2	54
783	Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations. Journal of Thoracic Oncology, 2011, 6, 1895-1901.	0.5	117
784	Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Nonâ€“Small-Cell Lung Cancer Receiving Sorafenib. Clinical Cancer Research, 2011, 17, 1190-1199.	3.2	67
785	Notch signaling in lung cancer. Expert Review of Anticancer Therapy, 2011, 11, 533-540.	1.1	40
786	Effectiveness of Tyrosine Kinase Inhibitors on â€œUncommonâ€•Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2011, 17, 3812-3821.	3.2	413
787	Molecular Epidemiology of Female Lung Cancer. Cancers, 2011, 3, 1861-1876.	1.7	8

#	Article	IF	Citations
788	Biased Discordance of KRAS Mutation Detection in Archived Colorectal Cancer Specimens Between the ARMS-Scorpion Method and Direct Sequencing. Japanese Journal of Clinical Oncology, 2011, 41, 239-244.	0.6	20
789	The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer. Cancers, 2011, 3, 2667-2678.	1.7	7
790	The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer. Oncologist, 2011, 16, 1498-1507.	1.9	44
791	Epidermal Growth Factor Receptor in Pancreatic Cancer. Cancers, 2011, 3, 1513-1526.	1.7	114
792	Epidermal growth factor receptor mutations in female patients with postoperative recurrent non-small-cell lung cancer. Journal of Cancer Research and Therapeutics, 2012, 8, 373.	0.3	6
793	LKB1, TP16, EGFR, and KRAS somatic mutations in lung adenocarcinomas from a Chiba Prefecture, Japan cohort. Drug Discoveries and Therapeutics, 2012, , .	0.6	5
794	Ancillary Testing in Lung Cancer Diagnosis. Pulmonary Medicine, 2012, 2012, 1-8.	0.5	14
795	Personalized Targeted Therapy for Lung Cancer. International Journal of Molecular Sciences, 2012, 13, 11471-11496.	1.8	61
796	Lung cancer in women. Lung Cancer: Targets and Therapy, 2012, 3, 79.	1.3	41
797	Sex and SUVmax: Sex-Dependent Prognostication in Early Nonâ€“Small Cell Lung Cancer. Journal of Nuclear Medicine, 2012, 53, 1676-1685.	2.8	10
798	Targeted Therapy for Brain Metastases. Advances in Pharmacology, 2012, 65, 109-142.	1.2	11
799	Association between a Genome-Wide Association Study-Identified Locus and the Risk of Lung Cancer in Japanese Population. Journal of Thoracic Oncology, 2012, 7, 790-798.	0.5	37
800	Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1315-1326.	0.5	175
801	Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Annals of Oncology, 2012, 23, 2931-2936.	0.6	35
802	Prognostic value ofTP53,KRASandEGFRmutations in nonsmall cell lung cancer: the EUELC cohort. European Respiratory Journal, 2012, 40, 177-184.	3.1	92
803	Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung. Journal of Oncology Practice, 2012, 8, 267-274.	2.5	75
804	The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1. Journal of Clinical Pathology, 2012, 65, 1-7.	1.0	34
805	ROS1 Rearrangements in Lung Cancer: A New Genomic Subset of Lung Adenocarcinoma. Journal of Clinical Oncology, 2012, 30, 878-879.	0.8	42

#	Article	IF	Citations
806	Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers. Clinical Cancer Research, 2012, 18, 6169-6177.	3.2	503
807	Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?. Genes and Cancer, 2012, 3, 467-480.	0.6	116
809	Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 2012, 12, 237-246.	0.8	12
810	Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. Future Oncology, 2012, 8, 451-462.	1.1	48
811	Targeting the PI3K pathway for cancer therapy. Future Medicinal Chemistry, 2012, 4, 1153-1169.	1.1	53
812	Irreversible EGFR inhibitors in advanced non-small-cell lung carcinoma: rationale and clinical evidence. Clinical Investigation, 2012, 2, 317-325.	0.0	5
813	HER2 As Therapeutic Target for Overcoming ATP-Binding Cassette Transporterâ€“Mediated Chemoresistance in Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2012, 11, 830-841.	1.9	26
814	Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. OncoTargets and Therapy, 2012, 5, 439.	1.0	35
815	The Role of KRAS Mutational Analysis to Determine the Site of Origin of Metastatic Carcinoma to the Lung: A Case Report. Case Reports in Pathology, 2012, 2012, 1-4.	0.2	1
816	Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer. Biochemistry Research International, 2012, 2012, 1-18.	1.5	42
817	Noninferiority Trials in Second-Line Treatments of Nonsmall Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 593-599.	0.6	4
818	Direct serum and tissue assay for EGFR mutation in non-small cell lung cancer by high-resolution melting analysis. Oncology Reports, 2012, 28, 1815-1821.	1.2	40
819	Development of a rapid and practical mutation screening assay for human lung adenocarcinoma. International Journal of Oncology, 2012, 40, 1900-6.	1.4	1
820	Personalized medicine for lung cancer. Lung Cancer Management, 2012, 1, 83-86.	1.5	2
822	Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. Cancer Biomarkers, 2012, 10, 63-69.	0.8	41
823	Demographic profile of lung cancer patients at the Universitas Academic Hospital Bronchoscopy Unit in Bloemfontein. The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa, 2012, 27, 130-132.	0.2	0
824	Systemic Therapies for Pancreatic Cancer - The Role of Pharmacogenetics. Current Drug Targets, 2012, 13, 811-828.	1.0	15
825	High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions, and Clinical Features. Journal of Thoracic Oncology, 2012, 7, 323-330.	0.5	143

#	Article	IF	Citations
826	A 66-Year-Old Woman With Newly Diagnosed Oligometastatic Nonâ€“Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 297-301.	2.3	1
827	Prognostic Models to Predict Survival in Nonâ€“Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab. Journal of Thoracic Oncology, 2012, 7, 1361-1368.	0.5	57
828	Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy. International Journal of Oncology, 2012, 40, 1763-9.	1.4	9
829	Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations. Experimental and Therapeutic Medicine, 2012, 3, 207-213.	0.8	19
830	High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and Mutation. Journal of Thoracic Oncology, 2012, 7, 833-840.	0.5	123
831	Mutation status of epidermal growth factor receptor and clinical features of patients with combined small cell lung cancer who received surgical treatment. Oncology Letters, 2012, 3, 1288-1292.	0.8	18
832	Expression and mutation of the c-kit gene and correlation with prognosis of small cell lung cancer. Oncology Letters, 2012, 4, 89-93.	0.8	33
833	First- and second-line treatment of non-small-cell lung cancer patients withEGFRmutation-positive tumors. Lung Cancer Management, 2012, 1, 201-217.	1.5	0
834	Gene fusions in non-small-cell lung cancer. Lung Cancer Management, 2012, 1, 283-292.	1.5	1
835	Association between Tumor Epidermal Growth Factor Receptor Mutation and Pulmonary Tuberculosis in Patients with Adenocarcinoma of the Lungs. Journal of Thoracic Oncology, 2012, 7, 299-305.	0.5	52
836	Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma. Journal of Thoracic Oncology, 2012, 7, 993-1000.	0.5	32
837	Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Nonâ€“Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Projectâ€”Part 2). Journal of Thoracic Oncology, 2012, 7, 1490-1502.	0.5	69
838	Gefitinib for a Poor Performance Status Patient with Squamous Cell Carcinoma of the Lung Harboring EGFR Mutation. Internal Medicine, 2012, 51, 659-661.	0.3	9
839	Morphologic and Molecular Analysis of 39 Spontaneous Feline Pulmonary Carcinomas. Veterinary Pathology, 2012, 49, 971-978.	0.8	44
840	Analysis of EGFR, KRAS and P53 mutations in lung cancer using cells in the curette lavage fluid obtained by bronchoscopy. Lung Cancer, 2012, 78, 201-206.	0.9	32
841	Impact of age on epidermal growth factor receptor mutation in lung cancer. Lung Cancer, 2012, 78, 207-211.	0.9	35
842	RUNX3 Downregulation in Human Lung Adenocarcinoma is Independent of p53, EGFR or KRAS Status. Pathology and Oncology Research, 2012, 18, 783-792.	0.9	12
843	Advances in Treatment of Lung Cancer With Targeted Therapy. Archives of Pathology and Laboratory Medicine, 2012, 136, 504-509.	1.2	75

#	Article	IF	Citations
844	Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer, 2012, 77, 319-325.	0.9	102
845	Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma. British Journal of Cancer, 2012, 107, 1745-1753.	2.9	23
846	Frequency of Driver Mutations in Lung Adenocarcinoma from Female Never-Smokers Varies with Histologic Subtypes and Age at Diagnosis. Clinical Cancer Research, 2012, 18, 1947-1953.	3.2	161
847	Utility of small biopsies for diagnosis of lung nodules: doing more with less. Modern Pathology, 2012, 25, S43-S57.	2.9	29
848	Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Investigational New Drugs, 2012, 30, 2352-2363.	1.2	62
849	EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncology, The, 2012, 13, e23-e31.	5.1	505
850	Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncology, The, 2012, 13, 300-308.	5.1	360
851	Direct Comparison of 3 PCR Methods in Detecting EGFR Mutations in Patients with Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 369-374.	1.1	10
852	EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma. Cancer Cell, 2012, 22, 318-330.	7.7	339
853	Molecular Pathology of Nonâ€“Small Cell Lung Cancer. Surgical Pathology Clinics, 2012, 5, 903-918.	0.7	3
854	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2012, 58, 263-268.	0.3	6
855	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira (English Edition), 2012, 58, 263-268.	0.1	0
856	Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung Adenocarcinomas. Annals of Surgical Oncology, 2012, 19, 347-354.	0.7	49
857	Analysis of Receptor Tyrosine Kinase ROS1-Positive Tumors in Nonâ€“Small Cell Lung Cancer: Identification of a FIG-ROS1 Fusion. Clinical Cancer Research, 2012, 18, 4449-4457.	3.2	266
858	Diagnostic Criteria for Invasive Pulmonary Aspergillosis in Critically Ill Patients. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 8-10.	2.5	21
859	Hotspot oncomutations: implications for personalized cancer treatment. Expert Review of Molecular Diagnostics, 2012, 12, 603-620.	1.5	13
860	EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma. Clinical Cancer Research, 2012, 18, 1790-1797.	3.2	134
861	Elevated Expression of Fn14 in Non-Small Cell Lung Cancer Correlates with Activated EGFR and Promotes Tumor Cell Migration and Invasion. American Journal of Pathology, 2012, 181, 111-120.	1.9	52

#	Article	IF	Citations
862	Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treatment Reviews, 2012, 38, 173-184.	3.4	31
863	EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects. Cancer Treatment Reviews, 2012, 38, 416-430.	3.4	114
864	Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib. World Journal of Surgical Oncology, 2012, 10, 235.	0.8	16
865	Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer. Diagnostic Pathology, 2012, 7, 146.	0.9	16
866	Molecular Pathology of Nonâ€“Small Cell Lung Cancer. American Journal of Clinical Pathology, 2012, 138, 332-346.	0.4	115
867	Lung Cancer: New Therapeutic Targets, New Definitions. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 7-8.	2.5	3
868	Targeting the EGFR signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets, 2012, 16, 15-31.	1.5	688
869	Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases. Pathology International, 2012, 62, 785-791.	0.6	81
870	Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opinion on Therapeutic Targets, 2012, 16, 771-781.	1.5	28
871	Genomic biomarkers for patient selection and stratification: the cancer paradigm. Bioanalysis, 2012, 4, 2499-2511.	0.6	8
872	Loss of TIMP-3 Promotes Tumor Invasion via Elevated IL-6 Production and Predicts Poor Survival and Relapse in HPV-Infected Nonâ€“Small Cell Lung Cancer. American Journal of Pathology, 2012, 181, 1796-1806.	1.9	49
873	Ethnic variation in response to EGFR inhibitors. Drug Discovery Today: Therapeutic Strategies, 2012, 9, e61-e66.	0.5	1
874	Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras. Lung Cancer, 2012, 75, 313-320.	0.9	73
875	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer, 2012, 76, 1-18.	0.9	206
876	Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer. Lung Cancer, 2012, 76, 235-241.	0.9	29
877	Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer. Lung Cancer, 2012, 77, 246-251.	0.9	31
878	Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study. Lung Cancer, 2012, 77, 339-345.	0.9	34
879	EGFR and myosin II inhibitors cooperate to suppress EGFRâ€T790Mâ€mutant NSCLC cells. Molecular Oncology, 2012, 6, 299-310.	2.1	12

#	Article	IF	Citations
880	Predictive markers in early research and companion diagnostic developments in oncology. New Biotechnology, 2012, 29, 651-655.	2.4	11
881	Do companion diagnostics make economic sense for drug developers?. New Biotechnology, 2012, 29, 695-708.	2.4	11
882	Biomarkers That Currently Affect Clinical Practice: EGFR, ALK, MET, KRAS. Current Oncology, 2012, 19, 33-44.	0.9	46
883	Targeted therapies: how personal should we go?. Nature Reviews Clinical Oncology, 2012, 9, 87-97.	12.5	94
884	Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib. Medical Oncology, 2012, 29, 1614-1621.	1.2	18
885	Molecular Diagnosis of Lung Cancer. Molecular Pathology Library, 2012, , 87-97.	0.1	0
886	Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation. Drugs, 2012, 72, 3-10.	4.9	6
887	The Peptide Nucleic Acid-Locked Nucleic Acid Polymerase Chain Reaction Clamp-Based Test for Epidermal Growth Factor Receptor Mutations in Bronchoscopic Cytological Specimens of Non-Small Cell Lung Cancer. Oncology, 2012, 82, 341-346.	0.9	11
889	Cancer Epigenetics. Methods in Molecular Biology, 2012, , .	0.4	5
890	Molecular Pathology of Lung Cancer. Molecular Pathology Library, 2012, , .	0.1	6
891	Molecular Basis for the Current Lung Cancer Classification. Molecular Pathology Library, 2012, , 75-85.	0.1	0
892	Molecular Pathogenesis of Non-Small Cell Lung Carcinomas. Journal of Lung Cancer, 2012, 11, 12.	0.2	4
893	Non-small cell lung cancer: the era of targeted therapy. Lung Cancer: Targets and Therapy, 2012, 3, 31.	1.3	8
894	Epidermal Growth Factor Receptor Mutation in Small Cell Lung Cancer Patients Detected by Mutant-Enriched Liquidchip Technology from Plasma. Annals of Oncology, 2012, 23, ix495.	0.6	0
895	The Role of Mutation Status of the Epidermal Growth Factor Receptor Gene In Advanced Nonâ€“Small Cell Lung Cancer. Medicina (Lithuania), 2012, 48, 25.	0.8	2
896	Skin Rash as Useful Marker of Erlotinib Efficacy in NSCLC and Its Impact on Clinical Practice. Neoplasma, 2012, 60, 26-32.	0.7	20
897	EGFRPolymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated withEGFR-TKI. Yonsei Medical Journal, 2012, 53, 1128.	0.9	23
898	Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer. Wspolczesna Onkologia, 2012, 5, 401-406.	0.7	5

#	Article	IF	Citations
899	Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population. Clinics, 2012, 67, 845-847.	0.6	17
900	Screening of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Using a PCR-Based Enzymatic Digestion Method. Journal of Lung Cancer, 2012, 11, 77.	0.2	0
901	Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Yonsei Medical Journal, 2012, 53, 931.	0.9	17
902	Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer Patients Who Received Surgical Resection in China. Neoplasma, 2012, 59, 100-104.	0.7	25
903	Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial. Journal of Clinical Oncology, 2012, 30, 2063-2069.	0.8	225
904	Molecular pathology of lung cancer: key to personalized medicine. Modern Pathology, 2012, 25, 347-369.	2.9	215
905	p40 (Î”Np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Modern Pathology, 2012, 25, 405-415.	2.9	343
906	Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2127-33.	3.3	410
907	Epidermal growth factor receptorâ€tyrosine kinase inhibitor therapy is effective as firstâ€line treatment of advanced nonâ€smallâ€cell lung cancer with mutated EGFR: A metaâ€analysis from six phase III randomized controlled trials. International Journal of Cancer, 2012, 131, E822-9.	2.3	119
908	EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cellular Oncology (Dordrecht), 2012, 35, 189-196.	2.1	104
909	The Biology and Clinical Features of Nonâ€“small Cell Lung Cancers with EML4-ALK Translocation. Current Oncology Reports, 2012, 14, 105-110.	1.8	35
910	Pulmonary adenocarcinoma: A renewed entity in 2011. Respirology, 2012, 17, 50-65.	1.3	65
911	Smoking History as a Predictive Factor of Treatment Response in Advanced Nonâ€“Small-Cell Lung Cancer: A Systematic Review. Clinical Lung Cancer, 2012, 13, 239-251.	1.1	27
912	The Value of Biomarkers in Patients With Sarcomatoid Carcinoma of the Lung: Molecular Analysis of 33 Cases. Clinical Lung Cancer, 2012, 13, 288-296.	1.1	45
913	Routine EGFR and KRAS Mutation analysis using COLD-PCR in non-small cell lung cancer. International Journal of Clinical Practice, 2012, 66, 748-752.	0.8	19
914	Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 267-274.	0.7	3
915	The positive impact of cytological specimens for EGFR mutation testing in nonâ€small cell lung cancer: a single South East Asian laboratoryâ€™s analysis of 670 cases. Cytopathology, 2012, 23, 229-236.	0.4	48
916	RET finger protein expression is associated with prognosis in lung cancer with epidermal growth factor receptor mutations. Pathology International, 2012, 62, 324-330.	0.6	25

#	Article	IF	Citations
917	Biomarkers and transcriptome profiling of lung cancer. Respirology, 2012, 17, 620-626.	1.3	20
918	EGFR mutations in nonâ€smallâ€cell lung cancer among smokers and nonâ€smokers: A metaâ€analysis. Environmental and Molecular Mutagenesis, 2012, 53, 78-82.	0.9	40
919	Distinct clinical features and outcomes in neverâ€smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer, 2012, 118, 729-739.	2.0	132
920	Authors' reply to Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. International Journal of Cancer, 2012, 130, 2217-2218.	2.3	2
921	Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. International Journal of Cancer, 2012, 130, 2215-2217.	2.3	7
922	Mitochondrial DNA mutations in respiratory complexâ€I in neverâ€smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation. Journal of Cellular Physiology, 2012, 227, 2451-2460.	2.0	74
923	Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 289-299.	1.1	50
924	Second-line epidermal growth factor receptor inhibitors followed by third-line pemetrexed or the reverse sequence: a retrospective analysis of 83 Chinese patients with advanced lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2012, 138, 285-291.	1.2	1
925	The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. Human Genetics, 2012, 131, 365-372.	1.8	45
926	EGFR exon 19 inâ€frame deletion and polymorphisms of DNA repair genes in neverâ€smoking female lung adenocarcinoma patients. International Journal of Cancer, 2013, 132, 449-458.	2.3	12
927	FrequentEGFRmutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis. European Respiratory Journal, 2013, 41, 417-424.	3.1	41
928	Advanced non-squamous non-small-cell lung cancer: who and when should be biologically screened today? Tomorrow?. Current Respiratory Care Reports, 2013, 2, 17-21.	0.6	1
930	Determinants of Survival in Advanced Nonâ€“Small-Cell Lung Cancer in the Era ofÂTargeted Therapies. Clinical Lung Cancer, 2013, 14, 581-591.	1.1	39
931	Prognostic impact of serum CYFRA 21â€“1 in patients with advanced lung adenocarcinoma: a retrospective study. BMC Cancer, 2013, 13, 354.	1.1	42
932	Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis. BMC Cancer, 2013, 13, 39.	1.1	20
933	Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes. BMC Cancer, 2013, 13, 8.	1.1	4
934	Journey of the ALK-inhibitor CH5424802 to phase II clinical trial. Archives of Pharmacal Research, 2013, 36, 1051-1054.	2.7	17
936	Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung. Cancer Chemotherapy and Pharmacology, 2013, 71, 859-865.	1.1	7

#	Article	IF	Citations
937	Erlotinib in patients with advanced lung squamous cell carcinoma. Cancer Chemotherapy and Pharmacology, 2013, 71, 203-208.	1.1	7
938	Skin rash by gefitinib is a sign of favorable outcomes for patients of advanced lung adenocarcinoma in Japanese patients. SpringerPlus, 2013, 2, 22.	1.2	7
939	First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments. Drugs, 2013, 73, 357-369.	4.9	12
940	Molecular sputum analysis for the diagnosis of lung cancer. British Journal of Cancer, 2013, 109, 530-537.	2.9	92
941	EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. British Journal of Cancer, 2013, 109, 1821-1828.	2.9	118
942	Molecular Surgical Pathology. , 2013, , .		23
943	Clinicopathological characteristics of <scp>EGFR</scp> mutated adenosquamous carcinoma of the lung. Pathology International, 2013, 63, 77-84.	0.6	22
944	Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma. Lung Cancer, 2013, 80, 159-164.	0.9	28
945	Genetically engineered mouse models of pancreatic adenocarcinoma. Molecular Oncology, 2013, 7, 232-247.	2.1	140
946	Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treatment Reviews, 2013, 39, 839-850.	3.4	100
947	Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. Human Pathology, 2013, 44, 2636-2642.	1.1	41
948	Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives. Expert Review of Anticancer Therapy, 2013, 13, 1207-1218.	1.1	13
949	Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer, 2013, 82, 179-189.	0.9	262
950	Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. Science Translational Medicine, 2013, 5, 216ra177.	5.8	438
951	Next-generation sequencing for lung cancer. Future Oncology, 2013, 9, 1323-1336.	1.1	38
952	Driver mutations among never smoking female lung cancer tissues in China identify unique EGFR and KRAS mutation pattern associated with household coal burning. Respiratory Medicine, 2013, 107, 1755-1762.	1.3	30
953	Role of the Pulmonologist in Ordering Post-Procedure Molecular Markers in Nonâ€“Small-Cell Lung Cancer: Implications for Personalized Medicine. Clinical Lung Cancer, 2013, 14, 609-626.	1.1	15
954	Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma. Critical Reviews in Oncology/Hematology, 2013, 88, 477-493.	2.0	71

#	Article	IF	Citations
955	HER2 and lung cancer. Expert Review of Anticancer Therapy, 2013, 13, 1219-1228.	1.1	63
956	KRAS Mutations in Lung Cancer. Clinical Lung Cancer, 2013, 14, 205-214.	1.1	182
957	ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 4273-4281.	3.2	521
958	Detecting EGFR alterations in clinical specimensâ€”pitfalls and necessities. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 755-764.	1.4	7
959	Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncology, The, 2013, 14, 953-961.	5.1	389
961	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitorâ€“Resistant Disease. Journal of Clinical Oncology, 2013, 31, 1070-1080.	0.8	425
962	EGFRmutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activatingEGFRmutations in lung adenocarcinoma. Journal of Clinical Pathology, 2013, 66, 744-748.	1.0	19
963	EGFR mutational status in penile cancer. Expert Opinion on Therapeutic Targets, 2013, 17, 501-505.	1.5	14
964	LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both. Journal of Clinical Oncology, 2013, 31, 3335-3341.	0.8	303
965	Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops. Oncogene, 2013, 32, 2403-2411.	2.6	15
966	EGFR mutation status in brain metastases of non-small cell lung carcinoma. Journal of Neuro-Oncology, 2013, 111, 1-10.	1.4	62
967	New Targetable Oncogenes in Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 1097-1104.	0.8	280
968	KRAS Mutation: Should We Test for It, and Does It Matter?. Journal of Clinical Oncology, 2013, 31, 1112-1121.	0.8	219
969	Clinical testing for molecular targets for personalized treatment in lung cancer. Respirology, 2013, 18, 233-237.	1.3	4
970	EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. Molecular Cancer Therapeutics, 2013, 12, 220-229.	1.9	367
971	Molecular profile of lung cancer in never smokers. European Journal of Cancer, Supplement, 2013, 11, 248-253.	2.2	30
972	Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. Cancer Genetics, 2013, 206, 73-80.	0.2	39
973	Epidermal Growth Factor Receptor Exon 20 Mutation Increased inPost-Chemotherapy Patients with Non-Small Cell Lung Cancer Detected with Patients' Blood Samples. Translational Oncology, 2013, 6, 504-510.	1.7	9

#	Article	IF	Citations
974	The Importance of Molecular Profiling in Predicting Response to Epidermal Growth Factor Receptor Family Inhibitors in Nonâ€“Small-Cell Lung Cancer: Focus on Clinical Trial Results. Clinical Lung Cancer, 2013, 14, 311-321.	1.1	11
975	Impact of family history of cancer on the incidence of mutation in epidermal growth factor receptor gene in non-small cell lung cancer patients. Lung Cancer, 2013, 81, 162-166.	0.9	26
976	Distinct features of distant metastasis and lymph node stage in lung adenocarcinoma patients with epidermal growth factor receptor gene mutations. Respiratory Investigation, 2013, 51, 153-157.	0.9	26
977	Medical treatment of advanced non-small cell lung cancer in elderly patients: A review of the role of chemotherapy and targeted agents. Journal of Geriatric Oncology, 2013, 4, 282-290.	0.5	41
978	Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance. Lung Cancer, 2013, 80, 235-241.	0.9	96
979	Comparison Study of the Performance of the QIAGEN EGFR RGQ and EGFR Pyro Assays for Mutation Analysis in Nonâ€“Small Cell Lung Cancer. American Journal of Clinical Pathology, 2013, 140, 7-19.	0.4	12
980	Prognostic factors after complete resection of pN2 nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 788-795.	0.4	34
981	Estudo da mutaÃ§Ã£o do recetor do fator de crescimento epidÃ©rmico, durante 5 anos, numa populaÃ§Ã£o de doentes com cancro do pulmÃ£o de nÃ£o pequenas cÃ©lulas. Revista Portuguesa De Pneumologia, 2013, 19, 7-12.	0.7	17
982	Suitability of Computed Tomography-Guided Biopsy Specimens for Subtyping and Genotyping of Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2013, 14, 719-725.	1.1	19
983	Epidermal Growth Factor Recetor mutation study for 5 years, in a population of patients with non-small cell lung cancer. Revista Portuguesa De Pneumologia, 2013, 19, 7-12.	0.7	16
985	p14ARF inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway. Oncogene, 2013, 32, 1050-1058.	2.6	13
986	Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treatment Reviews, 2013, 39, 252-260.	3.4	68
987	Detection of epidermal growth factor receptor mutations in formalin fixed paraffin embedded biopsies in Malaysian non-small cell lung cancer patients. Journal of Biomedical Science, 2013, 20, 22.	2.6	7
988	Identification of driver mutations in lung cancer: first step in personalized cancer. Targeted Oncology, 2013, 8, 3-14.	1.7	26
989	Erlotinib in the first-line treatment of non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2013, 13, 523-533.	1.1	17
990	The potential role of new targeted therapies in the treatment of advanced non-small-cell lung cancer. Clinical Investigation, 2013, 3, 369-383.	0.0	3
991	Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies. Pharmacogenomics and Personalized Medicine, 2013, 6, 25.	0.4	30
992	Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma. Journal of Surgical Research, 2013, 185, 217-224.	0.8	35

#	Article	IF	Citations
993	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. Journal of Molecular Diagnostics, 2013, 15, 415-453.	1.2	397
994	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Archives of Pathology and Laboratory Medicine, 2013, 137, 828-860.	1.2	415
995	Molecular and Genetic Aspects of Lung Cancer. Biotechnology and Biotechnological Equipment, 2013, 27, 4051-4060.	0.5	3
996	Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Lung Cancer, 2013, 82, 31-37.	0.9	48
997	Activating Germline R776H Mutation in the Epidermal Growth Factor Receptor Associated With Lung Cancer With Squamous Differentiation. Journal of Clinical Oncology, 2013, 31, e161-e164.	0.8	44
998	Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma. Head and Neck, 2013, 35, 1323-1330.	0.9	23
999	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology, 2013, 8, 823-859.	0.5	792
1000	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer. Current Pharmaceutical Design, 2013, 19, 818-832.	0.9	24
1001	Radiologic Implications of the 2011 Classification of Adenocarcinoma of the Lung. Radiology, 2013, 266, 62-71.	3.6	201
1002	Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers. Oncology Letters, 2013, 6, 1207-1212.	0.8	23
1003	Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. Molecular and Clinical Oncology, 2013, 1, 575-581.	0.4	42
1004	Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic Subtypes. Radiology, 2013, 268, 254-264.	3.6	156
1005	Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study. Journal of Carcinogenesis, 2013, 12, 12.	2.5	35
1006	Gefitinib, Fluorouracil, Oxaliplatin, and Leucovorin (IFOX) Regimen for Colorectal Cancer. Hospital Pharmacy, 2013, 48, 905-911.	0.4	1
1007	Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients. Indian Journal of Cancer, 2013, 50, 107.	0.2	23
1008	Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Annals of Oncology, 2013, 24, 2371-2376.	0.6	510
1009	Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review. Onkologie, 2013, 36, 5-5.	1.1	77
1010	The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Nonâ€“Small Cell Lung Cancer Growth. Molecular Cancer Therapeutics, 2013, 12, 890-900.	1.9	67

#	Article	IF	Citations
1011	Molecular determinations ofEGFRandEML4-ALKon a single slide of NSCLC tissue. Journal of Clinical Pathology, 2013, 66, 708-710.	1.0	11
1012	A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 5523-5532.	3.2	82
1013	The Effectiveness of Erlotinib Against Brain Metastases in Non-Small Cell Lung Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 110-115.	0.6	32
1014	Efficacy of tyrosine kinase inhibitors in routine clinical practice: Epidermal growth factor mutations and their implications. Journal of Cancer Research and Therapeutics, 2013, 9, 261.	0.3	5
1015	Association of epidermal growth factor receptor mutations with human papillomavirus 16/18 E6 oncoprotein expression in nonâ€“small cell lung cancer. Cancer, 2013, 119, 3367-3376.	2.0	17
1016	<scp>PBK</scp>/<scp>TOPK</scp> expression in nonâ€smallâ€cell lung cancer: its correlation and prognostic significance with <scp>K</scp>i67 and p53 expression. Histopathology, 2013, 63, 696-703.	1.6	62
1017	Sensitivity and kinase activity of epidermal growth factor receptor (<scp>EGFR</scp>) exon 19 and others to <scp>EGFR</scp>â€tyrosine kinase inhibitors. Cancer Science, 2013, 104, 584-589.	1.7	51
1018	Mechanisms of resistance to EGFR targeted therapies. Cancer Biology and Therapy, 2013, 14, 304-314.	1.5	56
1019	Rare mutations in non-small-cell lung cancer. Future Oncology, 2013, 9, 699-711.	1.1	23
1020	Efficacy of thirdâ€generation chemotherapeutic agents combined with cisplatin or carboplatin in 3100 <scp>C</scp>hinese patients with advanced nonâ€smallâ€cell lung cancer. Thoracic Cancer, 2013, 4, 117-122.	0.8	2
1021	Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Nonâ€“Small Cell Lung Cancer. Science Translational Medicine, 2013, 5, 171ra18.	5.8	63
1022	Immunohistochemical staining with EGFR mutation-specific antibodies: high specificity as a diagnostic marker for lung adenocarcinoma. Modern Pathology, 2013, 26, 1197-1203.	2.9	22
1023	Integration of targeted therapy in the management of locally advanced, unresectable non-small-cell lung cancer. Lung Cancer Management, 2013, 2, 75-85.	1.5	0
1024	Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Oncology Reports, 2013, 30, 2311-2315.	1.2	20
1025	Frequency and Type of Epidermal Growth Factor Receptor Mutations in Moroccan Patients with Lung Adenocarcinoma. Journal of Thoracic Oncology, 2013, 8, 1212-1214.	0.5	37
1026	CDKN2A/p16 Inactivation Mechanisms and Their Relationship to Smoke Exposure and Molecular Features in Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 1378-1388.	0.5	71
1027	Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions. Journal of Thoracic Oncology, 2013, 8, 179-184.	0.5	269
1028	Ethnic differences in non-small-cell lung cancer treatment: the Asian perspective. Lung Cancer Management, 2013, 2, 309-315.	1.5	2

#	Article	IF	Citations
1029	Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma in Malaysian Patients. Journal of Thoracic Oncology, 2013, 8, 766-772.	0.5	35
1030	Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients. Oncology Letters, 2013, 5, 271-276.	0.8	31
1031	Cytokeratin 19 Fragment Predicts the Efficacy of Epidermal Growth Factor Receptorâ€“Tyrosine Kinase Inhibitor in Nonâ€“Small-Cell Lung Cancer Harboring EGFR Mutation. Journal of Thoracic Oncology, 2013, 8, 892-898.	0.5	44
1032	Detection of EGFR gene mutations in non-small cell lung cancer: Lessons from a single-institution routine analysis of 1,403 tumor samples. International Journal of Oncology, 2013, 43, 1045-1051.	1.4	32
1033	Gefitinib: re-emerging from the shadows. Lung Cancer Management, 2013, 2, 423-437.	1.5	0
1034	Association of epidermal growth factor receptor and K-Ras mutations with smoking history in non-small cell lung cancer patients. Experimental and Therapeutic Medicine, 2013, 5, 495-498.	0.8	13
1035	ROS1-Rearranged Lung Cancer. American Journal of Surgical Pathology, 2013, 37, 554-562.	2.1	155
1036	How Sensitive Are Epidermal Growth Factor Receptorâ€“Tyrosine Kinase Inhibitors for Squamous Cell Carcinoma of the Lung Harboring EGFR Geneâ€“Sensitive Mutations?. Journal of Thoracic Oncology, 2013, 8, 89-95.	0.5	68
1037	-216G/T (rs712829), a functional variant of the EGFR promoter, is associated with the pleural metastasis of lung adenocarcinoma. Oncology Letters, 2013, 6, 693-698.	0.8	15
1038	Sex Disparities in the Association of Lung Adenocarcinoma with Colorectal Cancer. Journal of Cancer, 2013, 4, 691-696.	1.2	1
1039	A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Nonâ€“Small-Cell Lung Cancer. PLoS ONE, 2013, 8, e55917.	1.1	46
1040	Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity. PLoS ONE, 2013, 8, e76164.	1.1	94
1041	An Integrated Inspection of the Somatic Mutations in a Lung Squamous Cell Carcinoma Using Next-Generation Sequencing. PLoS ONE, 2013, 8, e78823.	1.1	5
1042	Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma. PLoS ONE, 2013, 8, e81975.	1.1	18
1043	Expression of the Mismatch Repair Gene hMLH1 Is Enhanced in Non-Small Cell Lung Cancer with EGFR Mutations. PLoS ONE, 2013, 8, e78500.	1.1	15
1045	Adenocarcinoma of the lung. , 2013, , 1043-1092.		1
1046	Lung Cancer in Women. Southern Medical Journal, 2013, 106, 582-587.	0.3	6
1047	New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Management and Research, 2014, 6, 63.	0.9	68

#	Article	IF	Citations
1048	Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Brazilian Journal of Medical and Biological Research, 2014, 47, 929-939.	0.7	94
1049	Opposing Functions of Akt Isoforms in Lung Tumor Initiation and Progression. PLoS ONE, 2014, 9, e94595.	1.1	58
1050	A Laboratory Prognostic Index Model for Patients with Advanced Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e114471.	1.1	41
1051	EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Design, Development and Therapy, 2014, 8, 1595.	2.0	36
1052	In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies. Current Medicinal Chemistry, 2014, 21, 1595-1606.	1.2	52
1053	Chronic Nicotine Exposure Mediates Resistance to Egfr-Tki in Egfr-Mutated Lung Cancer Via Egfr Signal. Annals of Oncology, 2014, 25, v73.	0.6	0
1054	Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors. Investigational New Drugs, 2014, 32, 1311-1315.	1.2	28
1055	Improving access to lung cancer treatment in northern Canada: the role of oral molecularly targeted agents. Cmaj, 2014, 186, 485-486.	0.9	0
1056	Somatic mutations of the HER2 in metastatic breast cancer. Tumor Biology, 2014, 35, 11851-11854.	0.8	13
1057	Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 1199-1206.	1.1	14
1058	TD-19, an Erlotinib Derivative, Induces Epidermal Growth Factor Receptor Wild-Type Nonsmall-Cell Lung Cancer Apoptosis through CIP2A-Mediated Pathway. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 352-358.	1.3	27
1059	Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer. British Journal of Cancer, 2014, 111, 2203-2204.	2.9	37
1060	Relationship of Thyroid Transcription Factor 1 to EGFR Status in Non-Small-Cell Lung Cancer. Current Oncology, 2014, 21, 305-308.	0.9	8
1061	Significance of the progesterone receptor and epidermal growth factor receptor, but not the estrogen receptor, in chemically induced lung carcinogenesis in female A/J mice. Oncology Letters, 2014, 8, 2379-2386.	0.8	7
1062	Protein expression, gene amplification, epidermal growth factor receptor mutations and lung carcinoma. Vojnosanitetski Pregled, 2014, 71, 679-684.	0.1	1
1063	Drug Resistance to Molecular Targeted Therapy and Its Consequences for Treatment Decisions in Non-Small-Cell Lung Cancer. Frontiers in Oncology, 2014, 4, 190.	1.3	50
1064	Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Frontiers in Oncology, 2014, 4, 204.	1.3	137
1065	First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era. Future Oncology, 2014, 10, 1081-1093.	1.1	5

#	Article	IF	Citations
1066	Identification of Recurrent FGFR3â€“TACC3 Fusion Oncogenes from Lung Adenocarcinoma. Clinical Cancer Research, 2014, 20, 6551-6558.	3.2	85
1067	Echinoderm microtubuleâ€associated proteinâ€like 4â€anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in <scp>C</scp>hinese patients with lung adenocarcinoma. Thoracic Cancer, 2014, 5, 411-416.	0.8	7
1068	Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer. Annals of Oncology, 2014, 25, 1578-1584.	0.6	10
1069	Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. Expert Opinion on Pharmacotherapy, 2014, 15, 2693-2708.	0.9	20
1070	Imaging EGFR and HER2 by PET and SPECT: A Review. Medicinal Research Reviews, 2014, 34, 596-643.	5.0	55
1071	Patients harboring epidermal growth factor receptor (<scp>EGFR)</scp> double mutations had a lower objective response rate than those with a single mutation in nonâ€small cell lung cancer when treated with <scp>EGFR</scp>â€tyrosine kinase inhibitors. Thoracic Cancer, 2014, 5, 126-132.	0.8	21
1072	Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: Integrating with lung specific GPA score. Lung Cancer, 2014, 86, 363-368.	0.9	17
1073	Clinicopathological and prognostic significances of <scp>EGFR</scp>, <scp>KRAS</scp> and <scp>BRAF</scp> mutations in biliary tract carcinomas in <scp>T</scp>aiwan. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1119-1125.	1.4	28
1074	Molecular alterations in nonâ€smallâ€cell lung cancer: Perspective for targeted therapy and specimen management for the bronchoscopist. Respirology, 2014, 19, 1117-1125.	1.3	15
1075	Molecular alterations in nonâ€“small cell lung carcinomas of the young. Human Pathology, 2014, 45, 2379-2387.	1.1	33
1076	Resection for subcentimeter nonâ€small cell lung cancer: Outcomes for a Chinese population with 70% adenocarcinoma. Journal of Surgical Oncology, 2014, 110, 225-226.	0.8	3
1077	Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with nonâ€smallâ€cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage. Journal of Surgical Oncology, 2014, 110, 245-251.	0.8	32
1078	The evolving genomic classification of lung cancer. Journal of Pathology, 2014, 232, 121-133.	2.1	87
1079	Human papillomavirus infections as a marker to predict overall survival in lung adenocarcinoma. International Journal of Cancer, 2014, 134, 65-71.	2.3	23
1080	Pooled analysis of clinical outcome for <scp>EGFR TKI</scp>â€treated patients with <scp>EGFR</scp> mutationâ€positive <scp>NSCLC</scp>. Journal of Cellular and Molecular Medicine, 2014, 18, 1519-1539.	1.6	33
1081	p40 (Î”Np63) is more specific than p63 and cytokeratin 5 in identifying squamous cell carcinoma of bronchopulmonary origin: A review and comparative analysis. Diagnostic Cytopathology, 2014, 42, 453-458.	0.5	17
1082	Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer. Oncology, 2014, 86, 86-93.	0.9	19
1083	New Aspects of the Clinicopathology and Genetic Profile of Metachronous Multiple Lung Cancers. Annals of Surgery, 2014, 259, 1018-1024.	2.1	28

#	Article	IF	Citations
1084	Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA. BMC Gastroenterology, 2014, 14, 221.	0.8	12
1085	Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations. Journal of Thoracic Oncology, 2014, 9, 456-463.	0.5	112
1086	EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas. Journal of Thoracic Oncology, 2014, 9, 195-199.	0.5	245
1087	Impact of Nonâ€“Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome. Journal of Thoracic Oncology, 2014, 9, 1540-1546.	0.5	24
1088	Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines. Nucleic Acids Research, 2014, 42, 13557-13572.	6.5	102
1089	EGFR Mutations in Lung Cancer: Different Frequencies for Different Folks. Journal of Thoracic Oncology, 2014, 9, 139-140.	0.5	13
1090	Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Nonâ€“Small Cell Lung Cancer Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 343-349.	0.6	20
1091	Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Nonâ€“Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial. Journal of Thoracic Oncology, 2014, 9, 1523-1531.	0.5	19
1092	Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations. Clinical Cancer Research, 2014, 20, 3613-3622.	3.2	39
1093	Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients. Genetical Research, 2014, 96, e002.	0.3	16
1094	Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancer. Molecular and Clinical Oncology, 2014, 2, 8-12.	0.4	33
1095	Histological subtype and smoking status, but not gender, are associated with epidermal growth factor receptor mutations in non-small-cell lung cancer. Molecular and Clinical Oncology, 2014, 2, 252-258.	0.4	11
1096	Whole-Genome Sequencing of Asian Lung Cancers: Second-Hand Smoke Unlikely to Be Responsible for Higher Incidence of Lung Cancer among Asian Never-Smokers. Cancer Research, 2014, 74, 6071-6081.	0.4	40
1097	A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Nonâ€“Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). Journal of Thoracic Oncology, 2014, 9, 154-162.	0.5	1,131
1098	Signal Transducer and Activator of Transcription 3 as Molecular Therapy for Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 488-496.	0.5	11
1099	Clinical Significance of BIM Deletion Polymorphism in Nonâ€“Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation. Journal of Thoracic Oncology, 2014, 9, 483-487.	0.5	67
1100	EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients. Journal of Thoracic Oncology, 2014, 9, e10-e11.	0.5	5
1101	Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma. American Journal of Surgical Pathology, 2014, 38, 1118-1127.	2.1	131

#	Article	IF	Citations
1102	Targeting Epidermal Growth Factor Receptor in the Management of Lung Cancer. Seminars in Oncology, 2014, 41, 101-109.	0.8	19
1103	Detection of mutation-specific epidermal growth factor receptor (E746â€“A750del) and lack of detection of human papillomavirus in oral squamous cell carcinoma. International Journal of Oral and Maxillofacial Surgery, 2014, 43, 1199-1205.	0.7	4
1104	The mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance. Surgery Today, 2014, 44, 478-486.	0.7	27
1105	Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. Medical Oncology, 2014, 31, 771.	1.2	48
1106	Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. Breast Cancer Research and Treatment, 2014, 143, 385-392.	1.1	54
1107	The impact of germline mutations on targeted therapy. Journal of Pathology, 2014, 232, 230-243.	2.1	7
1108	Highly sensitive EGFR mutation detection by specific amplification of mutant alleles. Experimental and Molecular Pathology, 2014, 96, 85-91.	0.9	2
1109	EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer. Lung Cancer, 2014, 83, 224-230.	0.9	41
1110	RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer. Lung Cancer, 2014, 83, 23-29.	0.9	12
1111	Establishment and characterization of a lung cancer cell line, SMC-L001, from a lung adenocarcinoma. In Vitro Cellular and Developmental Biology - Animal, 2014, 50, 519-526.	0.7	3
1112	Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. Journal of Biological Inorganic Chemistry, 2014, 19, 259-270.	1.1	21
1113	Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced nonâ€small cell lung cancer. Cancer, 2014, 120, 2289-2298.	2.0	30
1114	Pharmacogenomics and Personalized Medicines in Cancer Treatment. , 2014, , 55-90.		0
1115	The impact of personalized medicine on survival: Comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers. Cancer Treatment Reviews, 2014, 40, 485-494.	3.4	21
1116	Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients. Journal of Clinical Oncology, 2014, 32, 121-128.	0.8	176
1119	Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas â‰¤2â€‰cm in maximal dimension. Journal of Surgical Oncology, 2014, 110, 99-106.	0.8	32
1120	A worldwide trend of increasing primary adenocarcinoma of the lung. Surgery Today, 2014, 44, 1004-1012.	0.7	89
1121	Epidermal growth factor receptor (EGFR) mutations as biomarker for head and neck squamous cell carcinomas (HNSCC). Biomarkers, 2014, 19, 198-206.	0.9	18

#	Article	IF	Citations
1122	Serum 25-hydroxyvitamin D levels correlate with EGFR mutational status in pulmonary adenocarcinoma. Endocrine-Related Cancer, 2014, 21, 715-721.	1.6	6
1123	A microRNA gene signature for identification of lung cancer. Surgical Oncology, 2014, 23, 126-131.	0.8	18
1124	The prognostic impact of the amount of tobacco smoking in non-small cell lung cancerâ€"Differences between adenocarcinoma and squamous cell carcinoma. Lung Cancer, 2014, 85, 125-130.	0.9	29
1125	First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial. European Journal of Cancer, 2014, 50, 2219-2230.	1.3	44
1126	Value of 18F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1889-1897.	3.3	54
1127	Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?. Cancer Chemotherapy and Pharmacology, 2014, 73, 1063-1070.	1.1	18
1128	Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis. Clinical and Experimental Metastasis, 2014, 31, 543-551.	1.7	49
1129	Epidermal growth factor receptor mutations in lung adenocarcinoma. Laboratory Investigation, 2014, 94, 129-137.	1.7	188
1130	Evaluation of the new IASLC/ATS/ERS proposed classification of adenocarcinoma based on lepidic pattern in patients with pathological stage IA pulmonary adenocarcinoma. General Thoracic and Cardiovascular Surgery, 2014, 62, 671-677.	0.4	26
1131	A novel point mutation in exon 20 of EGFR showed sensitivity to erlotinib. Medical Oncology, 2014, 31, 36.	1.2	7
1132	SNP rs10248565 in HDAC9 as a novel genomic aberration biomarker of lung adenocarcinoma in non-smoking women. Journal of Biomedical Science, 2014, 21, 24.	2.6	11
1133	Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients. BMC Cancer, 2014, 14, 369.	1.1	33
1134	Customized Adjuvant Phase II Trial in Patients With Nonâ€"Small-Cell Lung Cancer: IFCT-0801 TASTE. Journal of Clinical Oncology, 2014, 32, 1256-1261.	0.8	66
1135	Treatment algorithm in 2014 for advanced non-small cell lung cancer: Therapy selection by tumour histology and molecular biology. Advances in Medical Sciences, 2014, 59, 308-313.	0.9	21
1136	Current concepts on the molecular pathology of non-small cell lung carcinoma. Seminars in Diagnostic Pathology, 2014, 31, 306-313.	1.0	43
1137	Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer, 2014, 84, 161-167.	0.9	81
1138	Prospective screening for ALK: Clinical features and outcome according to ALK status. European Journal of Cancer, 2014, 50, 1239-1246.	1.3	46
1139	CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. Lung Cancer, 2014, 85, 152-160.	0.9	29

#	Article	IF	Citations
1141	Learning curve for endobronchial ultrasound-guided transbronchial needle aspiration: Experience of a community-based teaching hospital. Molecular Medicine Reports, 2014, 10, 2441-2446.	1.1	2
1142	Lung Carcinomas with EGFR Exon 19 Insertions Are Sensitive to Gefitinib Treatment. Journal of Thoracic Oncology, 2014, 9, e31-e33.	0.5	12
1143	Comprehensive Analysis of the Incidence and Survival Patterns of Lung Cancer by Histologies, Including Rare Subtypes, in the Era of Molecular Medicine and Targeted Therapy. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	6.4	23
1144	Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2015, 10, 738-746.	0.5	70
1145	Relationship between icotinib hydrochloride exposure and clinical outcome in Chinese patients with advanced nonâ€“small cell lung cancer. Cancer, 2015, 121, 3146-3156.	2.0	11
1146	Assessment of EGFR and KRAS mutation status from FNAs and coreâ€needle biopsies of nonâ€small cell lung cancer. Cancer Cytopathology, 2015, 123, 230-236.	1.4	25
1147	Risk of lung cancer and consumption of vegetables and fruit in Japanese: A pooled analysis of cohort studies in Japan. Cancer Science, 2015, 106, 1057-1065.	1.7	13
1148	Clinical features of lung adenocarcinomas with epidermal growth factor receptor mutations and miliary disseminated carcinomatosis. Thoracic Cancer, 2015, 6, 629-635.	0.8	12
1149	Elevated Î²-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs. Scientific Reports, 2015, 5, 13076.	1.6	40
1150	A case of lung adenocarcinoma with a concurrent EGFR mutation and ALK rearrangement: A case report and literature review. Molecular Medicine Reports, 2015, 12, 4370-4375.	1.1	14
1151	L858R-positive lung adenocarcinoma with KRAS G12V, EGFR T790M and EGFR L858R mutations: A case report. Oncology Letters, 2015, 10, 1293-1296.	0.8	7
1152	A new rapid method for detecting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncology Reports, 2015, 33, 1040-1048.	1.2	7
1153	Feasibility of Rebiopsy in Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. Internal Medicine, 2015, 54, 1977-1980.	0.3	33
1154	QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC. Scientific Reports, 2015, 5, 11934.	1.6	9
1155	Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing. Cancer Informatics, 2015, 14, CIN.S22941.	0.9	16
1156	Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. Oncology Letters, 2015, 10, 1775-1782.	0.8	27
1157	Reply. Journal of Thoracic Oncology, 2015, 10, e82-e83.	0.5	0
1158	Afatinib administration in a patient with non-small cell lung cancer harboring uncommon EGFR mutation G719A undergoing hemodialysis. Cancer Treatment Communications, 2015, 4, 169-171.	0.4	5

#	Article	IF	Citations
1159	Structural investigations of T854A mutation in EGFR and identification of novel inhibitors using structure activity relationships. BMC Genomics, 2015, 16, S8.	1.2	27
1160	Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations. BMC Cancer, 2015, 15, 908.	1.1	30
1161	The ensemble of genetic factors and angiogenic signals via VEGF receptors in lung cancer progression. Cancer Biomarkers, 2015, 15, 619-633.	0.8	2
1162	Investigation of Prognostic Factors Affecting Efficacy in Carboplatin- and Paclitaxel-based First-line Chemotherapies for Advanced Non-small-cell Lung Cancer. Tumori, 2015, 101, 424-432.	0.6	5
1163	From Uniplex to Multiplex Molecular Profiling in Advanced Nonâ€“Small Cell Lung Carcinoma. Cancer Journal (Sudbury, Mass), 2015, 21, 413-424.	1.0	3
1164	Detection of EML4-ALK Fusion Gene in Chinese Nonâ€“Small Cell Lung Cancer by Using a Sensitive Quantitative Real-Time Reverse Transcriptase PCR Technique. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 245-254.	0.6	12
1165	Pulmonary Adenocarcinoma In Situ. American Journal of Surgical Pathology, 2015, 39, 912-921.	2.1	12
1166	Emerging Immunotherapies in the Treatment of Nonâ€“small Cell Lung Cancer (NSCLC). American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 422-430.	0.6	64
1167	Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma. Medicine (United States), 2015, 94, e1784.	0.4	17
1168	FDG Uptake in Nonâ€“Small Cell Lung Cancer Is Not an Independent Predictor of EGFR or KRAS Mutation Status. Clinical Nuclear Medicine, 2015, 40, 950-958.	0.7	47
1169	Implications of Evolving Medical Science for Proof of Lung Cancer Causation. Beitrage Zur Tabakforschung International/ Contributions To Tobacco Research, 2015, 26, 298-311.	0.3	0
1170	Impact of tissue type and content of neoplastic cells of samples on the quality of epidermal growth factor receptor mutation analysis among patients with lung adenocarcinoma. Molecular Medicine Reports, 2015, 12, 187-191.	1.1	14
1171	Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent. Drug Design, Development and Therapy, 2015, 9, 3837.	2.0	7
1172	Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer. OncoTargets and Therapy, 2015, 9, 13.	1.0	3
1173	Imaging Characteristics in <i>ALK</i> Fusion-Positive Lung Adenocarcinomas by Using HRCT. Annals of Thoracic and Cardiovascular Surgery, 2015, 21, 102-108.	0.3	20
1174	Afatinib for the treatment of metastatic non-small cell lung cancer. Cancer Management and Research, 2015, 7, 75.	0.9	31
1175	EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features. Wspolczesna Onkologia, 2015, 1, 22-27.	0.7	4
1176	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget, 2015, 6, 14209-14219.	0.8	209

#	Article	IF	Citations
1177	The Use of a Two-Tiered Testing Strategy for the Simultaneous Detection of Small EGFR Mutations and EGFR Amplification in Lung Cancer. PLoS ONE, 2015, 10, e0117983.	1.1	16
1178	TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells. PLoS ONE, 2015, 10, e0129838.	1.1	9
1179	Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations. PLoS ONE, 2015, 10, e0142306.	1.1	28
1180	Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation. OncoTargets and Therapy, 2015, 8, 905.	1.0	14
1181	Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors. Clinical Journal of Oncology Nursing, 2015, 19, 734-742.	0.3	3
1182	Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy. Critical Reviews in Oncogenesis, 2015, 20, 357-371.	0.2	8
1183	A Mutation-Sensitive Switch Assay to Detect Five Clinically Significant Epidermal Growth Factor Receptor Mutations. Genetic Testing and Molecular Biomarkers, 2015, 19, 316-323.	0.3	3
1184	Exploring Stage I non-small-cell lung cancer: development of a prognostic model predicting 5-year survival after surgical resectionâ€. European Journal of Cardio-thoracic Surgery, 2015, 47, 1037-1043.	0.6	37
1185	Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status. Revista Portuguesa De Pneumologia, 2015, 21, 113-125.	0.7	3
1186	Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptorâ€“Driven Lung Adenocarcinoma. Cancer Discovery, 2015, 5, 534-549.	7.7	57
1187	Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib. Lung Cancer, 2015, 88, 187-194.	0.9	68
1188	New strategies to develop new medications for lung cancer and metastasis. Cancer and Metastasis Reviews, 2015, 34, 265-275.	2.7	10
1189	Targeting EGFR in lung cancer: Lessons learned and future perspectives. Molecular Aspects of Medicine, 2015, 45, 67-73.	2.7	42
1190	Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future Oncology, 2015, 11, 2175-2191.	1.1	5
1191	Genetic Polymorphism, Telomere Biology and Non-Small Lung Cancer Risk. Journal of Genetics and Genomics, 2015, 42, 549-561.	1.7	26
1192	Therapeutic options in advanced squamous cell lung carcinoma. Lung Cancer Management, 2015, 4, 75-86.	1.5	0
1193	Advances in Molecular Biology of Lung Disease. Chest, 2015, 148, 1063-1072.	0.4	18
1194	Prospective Assessment of Pemetrexed or Pemetrexed Plus Platinum in Combination With Gefitinib or Erlotinib in Patients With Acquired Resistance to Gefitinib or Erlotinib: A Phase II Exploratory and Preliminary Study. Clinical Lung Cancer, 2015, 16, 121-127.	1.1	12

#	Article	IF	Citations
1195	Impact of Smoking Status on EGFR-TKI Efficacy for Advanced Nonâ€“Small-Cell Lung Cancer in EGFR Mutants: A Meta-analysis. Clinical Lung Cancer, 2015, 16, 144-151.e1.	1.1	60
1196	Gefitinib: a review of its use in adults with advanced non-small cell lung cancer. Targeted Oncology, 2015, 10, 153-170.	1.7	51
1197	Somatic Diseases (Cancer). , 2015, , 343-360.		0
1198	Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Scientific Reports, 2014, 4, 6269.	1.6	187
1199	Current and Future Approaches in the Management of Nonâ€“Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs. Clinical Lung Cancer, 2015, 16, 252-261.	1.1	27
1200	Molecular Spectrum of Somatic EGFR and KRAS Gene Mutations in non Small Cell Lung Carcinoma: Determination of Frequency, Distribution Pattern and Identification of Novel Variations in Indian Patients. Pathology and Oncology Research, 2015, 21, 675-687.	0.9	11
1201	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. Future Oncology, 2015, 11, 409-420.	1.1	34
1202	Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?. Lung Cancer, 2015, 87, 155-161.	0.9	8
1203	Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations. International Journal of Clinical Oncology, 2015, 20, 674-679.	1.0	133
1204	First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation. Clinical Lung Cancer, 2015, 16, e259-e261.	1.1	5
1205	EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Nonâ€“Small Cell Lung Cancer in Germany: An Observational Study. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1254-1261.	1.1	38
1206	TERT Polymorphism rs2736100-C Is Associated with EGFR Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 5173-5180.	3.2	47
1207	First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Annals of Oncology, 2015, 26, 1883-1889.	0.6	616
1208	Emerging treatment for advanced lung cancer withEGFRmutation. Expert Opinion on Emerging Drugs, 2015, 20, 597-612.	1.0	22
1209	Kras, Egfr, and Tp53 Mutations in B6C3F1/N Mouse and F344/NTac Rat Alveolar/Bronchiolar Carcinomas Resulting from Chronic Inhalation Exposure to Cobalt Metal. Toxicologic Pathology, 2015, 43, 872-882.	0.9	14
1210	Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation. Journal of Thoracic Oncology, 2015, 10, 910-923.	0.5	534
1211	Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). Journal of Thoracic Oncology, 2015, 10, 838-843.	0.5	156
1212	AZD9291 in EGFR Inhibitorâ€“Resistant Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 372, 1689-1699.	13.9	1,802

#	Article	IF	Citations
1213	Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma. Thoracic Cancer, 2015, 6, 224-226.	0.8	1
1214	Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States. Gynecologic Oncology, 2015, 136, 491-497.	0.6	58
1215	Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR -mutated lung cancer via an EGFR signal. Lung Cancer, 2015, 88, 16-23.	0.9	31
1216	Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung. Current Medical Research and Opinion, 2015, 31, 1117-1127.	0.9	7
1217	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. Journal of Clinical Oncology, 2015, 33, 1958-1965.	0.8	280
1218	Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma. Tumor Biology, 2015, 36, 693-700.	0.8	5
1219	Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil. Oncology, 2015, 89, 175-186.	0.9	21
1220	Epidermal growth factor receptor gene mutations in patients with lung adenocarcinoma differ by frequency and type between Uighur and Han ethnic groups in Xinjiang Autonomous Region. BMC Genetics, 2015, 16, 20.	2.7	4
1221	Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer. BMC Cancer, 2015, 15, 5.	1.1	54
1222	The epidermal growth factor receptor (EGRF) in lung cancer. Translational Respiratory Medicine, 2015, 3, 1.	3.8	34
1223	Notch1 Mutations Are Drivers of Oral Tumorigenesis. Cancer Prevention Research, 2015, 8, 277-286.	0.7	78
1225	Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. Clinical Lung Cancer, 2015, 16, e25-e35.	1.1	100
1226	Patient-Derived Xenografts from Nonâ€“Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy. Clinical Cancer Research, 2015, 21, 1172-1182.	3.2	58
1227	Application of clinical bioinformatics in lung cancer-specific biomarkers. Cancer and Metastasis Reviews, 2015, 34, 209-216.	2.7	32
1228	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clinical Cancer Research, 2015, 21, 3480-3491.	3.2	48
1229	Inhibition of Î²-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Nonâ€“small-cell Lung Cancer with a T790M Mutation. Journal of Thoracic Oncology, 2015, 10, 93-101.	0.5	44
1230	New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer. Anti-Cancer Drugs, 2015, 26, 1-14.	0.7	43
1231	The Association Between Tumor Epidermal Growth Factor Receptor (EGFR) Mutation and Multiple Primary Malignancies in Patients With Adenocarcinoma of the Lungs. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 147-151.	0.6	11

#	Article	IF	Citations
1232	Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy in Patients with Locally Advanced or Metastatic Nonâ€“Small-Cell Lung Cancer (INFORM; C-TONG 0804). Journal of Thoracic Oncology, 2015, 10, 655-664.	0.5	36
1233	Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer. Anti-Cancer Drugs, 2015, 26, 456-463.	0.7	6
1234	Molecular targeted therapy in the treatment of advanced stage nonâ€small cell lung cancer (<scp>NSCLC</scp>). Respirology, 2015, 20, 370-378.	1.3	119
1235	Management of EGFR mutated nonsmall cell lung carcinoma patients. European Respiratory Journal, 2015, 45, 1132-1141.	3.1	36
1236	Novel use for an EGFR mutationâ€specific antibody in discriminating lung adenocarcinoma from reactive pneumocyte hyperplasia. Histopathology, 2015, 66, 816-823.	1.6	4
1237	MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer. Pharmacological Research, 2015, 102, 90-106.	3.1	4
1238	Overcoming Resistance to Targeted Therapies in Cancer. Seminars in Oncology, 2015, 42, 896-908.	0.8	36
1239	Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed. Journal of Structural Biology, 2015, 192, 539-544.	1.3	106
1240	Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma. Lung Cancer, 2015, 90, 472-476.	0.9	14
1241	Antitumoral Activity of Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harbouring Rare Epidermal Growth Factor Receptor Mutations. Molecular Diagnosis and Therapy, 2015, 19, 267-272.	1.6	7
1242	Ligand-Independent EGFR Signaling. Cancer Research, 2015, 75, 3436-3441.	0.4	166
1243	Differential expression of bone morphogenetic protein 5 in human lung squamous cell carcinoma and adenocarcinoma. Acta Biochimica Et Biophysica Sinica, 2015, 47, 557-563.	0.9	26
1244	Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma. Clinical Cancer Research, 2015, 21, 2613-2623.	3.2	16
1245	Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?. Expert Opinion on Biological Therapy, 2015, 15, 1553-1566.	1.4	22
1246	PTEN and PI3K/AKT in non-small-cell lung cancer. Pharmacogenomics, 2015, 16, 1843-1862.	0.6	180
1248	Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer. European Journal of Cardio-thoracic Surgery, 2015, 47, 550-555.	0.6	29
1249	Analysis of the EGFR gene mutation in patients with nonsmall cell lung cancer in a Chinese population. Tropical Journal of Pharmaceutical Research, 2016, 15, 1637.	0.2	2
1250	Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature. OncoTargets and Therapy, 2016, Volume 9, 4301-4305.	1.0	21

#	Article	IF	Citations
1251	Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma. Oncotarget, 2016, 7, 22857-22864.	0.8	56
1252	Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations. OncoTargets and Therapy, 2016, 9, 355.	1.0	4
1253	Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations. Oncotarget, 2016, 7, 54965-54972.	0.8	6
1254	Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Oncotarget, 2016, 7, 61755-61763.	0.8	29
1255	Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung Adenocarcinoma. Tuberculosis and Respiratory Diseases, 2016, 79, 248.	0.7	41
1256	Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer. Oncotarget, 2016, 7, 3884-3896.	0.8	34
1257	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. Translational Lung Cancer Research, 2016, 5, 563-578.	1.3	30
1258	Targeted Therapy in Brain Metastases: Ready for Primetime?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e123-e130.	1.8	35
1259	The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. Journal of Thoracic Disease, 2016, 8, 3175-3186.	0.6	4
1260	Are there any differences in genomic characterization of non-small cell lung cancer between African Americans and Whites?. Journal of Thoracic Disease, 2016, 8, E1517-E1519.	0.6	1
1261	Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer. Mediators of Inflammation, 2016, 2016, 1-11.	1.4	29
1262	The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget, 2016, 7, 78985-78993.	0.8	500
1263	Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma. Current Drug Discovery Technologies, 2016, 13, 68-76.	0.6	15
1264	Clinical and genetic features of lung squamous cell cancer in never-smokers. Oncotarget, 2016, 7, 35979-35988.	0.8	22
1265	Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis. International Journal of Molecular Sciences, 2016, 17, 524.	1.8	28
1266	The Clinical Significance of the Insulin-Like Growth Factor-1 Receptor Polymorphism in Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation. International Journal of Molecular Sciences, 2016, 17, 763.	1.8	6
1267	Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia. Diagnostic Pathology, 2016, 11, 90.	0.9	9
1268	Fragment Length of Circulating Tumor DNA. PLoS Genetics, 2016, 12, e1006162.	1.5	502

#	Article	IF	Citations
1269	Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China. PLoS ONE, 2016, 11, e0151846.	1.1	17
1270	Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0152317.	1.1	10
1271	Comparative Analysis of Clinicopathologic Features of, Treatment in, and Survival of Americans with Lung or Bronchial Cancer. PLoS ONE, 2016, 11, e0156617.	1.1	9
1272	Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. Anti-Cancer Drugs, 2016, 27, 353-363.	0.7	5
1273	Association between GWAS-identified lung adenocarcinoma susceptibility loci andEGFRmutations in never-smoking Asian women, and comparison with findings from Western populations. Human Molecular Genetics, 2016, 26, ddw414.	1.4	50
1274	Genomic profiling of multiple sequentially acquired tumor metastatic sites from an â€œexceptional responderâ€•lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Journal of Physical Education and Sports Management, 2016, 2, a001263.	0.5	18
1275	KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. American Journal of Surgical Pathology, 2016, 40, 1579-1590.	2.1	50
1276	Regulatory mechanisms underlying sepsis progression in patients with tumor necrosis factor-Î± genetic variations. Experimental and Therapeutic Medicine, 2016, 12, 323-328.	0.8	5
1277	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutationâ€“Positive Nonâ€“Small Cell Lung Cancer: Status in 2016. Journal of Thoracic Oncology, 2016, 11, 946-963.	0.5	173
1278	6-Oxooxazolidineâ€“quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR. Bioorganic and Medicinal Chemistry, 2016, 24, 3359-3370.	1.4	17
1279	Changes of serum amino acid profiles by an epidermal growth factor receptor mutation and benzo[a]pyrene in mouse lung tumorigenesis. Toxicology Research, 2016, 5, 1182-1192.	0.9	0
1280	Safety of gefitinib in non-small cell lung cancer treatment. Expert Opinion on Drug Safety, 2016, 15, 993-1000.	1.0	14
1281	CT Features of Epidermal Growth Factor Receptorâ€“Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 819-826.	0.5	61
1282	Cigarette Smoking, BPDE-DNA Adducts, and Aberrant Promoter Methylations of Tumor Suppressor Genes (TSGs) in NSCLC from Chinese Population. Cancer Investigation, 2016, 34, 173-180.	0.6	17
1283	First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Nonâ€“Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial. Clinical Lung Cancer, 2016, 17, 150-160.	1.1	16
1284	Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma. Oncology, 2016, 90, 289-298.	0.9	9
1285	EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature. Oncology Letters, 2016, 11, 3546-3550.	0.8	14
1286	Association between histopathological subtype, 18F-fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in lung adenocarcinoma. Oncology Letters, 2016, 11, 1769-1777.	0.8	10

#	Article	IF	Citations
1287	Early Events in the Molecular Pathogenesis of Lung Cancer. Cancer Prevention Research, 2016, 9, 518-527.	0.7	82
1288	KRAS-related proteins in pancreatic cancer. , 2016, 168, 29-42.		151
1289	Clinical approach of intratumoral heterogeneity in lung adenocarcinoma. Two clinical cases with changing somatic driver mutations. Cancer Treatment and Research Communications, 2016, 9, 96-99.	0.7	0
1290	XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature, 2016, 538, 114-117.	13.7	162
1291	Synthetic lethality in lung cancer and translation to clinical therapies. Molecular Cancer, 2016, 15, 61.	7.9	31
1292	Similarities and differences between <scp>E</scp>ast and <scp>W</scp>est in COPD. Respirology, 2016, 21, 1340-1341.	1.3	8
1293	Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. Journal of Clinical Oncology, 2016, 34, 3258-3266.	0.8	153
1295	The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope. Future Oncology, 2016, 12, 2713-2727.	1.1	18
1296	Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Science, 2016, 107, 713-720.	1.7	174
1297	Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma. Annals of Thoracic Surgery, 2016, 102, 1821-1828.	0.7	14
1298	MET in the Driver's Seat: Exon 14 Skipping Mutations as Actionable Targets in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 1381-1383.	0.5	7
1299	Study of efficacy and safety of pulsatile administration of highâ€dose gefitinib or erlotinib for advanced nonâ€small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial. Thoracic Cancer, 2016, 7, 663-669.	0.8	19
1300	Hot spot mutations in Finnish non-small cell lung cancers. Lung Cancer, 2016, 99, 102-110.	0.9	21
1301	The impact of epidermal growth factor receptor mutations on patterns of disease recurrence after chemoradiotherapy for locally advanced nonâ€“small cell lung cancer: a literature review and pooled analysis. Journal of Radiation Research, 2016, 57, 449-459.	0.8	13
1302	Resistance to Therapy. Cancer Treatment and Research, 2016, 170, 183-202.	0.2	10
1303	Trends in Lung Cancer Incidence Rates by Histological Type in 1975–2008: A Population-Based Study in Osaka, Japan. Journal of Epidemiology, 2016, 26, 579-586.	1.1	37
1304	Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. British Journal of Cancer, 2016, 115, 1504-1512.	2.9	55
1305	The safety of afatinib for the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety, 2016, 15, 1563-1572.	1.0	15

#	Article	IF	Citations
1306	Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients. Medical Oncology, 2016, 33, 117.	1.2	13
1307	Novel therapeutic targets on the horizon for lung cancer. Lancet Oncology, The, 2016, 17, e347-e362.	5.1	156
1308	Identification of potential therapeutic targets for lung cancer by bioinformatics analysis. Molecular Medicine Reports, 2016, 13, 1975-1982.	1.1	15
1309	Genetics of Pancreatic Cancer and Its Implications on Therapy. Surgical Clinics of North America, 2016, 96, 1207-1221.	0.5	12
1310	Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers. Lung Cancer, 2016, 102, 122-134.	0.9	180
1311	Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer. Scientific Reports, 2016, 6, 31636.	1.6	10
1312	Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer. Cancer Control, 2016, 23, 338-346.	0.7	78
1313	Association between human papillomavirus and EGFR mutations in advanced lung adenocarcinoma. Oncology Letters, 2016, 12, 1953-1958.	0.8	9
1314	Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment. Medicine (United States), 2016, 95, e3998.	0.4	30
1315	EGFR Exon 20 Insertion/Duplication Mutations Characterize Fibrous Hamartoma of Infancy. American Journal of Surgical Pathology, 2016, 40, 1713-1718.	2.1	52
1316	Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance. Oncology Letters, 2016, 11, 393-398.	0.8	10
1317	Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey. SpringerPlus, 2016, 5, 482.	1.2	3
1318	Epidermal growth factor receptor gene mutation as risk factor for recurrence in patients with surgically resected lung adenocarcinoma: a matched-pair analysis. Interactive Cardiovascular and Thoracic Surgery, 2016, 23, 216-222.	0.5	13
1319	Genetic alterations in lung adenocarcinoma with a micropapillary component. Molecular and Clinical Oncology, 2016, 4, 195-200.	0.4	6
1320	Gene mutation discovery research of non-smoking lung cancer patients due to indoor radon exposure. Annals of Occupational and Environmental Medicine, 2016, 28, 13.	0.3	16
1321	Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 3383-3389.	0.8	236
1322	Does chronic rhinosinusitis increase the risk of lung cancer? A population cohort study. Clinical Respiratory Journal, 2016, 10, 435-439.	0.6	6
1323	BioCircos.js: an interactive Circos JavaScript library for biological data visualization on web applications. Bioinformatics, 2016, 32, 1740-1742.	1.8	119

#	Article	IF	Citations
1324	Improving Therapeutic Outcomes in Non-small Cell Lung Cancer not Suitable for Curative Intent Therapy â€" A Review of the Role of Radiation Therapy in an Era of Increasing Systemic Therapy Options. Clinical Oncology, 2016, 28, 327-333.	0.6	4
1325	Differential regulation and synthetic lethality of exclusive RB1 and CDKN2A mutations in lung cancer. International Journal of Oncology, 2016, 48, 367-375.	1.4	19
1326	Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. Journal of Clinical Oncology, 2016, 34, 91-101.	0.8	146
1327	Target Therapy in Lung Cancer. Advances in Experimental Medicine and Biology, 2016, 893, 127-136.	0.8	18
1329	Drugâ€"diagnostic co-development: challenges and issues. Expert Review of Molecular Diagnostics, 2016, 16, 187-204.	1.5	4
1330	Epidermal growth factor receptorâ€tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 <scp>L858R</scp> mutation in nonâ€smallâ€cell lung cancer: Systematic review and meta analysis. Thoracic Cancer, 2016, 7, 406-414.	0.8	22
1331	Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials. Clinical Oncology, 2016, 28, 283-291.	0.6	3
1332	Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Lung Cancer, 2016, 93, 59-68.	0.9	103
1333	Skin problems and EGFR-tyrosine kinase inhibitor. Japanese Journal of Clinical Oncology, 2016, 46, 291-298.	0.6	82
1334	Personalized chemotherapy of lung cancer: What the radiologist should know. Diagnostic and Interventional Imaging, 2016, 97, 287-296.	1.8	9
1335	First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Nonâ€"Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. Journal of Thoracic Oncology, 2016, 11, 370-379.	0.5	21
1336	CompoundEGFRmutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biology and Therapy, 2016, 17, 237-245.	1.5	92
1337	Drug Resistance to EGFR Inhibitors in Lung Cancer. Chemotherapy, 2016, 61, 223-235.	0.8	57
1338	Selectivity profile of afatinib for EGFR-mutated non-small-cell lung cancer. Molecular BioSystems, 2016, 12, 1552-1563.	2.9	6
1339	Wnt signaling as potential therapeutic target in lung cancer. Expert Opinion on Therapeutic Targets, 2016, 20, 999-1015.	1.5	44
1340	Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. Cancer Chemotherapy and Pharmacology, 2016, 77, 767-776.	1.1	118
1341	Combined Pan-HER and ALK/ROS1/MET Inhibition with Dacomitinib and Crizotinib in Advanced Nonâ€"Small Cell Lung Cancer: Results of a Phase I Study. Journal of Thoracic Oncology, 2016, 11, 737-747.	0.5	54
1342	Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study. Tumor Biology, 2016, 37, 10479-10486.	0.8	13

#	Article	IF	Citations
1343	The safety and efficacy of osimertinib for the treatment ofEGFRT790M mutation positive non-small-cell lung cancer. Expert Review of Anticancer Therapy, 2016, 16, 383-390.	1.1	58
1344	Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. Journal of Thoracic Oncology, 2016, 11, 556-565.	0.5	268
1345	Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer. Expert Review of Respiratory Medicine, 2016, 10, 547-556.	1.0	9
1346	Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development. Advances in Experimental Medicine and Biology, 2016, 890, 1-23.	0.8	7
1347	â€œComboâ€•nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy. Advanced Drug Delivery Reviews, 2016, 98, 3-18.	6.6	399
1348	EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan. Medical Oncology, 2016, 33, 1.	1.2	64
1349	Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer. Critical Reviews in Oncology/Hematology, 2016, 97, 85-95.	2.0	19
1350	EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib. Journal of Thoracic Oncology, 2017, 12, 884-889.	0.5	24
1351	Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma. Clinical Lung Cancer, 2017, 18, e215-e217.	1.1	5
1352	Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. , 2017, 174, 1-21.		123
1353	Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations. JAMA Oncology, 2017, 3, 801.	3.4	78
1354	Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. Future Oncology, 2017, 13, 1159-1171.	1.1	17
1355	Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France. Journal of Thoracic Oncology, 2017, 12, 963-973.	0.5	56
1356	Characterization of common and rare mutations in EGFR and associated clinicopathological features in a large population of Chinese patients with lung cancer. Pathology Research and Practice, 2017, 213, 749-758.	1.0	9
1357	Current status of research and treatment for non-small cell lung cancer in never-smoking females. Cancer Biology and Therapy, 2017, 18, 359-368.	1.5	66
1358	Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-Î² in advanced non-small cell lung cancer. Oncology Letters, 2017, 13, 2359-2365.	0.8	17
1359	Dynamic Contrast-enhanced MR Imaging Parameters in Bone Metastases from Nonâ€“Small Cell Lung Cancer: Comparison between Lesions with and Lesions without Epidermal Growth Factor Receptor Mutation in Primary Lung Cancer. Radiology, 2017, 284, 815-823.	3.6	14
1360	Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. Clinical Cancer Research, 2017, 23, 4753-4760.	3.2	56

#	Article	IF	Citations
1361	Proportion of Never-Smoker Nonâ€“Small Cell Lung Cancer Patients at Three Diverse Institutions. Journal of the National Cancer Institute, 2017, 109, djw295.	3.0	97
1362	The Role of ErbB Receptors in Infection. Trends in Microbiology, 2017, 25, 942-952.	3.5	58
1363	EGFR, Growth Factors. , 2017, , 707-717.		0
1364	EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies ofÂOsimertinib. Journal of Thoracic Oncology, 2017, 12, 1247-1256.	0.5	48
1365	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1376-1387.	0.5	39
1366	A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R. Journal of Thoracic Oncology, 2017, 12, 1368-1375.	0.5	79
1367	Effects of polymorphisms identified in genome-wide association studies of never-smoking females on the prognosis of non-small cell lung cancer. Cancer Genetics, 2017, 212-213, 8-12.	0.2	7
1368	Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs, 2017, 77, 813-827.	4.9	42
1369	Clinicopathological and prognostic features of surgically resected pathological stage <scp>I</scp> lung adenocarcinoma harboring epidermal growth factor receptor and <scp>K</scp>â€ras mutation. Thoracic Cancer, 2017, 8, 229-237.	0.8	6
1370	C -2 (E)-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR T790M mutant. Bioorganic and Medicinal Chemistry, 2017, 25, 2724-2729.	1.4	12
1371	Molecular biomarkers for lung adenocarcinoma. European Respiratory Journal, 2017, 49, 1601734.	3.1	110
1372	P3.02b-105 Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Journal of Thoracic Oncology, 2017, 12, S1256-S1257.	0.5	0
1373	Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 612-623.	0.5	203
1374	Understanding and targeting resistance mechanisms in NSCLC. Nature Reviews Cancer, 2017, 17, 637-658.	12.8	679
1375	Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland. Oncology Letters, 2017, 14, 5611-5618.	0.8	7
1376	Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?. Cancer Treatment Reviews, 2017, 61, 70-81.	3.4	62
1377	Sex differences in lung cancer survival: long-term trends using population-based cancer registry data in Osaka, Japan. Japanese Journal of Clinical Oncology, 2017, 47, 863-869.	0.6	28
1378	Precision Diagnosis and Treatment for Advanced Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 849-861.	13.9	578

#	Article	IF	Citations
1379	An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP). Lung Cancer, 2017, 113, 30-36.	0.9	27
1380	De novo activating epidermal growth factor mutations (<scp>EGFR</scp>) in smallâ€cell lung cancer. Internal Medicine Journal, 2017, 47, 1071-1074.	0.5	3
1381	MicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact. Tumor Biology, 2017, 39, 101042831770643.	0.8	16
1382	Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. ERJ Open Research, 2017, 3, 00092-2016.	1.1	33
1383	Stable Property Clusters and Their Grounds. Philosophy of Science, 2017, 84, 944-955.	0.5	5
1384	Metaâ€analysis of firstâ€line therapies with maintenance regimens for advanced nonâ€smallâ€cell lung cancer (NSCLC) in molecularly and clinically selected populations. Cancer Medicine, 2017, 6, 1847-1860.	1.3	23
1385	ChimiothÃ©rapies personnalisÃ©es du cancer bronchiqueÂ: ce que le radiologue doit connaÃ®tre. Diagnostic and Interventional Imaging, 2017, 98, 146-156.	0.0	0
1386	Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. Cancer Letters, 2017, 405, 100-110.	3.2	90
1387	Brain metastases in non-small cell lung cancer patients on epidermal growth factor receptor tyrosine kinase inhibitors: symptom and economic burden. Journal of Medical Economics, 2017, 20, 1136-1147.	1.0	21
1388	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. Journal of Thoracic Oncology, 2017, 12, 1588-1594.	0.5	21
1389	Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?. Current Opinion in Oncology, 2017, 29, 89-96.	1.1	13
1390	Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1979-1986.	1.4	10
1391	Chemotherapeutics-resistance â€œarmsâ€•race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer. Life Sciences, 2017, 186, 25-32.	2.0	17
1392	Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma. Lung Cancer, 2017, 114, 23-30.	0.9	12
1393	In vivo imaging xenograft models for the evaluation of antiâ€brain tumor efficacy of targeted drugs. Cancer Medicine, 2017, 6, 2972-2983.	1.3	2
1394	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Î²-blockers. Science Translational Medicine, 2017, 9, .	5.8	96
1395	EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs. Cancer Letters, 2017, 403, 186-194.	3.2	27
1396	Application of Immunohistochemistry in the Diagnosis of Pulmonary and Pleural Neoplasms. Archives of Pathology and Laboratory Medicine, 2017, 141, 1195-1213.	1.2	20

#	Article	IF	Citations
1397	The level of serum carcinoembryonic antigen is a surrogate marker for the efficacy of EGFR-TKIs but is not an indication of acquired resistance to EGFR-TKIs in NSCLC patients with EGFR mutationsm. Biomedical Reports, 2017, 7, 61-66.	0.9	5
1398	Sex-specific incidence of EGFR mutation and its association with age and obesity in lung adenocarcinomas: a retrospective analysis. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2283-2290.	1.2	13
1399	O6-methyl-guanine-DNA methyltransferase methylation and IDH1/2 mutation in small cell lung cancer. Experimental and Therapeutic Medicine, 2017, 14, 398-402.	0.8	5
1400	Comprehensive study of mutational and clinicopathologic characteristics of adenocarcinoma with lepidic pattern in surgical resected lung adenocarcinoma. Journal of Cancer Research and Clinical Oncology, 2017, 143, 181-186.	1.2	4
1401	Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance. Acta Pharmacologica Sinica, 2017, 38, 100-109.	2.8	14
1402	In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma. Oncogene, 2017, 36, 2309-2318.	2.6	27
1403	Progression of EGFR-Mutant Lung Adenocarcinoma is Driven By Alveolar Macrophages. Clinical Cancer Research, 2017, 23, 778-788.	3.2	38
1404	Lung cancer: current therapies and new targeted treatments. Lancet, The, 2017, 389, 299-311.	6.3	2,267
1405	Pathology and Molecular Pathology of Lung Cancer. , 2017, , 367-390.		1
1406	Clinical Implications of the Autophagy Core Gene Variations in Advanced Lung Adenocarcinoma Treated with Gefitinib. Scientific Reports, 2017, 7, 17814.	1.6	24
1407	The Importance of EGFR Mutation Detection Method for the Correct Clinical Management of Patients with Non-Small Cell Lung Cancer: A Case Report. , 2017, 07, .		0
1408	Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naÃ¯ve advanced lung adenocarcinoma. Journal of Thoracic Disease, 2017, 9, 3927-3937.	0.6	11
1409	Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. International Journal of Molecular Sciences, 2017, 18, 2420.	1.8	102
1410	Lipid-Based Nanoparticles for Targeted Drug Delivery of Anticancer Drug. , 2017, , 287-321.		2
1411	Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers, 2017, 9, 52.	1.7	1,153
1412	Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2017, 7, 113.	1.3	46
1413	Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. Frontiers in Oncology, 2017, 7, 193.	1.3	343
1414	Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Cancer, 2017, 8, 227-239.	1.2	18

#	Article	IF	Citations
1415	Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291). OncoTargets and Therapy, 2017, Volume 10, 1757-1766.	1.0	18
1416	Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma. Oncology Letters, 2017, 15, 3295-3304.	0.8	9
1417	Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study. OncoTargets and Therapy, 2017, Volume 10, 4989-4995.	1.0	19
1418	Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists. Korean Journal of Radiology, 2017, 18, 6.	1.5	12
1419	Combining PET/CT with serum tumor markers to improve the evaluation of histological type of suspicious lung cancers. PLoS ONE, 2017, 12, e0184338.	1.1	8
1420	Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma. PLoS ONE, 2017, 12, e0175622.	1.1	20
1421	Genetic variation in the eicosanoid pathway is associated with non-small-cell lung cancer (NSCLC) survival. PLoS ONE, 2017, 12, e0180471.	1.1	8
1422	The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?. Annals of Translational Medicine, 2017, 5, 46-46.	0.7	209
1423	BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations. Oncotarget, 2017, 8, 39945-39962.	0.8	29
1424	Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexedâ€“carboplatin chemotherapy. Ecancermedicalscience, 2017, 11, 776.	0.6	2
1425	Osimertinib â€“ effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors. Wspolczesna Onkologia, 2017, 3, 254-258.	0.7	8
1426	Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions. Oncotarget, 2017, 8, 11114-11126.	0.8	22
1428	Comment on prognostic value of epidermal growth factor receptor mutation subtypes in surgically resected non-small cell lung cancer. Journal of Thoracic Disease, 2017, 9, E499-E502.	0.6	0
1429	Overview of current systemic management of EGFR-mutant NSCLC. Annals of Oncology, 2018, 29, i3-i9.	0.6	229
1430	Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy. Clinical Cancer Research, 2018, 24, 2138-2147.	3.2	21
1431	Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma. Annals of Thoracic Surgery, 2018, 105, 1648-1654.	0.7	18
1432	Clinicopathological analysis of Large Cell Lung Carcinomas definitely diagnosed according to the New World Health Organization Criteria. Pathology Research and Practice, 2018, 214, 555-559.	1.0	4
1433	Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Nonâ€“Small Cell Lung Cancer Patients. Clinical Cancer Research, 2018, 24, 3097-3107.	3.2	357

#	Article	IF	Citations
1434	First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Nonâ€“Small CellÂLung Cancer: Safety, Efficacy, and PotentialÂMechanism of Resistance. Journal of Thoracic Oncology, 2018, 13, 968-977.	0.5	50
1435	Characteristics and Predictive Value of PD-L1 Status in Real-World Nonâ€“Small Cell Lung Cancer Patients. Journal of Immunotherapy, 2018, 41, 292-299.	1.2	30
1436	OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer. BMJ Open, 2018, 8, e020128.	0.8	11
1437	Transformation to smallâ€‘cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma. Oncology Letters, 2018, 15, 5799-5802.	0.8	7
1438	Concomitance of EGFR mutations and ALK rearrangement in patients with Lung Cancer. Gene Reports, 2018, 11, 196-204.	0.4	2
1439	Characterization of two splice variants of EGFR and their effects on the growth of the razor clam. Aquaculture and Fisheries, 2018, 3, 62-71.	1.2	5
1440	Updated Molecular Testing Guideline for theÂSelection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2018, 13, 323-358.	0.5	408
1441	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Archives of Pathology and Laboratory Medicine, 2018, 142, 321-346.	1.2	586
1442	EFEMP2. , 2018, , 1502-1502.		0
1443	Epidermal Surface Antigen (ESA). , 2018, , 1603-1603.		0
1444	Sequencing of circulating tumor DNA for dynamic monitoring of gene mutations in advanced non-small cell lung cancer. Oncology Letters, 2018, 15, 3726-3734.	0.8	6
1445	Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. Nature Communications, 2018, 9, 216.	5.8	136
1446	ETA Type Endothelin Receptor. , 2018, , 1653-1653.		0
1447	Validation of the digital PCR system in tyrosine kinase inhibitorâ€resistant EGFR mutant nonâ€smallâ€cell lung cancer. Pathology International, 2018, 68, 167-173.	0.6	6
1448	Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer. Targeted Oncology, 2018, 13, 141-156.	1.7	17
1449	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. Journal of Molecular Diagnostics, 2018, 20, 129-159.	1.2	241
1450	Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer. Genes Chromosomes and Cancer, 2018, 57, 211-220.	1.5	24
1451	Personalized Lung Cancer Treatment: A Teamwork. , 2018, , 333-348.		1

#	Article	IF	Citations
1452	PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. Lung Cancer, 2018, 116, 1-6.	0.9	51
1453	Populationâ€based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease. Cancer Medicine, 2018, 7, 1211-1220.	1.3	22
1454	EGFR mutations in earlyâ€stage and advancedâ€stage lung adenocarcinoma: Analysis based on largeâ€scale data from China. Thoracic Cancer, 2018, 9, 814-819.	0.8	42
1455	Influence of wellness education on first-line icotinib hydrochloride patients with stage IV nonâ€“small cell lung cancer and their family caregivers. Current Problems in Cancer, 2018, 42, 358-366.	1.0	8
1456	Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. Lung Cancer, 2018, 119, 36-41.	0.9	7
1457	A Decade of Never-smokers Among Lung CancerÂPatientsâ€”Increasing Trend and ImprovedÂSurvival. Clinical Lung Cancer, 2018, 19, e539-e550.	1.1	21
1458	Assessment of EGFR mutation status in Tunisian patients with pulmonary adenocarcinoma. Current Research in Translational Medicine, 2018, 66, 65-70.	1.2	12
1459	Fluorometric detection of EGFR exon 19 deletion mutation in lung cancer cells using graphene oxide. Analyst, The, 2018, 143, 1797-1804.	1.7	13
1460	Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib. Clinical Lung Cancer, 2018, 19, e431-e438.	1.1	14
1461	Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors. Clinical and Translational Oncology, 2018, 20, 140-149.	1.2	3
1462	A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2018, 19, 27-34.	1.1	21
1463	Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring RAS Mutations. Molecular Cancer Therapeutics, 2018, 17, 17-25.	1.9	37
1464	Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?. Journal of Cancer Research and Clinical Oncology, 2018, 144, 165-171.	1.2	6
1465	Lung Cancer in Never-Smokers. , 2018, , 23-29.e3.		5
1466	Clinical Presentation and Prognostic Factors in Lung Cancer. , 2018, , 186-198.e6.		0
1467	Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. Journal of Medical Economics, 2018, 21, 113-121.	1.0	30
1468	Comparison of genomeâ€wide analysis techniques to DNA methylation analysis in human cancer. Journal of Cellular Physiology, 2018, 233, 3968-3981.	2.0	32
1469	Molecular Diagnosis and Targeting for Lung Cancer. Current Human Cell Research and Applications, 2018, , 1-32.	0.1	0

#	Article	IF	Citations
1471	Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma. International Journal of Clinical Oncology, 2018, 23, 249-257.	1.0	7
1472	NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy. Respiration, 2018, 95, 169-176.	1.2	14
1473	Phosphorylation of Mig6 negatively regulates the ubiquitination and degradation of EGFR mutants in lung adenocarcinoma cell lines. Cellular Signalling, 2018, 43, 21-31.	1.7	14
1474	Discovery of anilino-furo[2,3- d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity. European Journal of Medicinal Chemistry, 2018, 144, 330-348.	2.6	30
1475	EGFR Mutation Detection and Its Association With Clinicopathological Characters of Lung Cancer Patients. World Journal of Oncology, 2018, 9, 151-155.	0.6	12
1476	Integrative Bioinformatics Analysis Reveals Potential Long Non-Coding RNA Biomarkers and Analysis of Function in Non-Smoking Females with Lung Cancer. Medical Science Monitor, 2018, 24, 5771-5778.	0.5	34
1477	Inherited lung cancer syndromes targeting never smokers. Translational Lung Cancer Research, 2018, 7, 498-504.	1.3	31
1478	Therapeutic bronchoscopy in the era of genotype directed lung cancer management. Journal of Thoracic Disease, 2018, 10, 6298-6309.	0.6	16
1479	Value of combining serum carcinoembryonic antigen and PET/CT in predicting EGFR mutation in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, 723-731.	0.6	20
1480	A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors. Journal of Thoracic Disease, 2018, 10, E739-E743.	0.6	1
1481	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precision Oncology, 2018, 2, 1-11.	1.5	2
1482	CT-pathologic correlation in lung adenocarcinoma and squamous cell carcinoma. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overl	0.4	13
1483	Essential roles of mitochondrial and heme function in lung cancer bioenergetics and tumorigenesis. Cell and Bioscience, 2018, 8, 56.	2.1	31
1484	Clinical factors associated with mortality within three months after radiosurgery of asymptomatic brain metastases from non-small cell lung cancer. Journal of Neuro-Oncology, 2018, 140, 705-715.	1.4	5
1485	Nonsmall cell lung cancer with rare exon 7 p.A289V mutation in the EGFR gene responds to Icotinib treatment. Medicine (United States), 2018, 97, e13809.	0.4	12
1486	Nile Tilapia Derived TP4 Shows Broad Cytotoxicity Toward to Non-Small-Cell Lung Cancer Cells. Marine Drugs, 2018, 16, 506.	2.2	17
1487	Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors. Oncotarget, 2018, 9, 1641-1655.	0.8	25
1488	Epidermal Growth Factor Receptor Gene in Non-Small-Cell Lung Cancer: The Importance of Promoter Polymorphism Investigation. Analytical Cellular Pathology, 2018, 2018, 1-9.	0.7	35

#	Article	IF	Citations
1489	Realâ€world EGFR testing in patients with stage IIIB/IV nonâ€smallâ€cell lung cancer in North China: A multicenter, nonâ€interventional study. Thoracic Cancer, 2018, 9, 1461-1469.	0.8	28
1490	Analysis of Racial/Ethnic Representation in Select Basic and Applied Cancer Research Studies. Scientific Reports, 2018, 8, 13978.	1.6	105
1491	Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment. DNA and Cell Biology, 2018, 37, 903-908.	0.9	2
1492	Diagnostic and Predictive Immunohistochemistry for Nonâ€“Small Cell Lung Carcinomas. Advances in Anatomic Pathology, 2018, 25, 374-386.	2.4	15
1493	Lung adenocarcinoma with concurrent ALK and ROS1 rearrangement: A case report and review of the literatures. Pathology Research and Practice, 2018, 214, 2103-2105.	1.0	7
1494	Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma. Oncology Letters, 2018, 16, 7057-7067.	0.8	3
1495	Identification of genes and analysis of prognostic values in nonsmoking females with non-small cell lung carcinoma by bioinformatics analyses. Cancer Management and Research, 2018, Volume 10, 4287-4295.	0.9	20
1496	EGFR-TKI-sensitive mutations in lung carcinomas: are they related to clinical features and CT findings?. Cancer Management and Research, 2018, Volume 10, 4019-4027.	0.9	6
1497	The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications. Journal of Experimental and Clinical Cancer Research, 2018, 37, 226.	3.5	107
1498	Multiple treatment modalities for brain metastasis in patients with EGFR-mutant non-small-cell lung cancer. OncoTargets and Therapy, 2018, Volume 11, 2149-2155.	1.0	10
1499	Detection of Rare Mutations inEGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing. Yonsei Medical Journal, 2018, 59, 13.	0.9	10
1500	Clinicopathological and genetic characteristics associated with brain metastases from lung adenocarcinoma and utility as prognostic factors. Oncology Letters, 2018, 16, 4243-4252.	0.8	6
1501	A curated target gene pool assisting disease prediction and patientâ€specific biomarker selection for lung squamous cell carcinoma. Oncology Letters, 2018, 16, 5140-5146.	0.8	16
1502	Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1601-1611.	1.2	8
1503	Discovery of a Potent and Mutant-Selective EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Lung Cancer. Targeted Oncology, 2018, 13, 389-398.	1.7	2
1504	An Observational Study Evaluating the Performance of LENT Score in the Selected Population of Malignant Pleural Effusion from Lung Adenocarcinoma in Singapore. Respiration, 2018, 96, 308-313.	1.2	17
1505	Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer. Cancer Treatment Reviews, 2018, 69, 143-151.	3.4	23
1506	Exosome-mediated transfer of lncRNA RP11â€‘838N2.4 promotes erlotinib resistance in non-small cell lung cancer. International Journal of Oncology, 2018, 53, 527-538.	1.4	74

#	Article	IF	Citations
1507	The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis. OncoTargets and Therapy, 2018, Volume 11, 2345-2353.	1.0	9
1508	Small Molecules in Oncology. Recent Results in Cancer Research, 2018, , .	1.8	5
1509	Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients. Frontiers in Pharmacology, 2018, 9, 360.	1.6	9
1510	Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, T790M, and Clinical Trials. Current Oncology, 2018, 25, 28-37.	0.9	23
1511	Gefitinib. Recent Results in Cancer Research, 2018, 211, 235-246.	1.8	68
1512	Update on Immunohistochemistry for the Diagnosis of Lung Cancer. Cancers, 2018, 10, 72.	1.7	94
1513	Factors associated with gene aberration test status and treatment decision in patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer: A multicenter survey in China (CTONG 1506). Lung Cancer, 2018, 123, 7-13.	0.9	2
1514	Outcome of advanced lung cancer with central airway obstruction versus without central airway obstruction. ERJ Open Research, 2018, 4, 00173-2017.	1.1	12
1515	Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression. International Journal of Molecular Sciences, 2018, 19, 1259.	1.8	98
1516	TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Molecular Cancer Therapeutics, 2018, 17, 1648-1658.	1.9	64
1517	Kinase-targeted cancer therapies: progress, challenges and future directions. Molecular Cancer, 2018, 17, 48.	7.9	796
1518	Xenograft tumors derived from malignant pleural effusion of the patients with nonâ€smallâ€cell lung cancer as models to explore drug resistance. Cancer Communications, 2018, 38, 1-12.	3.7	14
1519	Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Annals of Translational Medicine, 2018, 6, 144-144.	0.7	19
1520	Notch3-dependent Î²-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC. Nature Communications, 2018, 9, 3198.	5.8	61
1521	A Nexus model of cellular transition in cancer. Biological Research, 2018, 51, 23.	1.5	1
1522	Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. Genes Chromosomes and Cancer, 2018, 57, 513-521.	1.5	12
1523	EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry. BMC Pulmonary Medicine, 2018, 18, 132.	0.8	8
1524	LncRNAs and EGFRvIII sequestered in TEPs enable blood-based NSCLC diagnosis. Cancer Management and Research, 2018, Volume 10, 1449-1459.	0.9	38

#	Article	IF	Citations
1525	Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients. OncoTargets and Therapy, 2018, Volume 11, 529-538.	1.0	13
1526	Molecular Basis of Pulmonary Disease. , 2018, , 347-386.		0
1527	The prognostic effect of the epidermal growth factor receptor gene mutation on recurrence dynamics of lung adenocarcinoma. European Journal of Cardio-thoracic Surgery, 2018, 54, 1022-1027.	0.6	6
1528	Pulmonary Adenocarcinoma, Harboring Both an <i>EGFR</i> Mutation and <i>ALK</i> Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib. Internal Medicine, 2018, 57, 2377-2382.	0.3	5
1529	Molecular designing, virtual screening and docking study of novel curcumin analogue as mutation (S769L and K846R) selective inhibitor for EGFR. Saudi Journal of Biological Sciences, 2019, 26, 439-448.	1.8	20
1530	Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib. Supportive Care in Cancer, 2019, 27, 1029-1039.	1.0	4
1531	AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells. Journal of Cellular Biochemistry, 2019, 120, 756-767.	1.2	29
1532	Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy. Clinical and Translational Oncology, 2019, 21, 298-303.	1.2	9
1533	TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer. PLoS ONE, 2019, 14, e0220173.	1.1	6
1534	Permutation-based simultaneous confidence bounds for the false discovery proportion. Biometrika, 2019, 106, 635-649.	1.3	24
1535	Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. Cells, 2019, 8, 878.	1.8	17
1536	Role of tumor gene mutations in treatment response to immune checkpoint blockades. Precision Clinical Medicine, 2019, 2, 100-109.	1.3	11
1537	Deep targeted sequencing analysis of hot spot mutations in non-small cell lung cancer patients from the Middle Eastern population. Journal of Thoracic Disease, 2019, 11, 2383-2391.	0.6	3
1538	Association of EGFR mutations and HMGB1 genetic polymorphisms in lung adenocarcinoma patients. Journal of Cancer, 2019, 10, 2907-2914.	1.2	14
1539	Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. Lung Cancer, 2019, 135, 66-72.	0.9	22
1540	Effect of Wellness Education on Quality of Life of Patients With Nonâ€“Small Cell Lung Cancer Treated With First-Line Icotinib and on Their Family Caregivers. Integrative Cancer Therapies, 2019, 18, 153473541984237.	0.8	12
1541	Increased EGFR mRNA Expression Levels in Non-Small Cell Lung Cancer. Eurasian Journal of Medicine, 2019, 51, 176-184.	0.2	6
1542	EGFR Targeted Therapy. Current Cancer Research, 2019, , 1-30.	0.2	2

#	Article	IF	Citations
1543	Lung genotoxicity of benzo(a)pyrene in vivo involves reactivation of LINE-1 retrotransposon and early reprogramming of oncogenic regulatory networks. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L816-L822.	1.3	3
1544	A multiple signal amplification electrochemical biosensors based on target DNA recycling for detection of the EGFR mutation status in lung cancer patients. Journal of Electroanalytical Chemistry, 2019, 853, 113555.	1.9	6
1545	The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706). Cancer Communications, 2019, 39, 69.	3.7	19
1546	Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review. BMC Cancer, 2019, 19, 1068.	1.1	31
1547	Landscape on CT screening for lung cancer in Asia . Lung Cancer: Targets and Therapy, 2019, Volume 10, 107-124.	1.3	20
1548	Prognostic value of adjuvant therapy in T4 nonâ€small cell lung cancer: An inverse probability of treatment weighting analysis. Thoracic Cancer, 2019, 10, 472-482.	0.8	3
1549	Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. European Journal of Cancer, 2019, 119, 77-86.	1.3	23
1550	Identification of Recurrent ActivatingHER2Mutations in Primary Canine Pulmonary Adenocarcinoma. Clinical Cancer Research, 2019, 25, 5866-5877.	3.2	24
1551	Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study. BMC Cancer, 2019, 19, 896.	1.1	33
1552	Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor. Journal of Thoracic Oncology, 2019, 14, 1766-1783.	0.5	30
1553	Mechanism of Resistance to Third-Generation Inhibitors. , 2019, , 163-171.		1
1554	Conclusion and Future Perspectives. , 2019, , 179-181.		0
1555	Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. Future Oncology, 2019, 15, 805-816.	1.1	32
1556	Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial . Cancer Management and Research, 2019, Volume 11, 4449-4459.	0.9	5
1557	Potential Influence on Clinical Trials of Long-Term Survivors of Stage IV Non-small cell Lung Cancer. JNCI Cancer Spectrum, 2019, 3, pkz010.	1.4	8
1558	A safety, pharmacokinetic, pharmacogenomic and population pharmacokinetic analysis of the thirdâ€generation EGFR TKI, olmutinib (HM61713), after single oral administration in healthy volunteers. Basic and Clinical Pharmacology and Toxicology, 2019, 125, 370-381.	1.2	9
1559	Prognostic significance of GAD1 overexpression in patients with resected lung adenocarcinoma. Cancer Medicine, 2019, 8, 4189-4199.	1.3	16
1560	The p53/miR-193a/EGFR feedback loop function as a driving force for non-small cell lung carcinoma tumorigenesis. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591985066.	1.4	17

#	Article	IF	Citations
1561	MET in glioma: signaling pathways and targeted therapies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 270.	3.5	99
1562	The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies. Diagnostic Pathology, 2019, 14, 59.	0.9	17
1564	Molecular profile of non-small cell lung cancer in northeastern Brazil. Jornal Brasileiro De Pneumologia, 2019, 45, e20180181.	0.4	12
1565	Frequency and significance of epidermal growth factor receptor mutations detected by PCR methods in patients with nonâ€‘small cell lung cancer. Oncology Letters, 2019, 17, 5125-5131.	0.8	6
1566	An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report. Journal of Medical Case Reports, 2019, 13, 144.	0.4	0
1567	Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discovery, 2019, 9, 926-943.	7.7	220
1568	Targeted methods for molecular characterization of EGFR mutational profile in lung cancer Moroccan cohort. Gene, 2019, 705, 36-43.	1.0	5
1569	Implementation planning for lung cancer screening in China. Precision Clinical Medicine, 2019, 2, 13-44.	1.3	28
1570	Reâ€biopsy and liquid biopsy for patients with nonâ€small cell lung cancer after EGFRâ€tyrosine kinase inhibitor failure. Thoracic Cancer, 2019, 10, 957-965.	0.8	25
1571	Application of amplicon-based targeted sequencing with the molecular barcoding system to detect uncommon minor EGFR mutations in patients with treatment-naÃ¯ve lung adenocarcinoma. BMC Cancer, 2019, 19, 175.	1.1	1
1572	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Expert Review of Anticancer Therapy, 2019, 19, 547-559.	1.1	22
1573	Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduction and Targeted Therapy, 2019, 4, 5.	7.1	231
1574	Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer. Anticancer Research, 2019, 39, 1767-1775.	0.5	10
1575	Tobacco Smoking Modifies the Association between Hormonal Factors and Lung Cancer Occurrence among Post-Menopausal Chinese Women. Translational Oncology, 2019, 12, 819-827.	1.7	11
1576	The Diagnostic Value of Quantitative CT Analysis of Ground-Glass Volume Percentage in Differentiating Epidermal Growth Factor Receptor Mutation and Subtypes in Lung Adenocarcinoma. BioMed Research International, 2019, 2019, 1-8.	0.9	4
1577	Osimertinib Did Not Respond to a Pulmonary Adenocarcinoma with Triple Mutations of Epidermal Growth Factor Receptor, G719S, T790M and S768I. Case Reports in Oncology, 2019, 12, 178-182.	0.3	1
1578	Clinical development of targeted and immune based anti-cancer therapies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 156.	3.5	170
1579	Osimertinib for patients with EGFR T790M mutation-positive nonâ€“small-cell lung cancer and a poor performance status. Japanese Journal of Clinical Oncology, 2019, 49, 671-675.	0.6	17

#	Article	IF	Citations
1580	Clinical features and treatment of patients with lung adenocarcinoma with bone marrow metastasis. Tumori, 2019, 105, 388-393.	0.6	15
1581	Discovery Stories of RET Fusions in Lung Cancer: A Mini-Review. Frontiers in Physiology, 2019, 10, 216.	1.3	33
1582	Genetic and Immunohistochemical Studies Investigating the Histogenesis of Neuroendocrine and Carcinomatous Components of Combined Neuroendocrine Carcinoma. Annals of Surgical Oncology, 2019, 26, 1744-1750.	0.7	4
1583	Novel mechanism of resistance to targeted therapies in lung cancer. Molecular and Cellular Oncology, 2019, 6, 1551015.	0.3	1
1584	Disparities and Trends in Genetic Testing and Erlotinib Treatment among Metastatic Nonâ€“Small Cell Lung Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 926-934.	1.1	27
1585	Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations. Investigational New Drugs, 2019, 37, 1207-1217.	1.2	6
1586	First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease. Journal of Cancer, 2019, 10, 522-529.	1.2	43
1587	Genetic and epigenetic alterations of the EGFR and mutually independent association with BRCA1, MGMT, and RASSF1A methylations in Vietnamese lung adenocarcinomas. Pathology Research and Practice, 2019, 215, 885-892.	1.0	10
1588	The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer, 2019, 19, 145.	1.1	47
1589	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. Journal of Thoracic Oncology, 2019, 14, 867-875.	0.5	260
1590	Genotyping and cytomorphological subtyping of lung adenocarcinoma based on liquidâ€based cytology. Diagnostic Cytopathology, 2019, 47, 564-570.	0.5	9
1591	Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations. Cancer Science, 2019, 110, 867-874.	1.7	17
1592	Non-Smoking-Associated Lung Cancer: A distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition. Cancers, 2019, 11, 204.	1.7	48
1593	Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations. Scientific Reports, 2019, 9, 3209.	1.6	38
1594	Mechanisms of resistance to pemetrexed in non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 1107-1118.	1.3	34
1595	Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series. CNS Oncology, 2019, 8, CNS42.	1.2	3
1596	High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. , 2019, 7, 351.		39
1597	Assessing EGFR gene mutation status in non-small cell lung cancer with imaging features from PET/CT. Nuclear Medicine Communications, 2019, 40, 842-849.	0.5	30

#	Article	IF	Citations
1598	Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib. Medicine (United States), 2019, 98, e13890.	0.4	14
1599	Epidermal growth factor receptor first generation tyrosine-kinase inhibitors. Translational Lung Cancer Research, 2019, 8, S235-S246.	1.3	8
1600	The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduction and Targeted Therapy, 2019, 4, 61.	7.1	436
1601	Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients. Journal of Thoracic Disease, 2019, 11, 4992-5003.	0.6	14
1602	Knowledge base toward understanding actionable alterations and realizing precision oncology. International Journal of Clinical Oncology, 2019, 24, 123-130.	1.0	9
1603	Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers. Archives of Pathology and Laboratory Medicine, 2019, 143, 174-182.	1.2	15
1604	Emerging drugs for EGFR-mutated non-small cell lung cancer. Expert Opinion on Emerging Drugs, 2019, 24, 5-16.	1.0	10
1605	Prediction of EGFR mutations by conventional CT-features in advanced pulmonary adenocarcinoma. European Journal of Radiology, 2019, 112, 44-51.	1.2	11
1606	Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. Lung Cancer, 2019, 127, 25-33.	0.9	13
1607	Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. Seminars in Cancer Biology, 2019, 54, 14-28.	4.3	51
1608	Survival Disparities in Black Patients With EGFR-mutated Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2020, 21, 177-185.	1.1	10
1609	Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Nonâ€“small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy. Clinical Lung Cancer, 2020, 21, 1-14.e3.	1.1	19
1610	Cancer of the Lung. , 2020, , 1108-1158.e16.		11
1612	Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis. European Journal of Cancer, 2020, 124, 1-14.	1.3	32
1613	Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision. Lung Cancer, 2020, 139, 35-40.	0.9	35
1614	Brain malignancies: Glioblastoma and brain metastases. Seminars in Cancer Biology, 2020, 60, 262-273.	4.3	208
1615	Precision medicine at the academic-industry interface. , 2020, , 545-560.		1
1616	From clinical specimens to human cancer preclinical modelsâ€”a journey the NCIâ€cell line databaseâ€”25 years later. Journal of Cellular Biochemistry, 2020, 121, 3986-3999.	1.2	6

#	Article	IF	Citations
1617	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e191-e204.	1.1	26
1618	mPRÎ± mediates P4/Org OD02â€0 to improve the sensitivity of lung adenocarcinoma to EGFRâ€TKIs via the EGFRâ€SRCâ€ERK1/2 pathway. Molecular Carcinogenesis, 2020, 59, 179-192.	1.3	10
1619	Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Lung Cancer, 2020, 139, 207-215.	0.9	79
1620	Reproductive factors and lung cancer risk: a comprehensive systematic review and meta-analysis. BMC Public Health, 2020, 20, 1458.	1.2	14
1621	Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.4	1
1622	Frequency and types of EGFR mutations in Moroccan patients with nonâ€“small cell lung cancer. Tumori, 2021, 107, 335-340.	0.6	7
1623	Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis. Lung Cancer, 2020, 150, 83-89.	0.9	9
1624	Magnetic Iron Nanocubes Effectively Capture Epithelial and Mesenchymal Cancer Cells. ACS Omega, 2020, 5, 23724-23735.	1.6	2
1625	Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Nonâ€“Small-Cell Lung Cancer Patients With EGFR Mutation. Clinical Lung Cancer, 2020, 21, 273-280.e4.	1.1	21
1626	Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors . Cancer Management and Research, 2020, Volume 12, 5439-5450.	0.9	8
1627	Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors. Lung Cancer, 2020, 150, 178-185.	0.9	18
1628	How should molecular findings be integrated in the classification for lung cancer?. Translational Lung Cancer Research, 2020, 9, 2245-2254.	1.3	5
1629	Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way. Annals of Translational Medicine, 2020, 8, 1111-1111.	0.7	2
1630	Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer. Pharmaceuticals, 2020, 13, 374.	1.7	11
1631	A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity. Marine Drugs, 2020, 18, 604.	2.2	10
1632	SOX4 Mediates BRAF Inhibitor Resistance in Melanoma through Regulation of IGF-1R Signaling: In Vitro Study. International Journal of Dermatology and Venereology, 2020, 3, 156-165.	0.1	1
1633	High frequency of exon 20 <scp>S768I EGFR</scp> mutation detected in malignant pleural effusions: A poor prognosticator of <scp>NSCLC</scp>. Cancer Reports, 2020, 3, e1262.	0.6	4
1634	Molecular profiling of non-small cell lung cancer. PLoS ONE, 2020, 15, e0236580.	1.1	17

#	Article	IF	Citations
1635	Identification of a Microsatellite Stable, EGFR-Mutant Lung Adenocarcinoma Developing in a Patient With Lynch Syndrome. JCO Precision Oncology, 2020, 4, 818-822.	1.5	2
1636	Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 664-674.e7.	0.4	34
1637	The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models. BMC Cancer, 2020, 20, 738.	1.1	9
1638	Multiomics Reveals Ectopic ATP Synthase Blockade Induces Cancer Cell Death via a lncRNA-mediated Phospho-signaling Network. Molecular and Cellular Proteomics, 2020, 19, 1805-1825.	2.5	11
1639	Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types. Annals of Translational Medicine, 2020, 8, 860-860.	0.7	9
1640	Associations of TIMP-3 Genetic Polymorphisms with EGFR Statuses and Cancer Clinicopathologic Development in Lung Adenocarcinoma Patients. International Journal of Molecular Sciences, 2020, 21, 8023.	1.8	11
1641	An examination of two dichotomies: Women with lung cancer and living with lung cancer as a chronic disease. Respirology, 2020, 25, 24-36.	1.3	10
1642	Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms. Cancer Chemotherapy and Pharmacology, 2020, 86, 517-525.	1.1	3
1643	Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan. BMJ Open, 2020, 10, e035615.	0.8	4
1644	Expression, intracellular localization, and mutation of EGFR in conjunctival squamous cell carcinoma and the association with prognosis and treatment. PLoS ONE, 2020, 15, e0238120.	1.1	6
1645	An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan. Frontiers in Oncology, 2020, 10, 1481.	1.3	25
1646	Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. Crystals, 2020, 10, 725.	1.0	4
1647	Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors. Frontiers in Oncology, 2020, 10, 602762.	1.3	59
1648	Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP). Frontiers in Oncology, 2020, 10, 588932.	1.3	4
1649	Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report. BMC Cancer, 2020, 20, 1177.	1.1	3
1650	Proteomic signatures of 16 major types of human cancer reveal universal and cancer-type-specific proteins for the identification of potential therapeutic targets. Journal of Hematology and Oncology, 2020, 13, 170.	6.9	25
1651	Sparse superlayered neural network-based multi-omics cancer subtype classification. International Journal of Data Mining and Bioinformatics, 2020, 24, 58.	0.1	2
1652	Bridging the Gap: The Impact of Genetic Ancestry on Routes to Tumorigenesis. Cancer Cell, 2020, 37, 619-621.	7.7	1

#	Article	IF	Citations
1653	Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. Investigational New Drugs, 2020, 38, 1854-1861.	1.2	18
1654	Epidermal growth factor receptor mutations in nonâ€“small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reactionâ€“based assays. Journal of the Chinese Medical Association, 2020, 83, 345-349.	0.6	2
1655	Combination effects of ellagic acid with erlotinib in a Ba/ F3 cell line expressing EGFR H773_V774 insH mutation. Thoracic Cancer, 2020, 11, 2101-2111.	0.8	5
1656	Multiâ€omics analysis reveals the functional transcription and potential translation of enhancers. International Journal of Cancer, 2020, 147, 2210-2224.	2.3	11
1657	Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Nonâ€“Small Cell Lung Cancer and Response to EGFR TKIs. Translational Oncology, 2020, 13, 100791.	1.7	17
1658	Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer. Future Oncology, 2020, 16, 1575-1584.	1.1	9
1659	Targeted Therapy for Non-Small Cell Lung Cancer. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 409-434.	0.8	11
1660	Molecular Diagnostics in Non-Small Cell Lung Carcinoma. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 386-399.	0.8	3
1661	Lung cancer histology-driven strategic therapeutic approaches. Shanghai Chest, 0, 4, 29-29.	0.3	4
1662	Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment. Cancers, 2020, 12, 1587.	1.7	24
1663	Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a firstâ€line treatment for advanced EGFRâ€mutant nonâ€small cell lung cancer. Clinical and Translational Medicine, 2020, 10, e33.	1.7	13
1664	The top 100 cited articles in lung cancer â€“ a bibliometric analysis. Wspolczesna Onkologia, 2020, 24, 17-28.	0.7	7
1665	Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance. Trends in Pharmacological Sciences, 2020, 41, 336-348.	4.0	60
1666	Integrative Analysis of Methylation and Gene Expression in Lung Adenocarcinoma and Squamous Cell Lung Carcinoma. Frontiers in Bioengineering and Biotechnology, 2020, 8, 3.	2.0	11
1667	Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis. Frontiers in Oncology, 2020, 10, 904.	1.3	34
1668	Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial . Cancer Management and Research, 2020, Volume 12, 4633-4643.	0.9	8
1669	Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. Advances in Cancer Research, 2020, 147, 1-57.	1.9	32
1670	Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature. World Journal of Surgical Oncology, 2020, 18, 153.	0.8	5

#	Article	IF	Citations
1671	Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients. Scientific Reports, 2020, 10, 2070.	1.6	13
1672	Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect onEGFRMutationâ€“Positive Lung Adenocarcinoma. Tuberculosis and Respiratory Diseases, 2020, 83, 51.	0.7	13
1673	Diagnostic Molecular Pathology. , 2020, , 2145-2159.		0
1674	Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. Critical Reviews in Oncology/Hematology, 2020, 148, 102906.	2.0	43
1675	Investigation of Potential Mechanisms Associated with Non-small Cell Lung Cancer. Journal of Computational Biology, 2020, 27, 1433-1442.	0.8	5
1676	Front-line Therapy in Advanced Nonâ€“Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis. Clinical Therapeutics, 2020, 42, 338-350.e4.	1.1	13
1677	Imaging-Based Surrogate Markers of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma: A Local Perspective. Canadian Association of Radiologists Journal, 2020, 71, 208-216.	1.1	2
1678	Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors. Advances in Therapy, 2020, 37, 946-954.	1.3	15
1679	Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer. BMC Cancer, 2020, 20, 76.	1.1	14
1680	Racial disparities in bone metastasis patterns and targeted screening and treatment strategies in newly diagnosed lung cancer patients. Ethnicity and Health, 2022, 27, 329-342.	1.5	8
1681	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. Molecular Oncology, 2021, 15, 27-42.	2.1	15
1682	Comparison of Detection of Epidermal Growth Factor Receptor (EFGR) Gene Mutation in Peripheral Blood Plasma (Liquid Biopsy) with Cytological Specimens in Lung Adenocarcinoma Patients. Indian Journal of Surgical Oncology, 2021, 12, 65-71.	0.3	6
1683	Development, internal validation and calibration of a risk score to predict survival in patients with EGFR-mutant non-small cell lung cancer. Journal of Clinical Pathology, 2021, 74, 116-122.	1.0	5
1684	Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers. Journal of Thoracic Oncology, 2021, 16, 113-126.	0.5	13
1685	Hormonal factors in association with lung cancer among Asian women: A pooled analysis from the International Lung Cancer Consortium. International Journal of Cancer, 2021, 148, 2241-2254.	2.3	9
1686	Clinical Characteristics, Treatments, and Concurrent Mutations in Nonâ€“Small Cell Lung Cancer Patients With NF1 Mutations. Clinical Lung Cancer, 2021, 22, 32-41.e1.	1.1	6
1687	Germline EGFR variants are over-represented in adolescents and young adults (AYA) with adrenocortical carcinoma. Human Molecular Genetics, 2021, 29, 3679-3690.	1.4	6
1688	Clinical and radiological predictors of epidermal growth factor receptor mutation in nonsmall cell lung cancer. Journal of Applied Clinical Medical Physics, 2021, 22, 271-280.	0.8	13

#	Article	IF	Citations
1689	Effectiveness of <scp>EGFR</scp> tyrosine kinase inhibitors in advanced nonâ€small cell lung cancer patients with uncommon <scp>EGFR</scp> mutations: A multicenter observational study. Thoracic Cancer, 2021, 12, 90-96.	0.8	5
1690	Cancer health disparities in racial/ethnic minorities in the United States. British Journal of Cancer, 2021, 124, 315-332.	2.9	447
1691	Deciphering the T790M/L858R-Selective Inhibition Mechanism of an Allosteric Inhibitor of EGFR: Insights from Molecular Simulations. ACS Chemical Neuroscience, 2021, 12, 462-472.	1.7	7
1692	Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110069.	1.4	4
1693	Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib. Journal of Cancer, 2021, 12, 644-651.	1.2	8
1694	Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 612.	1.8	79
1695	Advances in anti-BRAF therapies for lung cancer. Investigational New Drugs, 2021, 39, 879-890.	1.2	22
1696	Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US. Journal of Medical Economics, 2021, 24, 328-338.	1.0	0
1698	The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Reports Medicine, 2021, 2, 100186.	3.3	90
1699	Genomic Profiling and Prognostic Value Analysis of Genetic Alterations in Chinese Resected Lung Cancer With Invasive Mucinous Adenocarcinoma. Frontiers in Oncology, 2020, 10, 603671.	1.3	8
1700	Afatinib in EGFR TKI-naÃ¯ve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. Lung Cancer, 2021, 152, 127-134.	0.9	17
1701	Use tumor suppressor genes as biomarkers for diagnosis of non-small cell lung cancer. Scientific Reports, 2021, 11, 3596.	1.6	10
1702	Extensive functional evaluation of exon 20 insertion mutations of EGFR. Lung Cancer, 2021, 152, 135-142.	0.9	15
1703	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers, 2021, 13, 804.	1.7	76
1704	Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review. PLoS ONE, 2021, 16, e0247620.	1.1	43
1705	Synthesis and evaluation of azalamellarin N and its A-ring-modified analogues as non-covalent inhibitors of the EGFR T790M/L858R mutant. Bioorganic and Medicinal Chemistry, 2021, 34, 116039.	1.4	6
1706	Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice. Journal of Thoracic Disease, 2021, 13, 1658-1670.	0.6	4
1707	Potential Impacts of Interleukin-17A Promoter Polymorphisms on the EGFR Mutation Status and Progression of Non-Small Cell Lung Cancer in Taiwan. Genes, 2021, 12, 427.	1.0	4

#	Article	IF	Citations
1708	Genomic landscape of ground glass opacities (GGOs) in East Asians. Journal of Thoracic Disease, 2021, 13, 2393-2403.	0.6	2
1709	Targeted exome sequencing identifies mutational landscape in a cohort of 1500 Chinese patients with non-small cell lung carcinoma (NSCLC). Human Genomics, 2021, 15, 21.	1.4	8
1710	Non-Small-Cell Lung Cancer: New Rare Targetsâ€"New Targeted Therapiesâ€"State of The Art and Future Directions. Cancers, 2021, 13, 1829.	1.7	14
1711	Lung Cancer and Processing the Unknown: The Shoes of Damocles and 8 Coping Strategies. Clinical Therapeutics, 2021, 43, 1432-1434.	1.1	1
1712	Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective. Critical Reviews in Oncology/Hematology, 2021, 160, 103300.	2.0	6
1713	Application of the conventional and novel methods in testing EGFR variants for NSCLC patients in the last 10 years through different regions: a systematic review. Molecular Biology Reports, 2021, 48, 3593-3604.	1.0	12
1714	Comparison and Fusion of Machine Learning Algorithms for Prospective Validation of PET/CT Radiomic Features Prognostic Value in Stage II-III Non-Small Cell Lung Cancer. Diagnostics, 2021, 11, 675.	1.3	17
1715	Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers. Scientific Reports, 2021, 11, 10470.	1.6	7
1717	Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. Lung Cancer, 2021, 155, 127-135.	0.9	6
1718	The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2239-2248.	1.2	1
1719	EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP). JCO Precision Oncology, 2021, 5, 839-848.	1.5	3
1720	Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?. Translational Oncology, 2021, 14, 101056.	1.7	17
1721	Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer. Lung Cancer, 2021, 155, 34-39.	0.9	6
1722	Quantitative analysis of cell-free DNA by droplet digital PCR reveals the presence of EGFR mutations in non-malignant lung pathologies. Monaldi Archives for Chest Disease, 2021, 91, .	0.3	1
1723	Kinase drug discovery 20 years after imatinib: progress and future directions. Nature Reviews Drug Discovery, 2021, 20, 551-569.	21.5	497
1725	The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. Expert Opinion on Drug Discovery, 2021, 16, 1091-1103.	2.5	6
1726	Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer Research, 2021, 81, 3916-3929.	0.4	13
1727	Somatic mutation subtypes of lung adenocarcinoma in East Asian reveal divergent biological characteristics and therapeutic vulnerabilities. IScience, 2021, 24, 102522.	1.9	4

#	Article	IF	Citations
1728	Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas. Scientific Reports, 2021, 11, 14999.	1.6	5
1729	Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines. Future Oncology, 2021, 17, 2513-2527.	1.1	7
1730	Paradigm shift in the management of metastatic nonsmall cell lung cancer. International Journal of Clinical Practice, 2021, 75, e14533.	0.8	0
1731	Massage therapy as a complementary and alternative approach for people with multiple sclerosis: a systematic review. Disability and Rehabilitation, 2022, 44, 5758-5769.	0.9	5
1732	Amivantamab in EGFR Exon 20 Insertionâ€“Mutated Nonâ€“Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Journal of Clinical Oncology, 2021, 39, 3391-3402.	0.8	320
1733	Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Nonâ€“Squamous Nonâ€“Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy. Clinical Lung Cancer, 2021, 22, 587-595.	1.1	7
1734	Long-term survival in a patient with advanced lung adenocarcinoma harboring synchronous EGFR exon 18 G719A and BRAF V600E mutations and treated with afatinib. Anti-Cancer Drugs, 2021, Publish Ahead of Print, .	0.7	0
1735	Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC. Life, 2021, 11, 843.	1.1	5
1736	Cytoplasmic P120ctn Promotes Gefitinib Resistance in Lung Cancer Cells by Activating PAK1 and ERK Pathway. Applied Immunohistochemistry and Molecular Morphology, 2021, 29, 750-758.	0.6	8
1737	Survival of gefitinib treated advanced non-small cell lung cancer patients harbouring EGNR mutations. Pharmacy & Pharmacology International Journal, 2021, 9, 171-174.	0.1	0
1738	Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer. Chest, 2021, 160, 1095-1107.	0.4	23
1739	Updates in the molecular pathology of non-small cell lung cancer. Seminars in Diagnostic Pathology, 2021, 38, 54-61.	1.0	10
1740	A Novel Tool for the Risk Assessment and Personalized Chemo-/Immunotherapy Response Prediction of Adenocarcinoma and Squamous Cell Carcinoma Lung Cancer. International Journal of General Medicine, 2021, Volume 14, 5771-5785.	0.8	2
1741	Clinicopathologic features and prognostic value of epidermal growth factor receptor mutation in patients with pT1a and pT1b invasive lung adenocarcinoma after surgical resection. Journal of Thoracic Disease, 2021, 13, 5496-5507.	0.6	2
1742	Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer. Translational Lung Cancer Research, 2021, 10, 128-142.	1.3	13
1743	Clinical Effects of T790M Mutation in EGFR Tyrosine Kinase Inhibitor Resistant NSCLC Patients. Kocaeli Medical Journal, 2021, 10, 51-56.	0.1	0
1744	Supplements for Smoking-Related Lung Diseases. Encyclopedia, 2021, 1, 76-86.	2.4	5
1746	Molecular Biology of Preneoplastic Lesions of the Lung. , 0, , 84-98.		1

#	Article	IF	Citations
1747	Antibodies as Cancer Immunotherapy. , 2013, , 335-376.		2
1748	Epidermal Growth Factor Receptor. , 2016, , 1-11.		1
1749	Molecular Basis of Lung Carcinogenesis. , 2017, , 447-496.		4
1750	Clinical Implications of Epigenetic Alterations in Human Thoracic Malignancies: Epigenetic Alterations in Lung Cancer. Methods in Molecular Biology, 2012, 863, 221-239.	0.4	7
1751	The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response. Advances in Experimental Medicine and Biology, 2020, 1219, 311-333.	0.8	6
1752	Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer. , 2008, , 1307-1366.		7
1753	DEFINITIVE MANAGEMENT OF INOPERABLE NONâ€“SMALL CELL LUNG CANCER. , 2008, , 804-821.		1
1754	Cancer of the Lung. , 2014, , 1143-1192.e13.		5
1755	Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell, 2020, 37, 639-654.e6.	7.7	151
1756	Next-Generation Sequencing. Journal of Molecular Diagnostics, 2017, 19, 870-880.	1.2	43
1757	Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2012, 58, 263-268.	0.3	4
1758	Genomic landscape of lung adenocarcinoma in East Asians. Nature Genetics, 2020, 52, 177-186.	9.4	281
1761	An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. Expert Review of Molecular Diagnostics, 2018, 18, 35-45.	1.5	42
1762	An overview of cancer health disparities: new approaches and insights and why they matter. Carcinogenesis, 2021, 42, 2-13.	1.3	39
1763	E12-01: NCI Director's challenge gene profiling of lung adenocarcinomas: impact on histologic classification. Journal of Thoracic Oncology, 2007, 2, S254-S256.	0.5	1
1764	Combined Analysis of Molecular and Clinical Predictors of Gefitinib Activity in Advanced Non???Small Cell Lung Cancer: Epidermal Growth Factor Receptor Mutations Do Not Tell the Whole Story. Journal of Thoracic Oncology, 2006, 1, 52-60.	0.5	13
1765	Clinico-Pathological and Biological Significance of Tyrosine Kinase Domain Gene Mutations and Overexpression of Epidermal Growth Factor Receptor for Lung Adenocarcinoma. Journal of Thoracic Oncology, 2006, 1, 787-795.	0.5	34
1766	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 22-28.	0.5	134

#	Article	IF	Citations
1767	The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 171-178.	0.5	79
1769	Abstract 275: Burkitt lymphoma cells express GLI1 but are not responsive to Hedgehog signaling. Cancer Research, 2011, 71, 275-275.	0.4	91
1770	New molecularly targeted therapies for lung cancer. Journal of Clinical Investigation, 2007, 117, 2740-2750.	3.9	180
1771	ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. Journal of Clinical Investigation, 2012, 122, 1869-1880.	3.9	109
1772	Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Tumor Biology, 2017, 39, 101042831770534.	0.8	4
1773	Novel visualized quantitative epigenetic imprinted gene biomarkers diagnose the malignancy of ten cancer types. Clinical Epigenetics, 2020, 12, 71.	1.8	13
1774	Correlation Between Nuclear Factor E2-Related Factor 2 Expression and Gastric Cancer Progression. Medical Science Monitor, 2015, 21, 2893-2899.	0.5	21
1775	Absence of Epidermal Growth Factor Receptor Gene Mutations in Lung and Liver Tumors in Rats. Journal of Toxicologic Pathology, 2007, 20, 65-69.	0.3	1
1776	Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells. PLoS ONE, 2009, 4, e7464.	1.1	205
1777	Curcumin Induces EGFR Degradation in Lung Adenocarcinoma and Modulates p38 Activation in Intestine: The Versatile Adjuvant for Gefitinib Therapy. PLoS ONE, 2011, 6, e23756.	1.1	95
1778	Cigarette Smoking and p16INK4Î± Gene Promoter Hypermethylation in Non-Small Cell Lung Carcinoma Patients: A Meta-Analysis. PLoS ONE, 2011, 6, e28882.	1.1	24
1779	Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e64816.	1.1	71
1780	Identification and Characterization of Cancer Mutations in Japanese Lung Adenocarcinoma without Sequencing of Normal Tissue Counterparts. PLoS ONE, 2013, 8, e73484.	1.1	41
1781	Colorectal Cancers from Distinct Ancestral Populations Show Variations in BRAF Mutation Frequency. PLoS ONE, 2013, 8, e74950.	1.1	34
1782	Anti-Cancer Effects of REIC/Dkk-3-encoding Adenoviral Vector for the Treatment of Non-small Cell Lung Cancer. PLoS ONE, 2014, 9, e87900.	1.1	23
1783	The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients. PLoS ONE, 2015, 10, e0124354.	1.1	17
1784	Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib. PLoS ONE, 2015, 10, e0125232.	1.1	27
1785	Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations. PLoS ONE, 2015, 10, e0135393.	1.1	9

#	Article	IF	Citations
1786	Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger. PLoS ONE, 2015, 10, e0136659.	1.1	13
1787	MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. PLoS ONE, 2015, 10, e0143333.	1.1	21
1788	Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients. PLoS ONE, 2016, 11, e0150623.	1.1	4
1789	Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines. PLoS ONE, 2016, 11, e0150963.	1.1	12
1790	A Histopathological Feature of EGFR-Mutated Lung Adenocarcinomas with Highly Malignant Potential â€“ An Implication of Micropapillary Element -. PLoS ONE, 2016, 11, e0166795.	1.1	13
1791	Identifying EGFR Mutations from SCLC Patient Plasma by Mutant-Enriched Liquidchip Technology. Advances in Clinical and Experimental Medicine, 2014, 23, 191-195.	0.6	1
1792	Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients. Oncotarget, 2016, 7, 53299-53308.	0.8	9
1793	A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?. Oncotarget, 2016, 7, 56998-57010.	0.8	51
1794	Predictive and prognostic value of preoperative serum tumor markers in resectable adenosqamous lung carcinoma. Oncotarget, 2016, 7, 64798-64809.	0.8	10
1795	BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations. Oncotarget, 2016, 7, 68933-68942.	0.8	26
1796	Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR. Oncotarget, 2017, 8, 5861-5873.	0.8	41
1797	Impact of country of birth on genetic testing of metastatic lung adenocarcinomas in France: African women exhibit a mutational spectrum more similar to Asians than to Caucasians. Oncotarget, 2017, 8, 50792-50803.	0.8	2
1798	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget, 2017, 8, 41474-41486.	0.8	13
1799	Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer. Oncotarget, 2017, 8, 100801-100818.	0.8	35
1800	EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget, 2017, 8, 98384-98393.	0.8	58
1801	Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. Oncotarget, 2017, 8, 105479-105491.	0.8	41
1802	Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget, 2014, 5, 8937-8946.	0.8	6
1803	Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget, 2018, 9, 14268-14284.	0.8	12

#	Article	IF	Citations
1804	Outcome analysis of Phase I trial patients with metastaticKRASand/orTP53mutant non-small cell lung cancer. Oncotarget, 2018, 9, 33258-33270.	0.8	9
1805	The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy. Oncotarget, 2020, 11, 1953-1960.	0.8	19
1806	Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. Oncotarget, 2015, 6, 2164-2179.	0.8	43
1807	Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget, 2015, 6, 4553-4561.	0.8	85
1808	Nuclear estrogen receptor-Î± expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration. Oncotarget, 2015, 6, 27505-27518.	0.8	21
1809	In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget, 2015, 6, 38789-38803.	0.8	137
1810	The status of epidermal growth factor receptor in borderline ovarian tumours. Oncotarget, 2016, 7, 10568-10577.	0.8	5
1811	Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status. Oncotarget, 2016, 7, 46628-46635.	0.8	36
1812	Drug resistance to EGFR tyrosine kinase inhibitors for non-small cell lung cancer. Acta Medica Okayama, 2014, 68, 191-200.	0.1	15
1813	The impact of epidermal growth factor receptor mutations on the prognosis of resected non-small cell lung cancer: a meta-analysis of literatures. Translational Lung Cancer Research, 2019, 8, 124-134.	1.3	30
1814	Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 543-552.	0.7	27
1815	Biomarkers for the targeted therapies of non-small cell lung cancer. Current Biomarker Findings, 0, , 7.	0.4	3
1816	IMPMD: An Integrated Method for Predicting Potential Associations Between miRNAs and Diseases. Current Genomics, 2020, 20, 581-591.	0.7	2
1817	From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2019, 18, 1235-1240.	0.9	9
1818	Lung Adenocarcinoma in Never Smokers: Problems of Primary Prevention from Aspects of Susceptible Genes and Carcinogens. Anticancer Research, 2016, 36, 6207-6224.	0.5	30
1819	Frequency of Epidermal Growth Factor Receptor Mutation in Smokers with Lung Cancer Without Pulmonary Emphysema. Anticancer Research, 2017, 37, 765-772.	0.5	6
1820	The frequency of EGFR And KRAS mutations in the Turkish population with non-small cell lung cancer and their response to erlotinib therapy. Balkan Journal of Medical Genetics, 2018, 21, 21-26.	0.5	11
1821	A Case of Small-cell Lung Carcinoma with EGFR Gene Mutation. Japanese Journal of Lung Cancer, 2011, 51, 798-802.	0.0	1

#	Article	IF	Citations
1822	Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC. Asian Pacific Journal of Cancer Prevention, 2019, 20, 3581-3589.	0.5	6
1823	Identifying the Causes of Cancer Health Disparities. Californian Journal of Health Promotion, 2010, 8, 101-111.	0.3	2
1824	Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. Frontiers in Oncology, 2019, 9, 263.	1.3	62
1825	Comprehensive Perspective for Lung Cancer Characterisation Based on AI Solutions Using CT Images. Journal of Clinical Medicine, 2021, 10, 118.	1.0	14
1826	Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). Pharmaceuticals, 2020, 13, 273.	1.7	28
1829	EGFR mutation status in a series of Turkish non-small cell lung cancer patients. Biomedical Reports, 2020, 13, 2.	0.9	5
1830	Placentaâ€‘specific protein 8 promotes the proliferation of lung adenocarcinoma PCâ€‘9 cells and their tolerance to an epidermal growth factor receptor tyrosine kinase inhibitor by activating the ERK signaling pathway. Oncology Letters, 2019, 18, 5621-5627.	0.8	7
1831	A Comparison of Patient Acceptance and Preferences Between CT Colonography and Conventional Colonoscopy in Colorectal Cancer Screening. Korean Journal of Internal Medicine, 2009, 24, 43.	0.7	41
1832	EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung. Korean Journal of Internal Medicine, 2009, 24, 48.	0.7	60
1833	A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC. Mathematical Biosciences and Engineering, 2019, 16, 5687-5696.	1.0	1
1834	The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. Journal of Thoracic Disease, 2010, 2, 144-53.	0.6	10
1835	Treatment of advanced non small cell lung cancer. Journal of Thoracic Disease, 2011, 3, 122-33.	0.6	99
1836	Molecular biology of lung cancer. Journal of Thoracic Disease, 2013, 5 Suppl 5, S479-90.	0.6	173
1837	The pivotal role of pathology in the management of lung cancer. Journal of Thoracic Disease, 2013, 5 Suppl 5, S463-78.	0.6	99
1838	Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. Journal of Thoracic Disease, 2014, 6, 387-98.	0.6	23
1839	Immunotherapy in lung cancer. Translational Lung Cancer Research, 2014, 3, 53-63.	1.3	50
1840	Epidermal growth factor receptor in non-small cell lung cancer. Translational Lung Cancer Research, 2015, 4, 110-8.	1.3	56
1841	Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer. Translational Lung Cancer Research, 2015, 4, 165-76.	1.3	103

#	Article	IF	Citations
1842	Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. Translational Lung Cancer Research, 2015, 4, 584-97.	1.3	52
1844	Association between thyroid cancer and epidermal growth factor receptor mutation in female with nonsmall cell lung cancer. Annals of Thoracic Medicine, 2017, 12, 36.	0.7	1
1845	Team Management of Skin Rash Associated with Use of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. Asia-Pacific Journal of Oncology Nursing, 2018, 5, 430-434.	0.7	4
1846	Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region. Annals of Thoracic Medicine, 2019, 14, 173.	0.7	8
1847	Saudi lung cancer management guidelines 2017. Annals of Thoracic Medicine, 2017, 12, 221.	0.7	16
1848	Targeted therapy in nonsmall cell lung cancer. Indian Journal of Cancer, 2017, 54, 83.	0.2	6
1849	Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?. Lung India, 2018, 35, 27.	0.3	3
1850	Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey. Journal of Pathology and Translational Medicine, 2015, 49, 481-488.	0.4	24
1851	Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial. Cancer Research and Treatment, 2015, 47, 616-629.	1.3	10
1852	Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study. Cancer Research and Treatment, 2017, 49, 937-946.	1.3	7
1853	Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer. Cancer Research and Treatment, 2018, 50, 95-102.	1.3	22
1854	Report of the Korean Association of Lung Cancer Registry (KALC-R), 2014. Cancer Research and Treatment, 2019, 51, 1400-1410.	1.3	49
1855	Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer Research and Treatment, 2020, 52, 284-291.	1.3	4
1856	Overexpression of Nrf2 promotes colon cancer progression via ERK and AKT signaling pathways. Annals of Surgical Treatment and Research, 2020, 98, 159.	0.4	19
1857	Better Selection Model for EML4-ALK Fusion Gene Test in Patients with Non-Small-Cell Lung Cancer. Journal of Cancer Therapy, 2013, 04, 54-58.	0.1	3
1858	Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population. Balkan Medical Journal, 2017, 34, 567-571.	0.3	7
1859	Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures. Pharmacy Practice, 2006, 4, 168-78.	0.8	9
1860	Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non- Small-Cell Lung Cancer. Turkish Thoracic Journal, 2017, 18, 66-71.	0.2	7

#	Article	IF	Citations
1861	Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. International Journal of Biological Markers, 2007, 22, 10-23.	0.7	5
1862	Tunable structure priors for Bayesian rule learning for knowledge integrated biomarker discovery. World Journal of Clinical Oncology, 2018, 9, 98-109.	0.9	2
1863	Correlation of genes associated with drug response to prognosis of large cell lung carcinoma. Chinese Journal of Cancer, 2011, 30, 497-504.	4.9	5
1864	Bronchioloalveolar Carcinoma: A Review of Current Concepts and Evolving Issues. Archives of Pathology and Laboratory Medicine, 2007, 131, 1027-1032.	1.2	53
1865	Is the Epidermal Growth Factor Receptor Status in Lung Cancers Reflected in Clinicopathologic Features?. Archives of Pathology and Laboratory Medicine, 2010, 134, 66-72.	1.2	86
1866	Molecular Testing of Solid Tumors. Archives of Pathology and Laboratory Medicine, 2011, 135, 67-82.	1.2	35
1867	The Abu Dhabi Declaration: Why the Hustle?. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, S-2-S-4.	2.3	3
1868	Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. Clinics, 2012, 67, 419-424.	0.6	41
1869	EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation. International Journal of Medical Sciences, 2013, 10, 320-330.	1.1	106
1870	A study of incidence of EGFR mutations in non-smoker adenocarcinoma of the lung: disparity between north and south indian patients. Journal of Cancer Therapeutics & Research, 2014, 3, 4.	1.2	5
1871	High Resolution Melting Analysis for Epidermal Growth Factor Receptor Mutations in Formalin-fixed Paraffin-embedded Tissue and Plasma Free DNA from Non-small Cell Lung Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6619-6623.	0.5	39
1872	Differences in Epidermal Growth Factor Receptor Gene Mutations and Relationship with Clinicopathological Features in NSCLC Between Uygur and Han Ethnic Groups. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2879-2883.	0.5	6
1873	Concomitant EGFR Inhibitors Combined with Radiation for Treatment of Non-small Cell Lung Carcinoma. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4485-4494.	0.5	16
1874	Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancers in a Multiethnic Malaysian Patient Population. Asian Pacific Journal of Cancer Prevention, 2014, 15, 321-326.	0.5	15
1875	Epidermal Growth Factor Receptor Mutations in Japanese Men with Lung Adenocarcinomas. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10627-10630.	0.5	8
1876	Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study. Asian Pacific Journal of Cancer Prevention, 2015, 16, 7071-7076.	0.5	8
1877	Correlation of EGFR G873R mutation with prognosis of docetaxel in non-small cell lung cancer. Journal of Thoracic Disease, 2021, 13, 5964-5972.	0.6	0
1878	Predictive value of EGFR mutation in nonâ€“smallâ€cell lung cancer patients treated with platinum doublet postoperative chemotherapy. Cancer Science, 2022, 113, 287-296.	1.7	10

#	Article	IF	Citations
1879	A Sensitive PCR-Based Method for Somatic Mutations Enrichment and Screening. Cancer Management and Research, 2021, Volume 13, 8099-8107.	0.9	0
1880	Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns. Journal of Cancer Research and Clinical Oncology, 2022, 148, 163-176.	1.2	4
1882	Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. Yearbook of Oncology, 2006, 2006, 253-254.	0.1	0
1883	Clinical Charicteristics of Primary Lung Cancer Patients in a Tertiary Hospital. Tuberculosis and Respiratory Diseases, 2006, 60, 321.	0.7	4
1884	Epidermal Growth Factor Receptor Targeted Therapyâ€"Markers of Sensitivity and Response. Translational Medicine Series, 2007, , 97-122.	0.0	0
1885	Signal Transduction Inhibitors, HER Family, EGFR Inhibition and Clinical Achievements. , 2007, , 19-44.		2
1886	EGFR å‰ç•°ã• Uracil-Tegafur ã«ã‚ˆã‚‹è……ç™Œè¡“å¾Œè£œåŠ©ç™‚æ³•ã®é–¢é€£æ€§ã«ã¤ã„ã¦ æœœè¨Ž. Okayama Igakkai Zasshi, 200		0
1887	Ilâ€€è‚ºç™Œã®å†…ç§˜çš„æ²»ç™‚. Okayama Igakkai Zasshi, 2008, 119, 285-292.	0.0	0
1888	Molecular Genetics of Lung and Pleural Neoplasms. , 2008, , 47-157.		2
1889	Response to Conventional Therapy and Targeted Molecular Therapy. Molecular Pathology Library, 2008, , 226-232.	0.1	0
1890	Molecular Pathology of Squamous Cell Carcinoma and Its Precursors. Molecular Pathology Library, 2008, , 270-278.	0.1	0
1891	Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. , 2008, , 317-365.		0
1892	EGFR K-ras é ºä¼ èå‰ç•°ã• DNA ãƒ¡ãƒãƒ«åŒ–ç•°å„ªã•‰ã¿ãŸè……ç™Œã®ç™ºç™Œæ©Ÿæ§‹. Okayama Igakkai Zasshi, 2008, 120, 7-1		0
1893	The intersection of EGFR and the Ras signaling pathway. , 2008, , 84-90.		1
1894	Adenocarcinoma and Its Precursor Lesions. Molecular Pathology Library, 2008, , 251-269.	0.1	0
1895	EGFR Mutations, Other Molecular Alterations Related To Sensitivity to EGFR Inhibitors, and Molecular Testing for EGFR-Targeted Therapies in Non-Small Cell Lung Cancer. , 2008, , 281-324.		0
1896	Genomics of Lung Cancer. , 2009, , 856-868.		0
1897	EGFR Mutation, But Not Sex and Smoking, Is Independently Associated with Favorable Prognosis of Gefitinib-treated Patients with Lung Adenocarcinoma. Japanese Journal of Lung Cancer, 2009, 49, 409-415.	0.0	0

#	Article	IF	Citations
1898	Targeted Approaches to Drug Development. , 2009, , 57-98.		3
1899	Intron 1 Polymorphism, Mutation and the Protein Expression of Epidermal Growth Factor Receptor in Relation to the Gefitinib Sensitivity of Korean Lung Cancer Patients. Korean Journal of Pathology, 2009, 43, 509.	1.2	0
1900	Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib. Archives of Pathology and Laboratory Medicine, 2009, 133, 470-477.	1.2	42
1901	Inhibitory Effect of Epidermal Growth Factor on the Proliferation of Lung Cancer Cell Lines. Journal of Lung Cancer, 2010, 9, 64.	0.2	0
1902	Molecular Pathology of Lung Cancer. , 2010, , 1-25.		1
1903	Pharmacogenetics in Lung Cancer. , 2010, , 87-99.		0
1904	Targeting EGFR in HPV-Associated Cancer. , 2010, , 211-234.		0
1905	Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer. , 2010, , 205-226.		2
1907	Genotyping non-small cell lung cancer (NSCLC) in Latin America (LATAM).. Journal of Clinical Oncology, 2011, 29, e21155-e21155.	0.8	0
1908	Pharmacogenomics in Developing Asian Countries. Advances in Microbial Ecology, 2012, , 183-214.	0.1	0
1909	Predictive Markers in Lung Cancer. , 2013, , 43-68.		0
1910	Molecular Pathology of Lung Cancers. , 2013, , 83-94.		1
1911	EGFR, Growth Factors. , 2013, , 1-11.		0
1912	Epidemiology of Lung Cancer in Women. , 2013, , 1191-1208.		0
1913	The Biology of K-Ras Signaling Pathways in Pancreatic Cancer. , 2013, , 83-115.		0
1914	Molecular Pathology and Diagnostics of Non-small Cell Lung Carcinoma. , 2014, , 75-118.		0
1915	Signal Transduction Inhibitors of the HER Family. , 2013, , 17-50.		0
1917	Gender Does Not Have a Potential Predictive Value for the Presence of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma. Advances in Lung Cancer (Irvine), 2014, 03, 82-87.	0.2	0

#	Article	IF	Citations
1918	Frequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung. Journal of Cancer Therapy, 2014, 05, 1012-1020.	0.1	1
1919	The 2013 Incentive Award of the Okayama Medical Association in General Medical Science (2013 Yuuki) Tj ETQq1 1 0.784314 rgBT /O	0.0	0
1920	Lung Cancer Among Asian Americans. , 2016, , 107-136.		0
1921	- Gene Body Methylation and Transcriptional Regulation: Statistical Modelling and More. , 2016, , 225-243.		0
1922	Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: Prevalence and relation with different clinical variables. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 189-195.	0.1	6
1923	Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Nonâ€“Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2016, 7, 514-524.	0.2	1
1924	Mutations in the tyrosine kinase domain of the EGFR gene are rare in the Korean Oral Squamous Cell Carcinoma. Journal of the Korea Society of Computer and Information, 2016, 21, 101-106.	0.0	0
1925	QUANTITATIVE ASSESSMENT OF BETA-III TUBULIN EXPRESSION IN LUNG ADENOCARCINOMA AND SQUAMOUS CELL CARCINOMA. , 2016, 15, 95-98.	0.3	0
1926	Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation. Bosnian Journal of Basic Medical Sciences, 2016, 16, 280-285.	0.6	2
1927	Management Strategies for Adverse Events Associated With EGFR TKIs in Nonâ€“Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2016, 7, .	0.2	6
1928	Companion Diagnostics. , 2017, , 117-136.		0
1929	Overview of Malignant Epithelial Neoplasms of Lung. , 2017, , 74-75.		0
1930	Comparison of Thoracic Radiotherapy Efficacy Between Patients With and Without EGFR-mutated Lung Adenocarcinoma. In Vivo, 2018, 32, 203-209.	0.6	1
1931	Epidermal Growth Factor Receptor. , 2018, , 1593-1603.		0
1932	Cross-Sectional Study of Gene Expression Analysis Identifies Critical Biological Pathways and Key Genes Implicated in Non-Small Cell Lung Cancer. Iranian Red Crescent Medical Journal, 2018, 20, .	0.5	0
1933	Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma. Anti-Cancer Drugs, 2018, 29, 281-285.	0.7	1
1934	KÃ¼Ã§Ã¼k HÃ¼creli DÄ±ÅŸÄ± AkciÄŸer Kanseri HastalarÄ±nda Onkogen MutasyonlarÄ±nÄ±n AraÅŞtÄ±rÄ±lmasÄ±. SÃ¼leyman Demi Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , .	0.0	0
1935	EGFR Tyrosine kinase inhibitors in the treatment of metastases of non-small cell lung cancer in the brain. , 2018, 17, 22-30.	0.3	0

#	Article	IF	Citations
1936	Non-small Cell Lung Cancer. , 2019, , 143-192.		0
1937	Proteomics for Cancer: Approaches and Challenges. , 2019, , 343-368.		0
1938	Possibilities of consistent targeted therapy for EGFR-positive NSCLC. Clinical case. Onkologiya Zhurnal Imeni P A Gertsena, 2019, 8, 289.	0.0	0
1939	Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer. Translational Cancer Research, 2019, 8, 736-751.	0.4	0
1940	Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation. Meditsinskiy Sovet, 2019, , 64-71.	0.1	2
1941	Application of International association for the study of lung cancer/American Thoracic Society/European Respiratory Society criteria for the diagnosis of lung carcinomas on small biopsies: A tertiary care center experience. South Asian Journal of Cancer, 2019, 08, 191-194.	0.2	0
1942	Lung and Respiratory Tract Cytology. , 2020, , 95-117.		0
1943	Epidermal growth factor receptor mutation subtype has differential effects on adjuvant chemotherapy for resected adenocarcinoma pathological stagesï¿½IIâ€“III. Oncology Letters, 2019, 18, 6451-6458.	0.8	0
1946	Next Generation of Advanced Non-Small Cell Lung Cancer Therapy: Targeted and Immuno-Therapies. International Journal of Medical Students, 2020, 8, 26-32.	0.2	0
1947	Greater specificity of p40 compared with p63 in distinguishing squamous cell carcinoma from adenocarcinoma in effusion cellblocks. CytoJournal, 2020, 17, 13.	0.8	2
1948	Characteristics of female lung cancer in Korea: analysis of Korean National Lung Cancer Registry. Journal of Thoracic Disease, 2020, 12, 4612-4622.	0.6	4
1949	Molecular typing of lung adenocarcinoma with computed tomography and CT image-based radiomics: a narrative review of research progress and prospects. Translational Cancer Research, 2021, 10, 4217-4231.	0.4	2
1950	Tumor Mutations Across Racial Groups in a Real-World Data Registry. JCO Precision Oncology, 2021, 5, 1654-1658.	1.5	16
1951	Platelet/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer. Journal of International Medical Research, 2020, 48, 030006052098020.	0.4	4
1952	Association of <scp>hOGG1â€Cys</scp> variants with occurrence of <scp>p53</scp> and <scp>EGFR</scp> deletion mutations in nonâ€small cell lung cancer. Thoracic Cancer, 2021, 12, 534-538.	0.8	3
1955	Comparison of the characteristics of uncommon epidermal growth factor receptor (EGFR) mutations and EGFRâ€tyrosine kinase inhibitor treatment in patients with nonâ€small cell lung cancer from different ethnic groups. Experimental and Therapeutic Medicine, 2020, 19, 3513-3520.	0.8	4
1956	The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non-Small Cell Lung Cancer. Cancer Research and Treatment, 2021, , .	1.3	3
1957	Racial and Ethnic Disparities Among Participants in Precision Oncology Clinical Studies. JAMA Network Open, 2021, 4, e2133205.	2.8	70

#	Article	IF	Citations
1960	Advanced Non-Small Cell Lung Carcinoma: Acquired Resistance to Gefitinib. , 2008, , 307-316.		1
1961	Non-Small Cell Lung Cancer with Brain Metastasis: Role of Epidermal Growth Factor Receptor Gene Mutation. , 2008, , 371-387.		0
1962	The Molecular Genetics of Lung Cancer. , 0, , 61-83.		24
1963	Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature. Tumori, 2013, 99, e241-4.	0.6	10
1965	Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung. American Journal of Translational Research (discontinued), 2010, 2, 309-15.	0.0	4
1966	A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells. Annals of Thoracic and Cardiovascular Surgery, 2009, 15, 213-20.	0.3	9
1967	Mutations in epidermal growth factor receptor gene in esophageal squamous cell carcinoma patients in kashmir- a high incidence area of India. International Journal of Health Sciences, 2008, 2, 17-25.	0.4	3
1968	Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors. International Journal of Clinical and Experimental Pathology, 2011, 4, 403-9.	0.5	3
1969	Claudins 10 and 18 are predominantly expressed in lung adenocarcinomas and in tumors of nonsmokers. International Journal of Clinical and Experimental Pathology, 2011, 4, 667-73.	0.5	11
1970	Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. Journal of Thoracic Disease, 2010, 2, 48-51.	0.6	223
1971	RAF1-MEK1-ERK/AKT axis may confer NSCLC cell lines resistance to erlotinib. International Journal of Clinical and Experimental Pathology, 2013, 6, 1493-504.	0.5	20
1974	Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC). Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 466-70.	0.7	6
1976	EGFR mutations in patients with non-small cell lung cancer from mainland China and their relationships with clinicopathological features: a meta-analysis. International Journal of Clinical and Experimental Medicine, 2014, 7, 1967-78.	1.3	16
1977	EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. American Journal of Cancer Research, 2014, 4, 411-35.	1.4	102
1978	Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts. Journal of Thoracic Disease, 2014, 6, S568-80.	0.6	10
1979	Does the order of factors affect the product? Lessons learned from the TORCH trial. Translational Lung Cancer Research, 2013, 2, 50-4.	1.3	0
1980	Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysis. American Journal of Cancer Research, 2015, 5, 2229-40.	1.4	9
1981	Correlation between expression of NF-E2-related factor 2 and progression of gastric cancer. International Journal of Clinical and Experimental Medicine, 2015, 8, 13235-42.	1.3	5

#	Article	IF	Citations
1982	EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). American Journal of Cancer Research, 2015, 5, 2892-911.	1.4	272
1983	Factors that predict progression-free survival in Chinese lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine kinase inhibitors. Journal of Thoracic Disease, 2016, 8, 68-78.	0.6	6
1984	Role of epidermal growth factor receptor in lung cancer and targeted therapies. American Journal of Cancer Research, 2017, 7, 187-202.	1.4	43
1986	Prognostic significance of EGFR and KRAS mutations in NSCLC patients with brain metastases treated with radiosurgery. Journal of Radiosurgery and SBRT, 2015, 3, 171-178.	0.2	2
1987	Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 2016, 7, 723-735.	0.2	4
1988	Identifying the Causes of Cancer Health Disparities: Biologic and Non Biologic Determinants. Californian Journal of Health Promotion, 2010, 8, 101-111.	0.3	1
1997	Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1735-1738.	0.5	1
2001	Comparison of clinicopathological and molecular features between young and old patients with lung cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 1031-1035.	0.5	2
2002	Impact of age on EGFR mutations in never-smoking female lung adenocarcinoma patients with malignant pleural effusion. International Journal of Clinical and Experimental Pathology, 2018, 11, 2811-2815.	0.5	0
2003	Comparison of clinicopathologic characteristics between patients with EGFR exon 19 deletion and EGFR L858R mutation in lung cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 4644-4649.	0.5	0
2004	Accuracy and clinical influence of plasma EGFR mutation detection in management of advanced lung adenocarcinoma. International Journal of Clinical and Experimental Pathology, 2017, 10, 9559-9566.	0.5	0
2005	Cell-Free Circulating Tumour DNA Blood Testing to Detect T790M Mutation in People With Advanced Non-Small Cell Lung Cancer: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2020, 20, 1-176.	3.0	7
2006	Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. Molecular Diagnosis and Therapy, 2022, 26, 7-18.	1.6	57
2007	Frequency of Epidermal Growth Factor Receptor and T790M Mutations Among Patients With Non-Small Cell Lung Carcinoma: A Hospital-Based Study in the King Khalid University Hospital (KKUH) Since 2009-2017. Cureus, 2021, 13, e19816.	0.2	0
2008	First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study. Investigational New Drugs, 2022, 40, 430-437.	1.2	8
2009	Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study. JTO Clinical and Research Reports, 2022, 3, 100257.	0.6	11
2010	Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer. Lung Cancer: Targets and Therapy, 2021, Volume 12, 133-138.	1.3	11
2011	Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials. Oncologist, 2022, 27, e286-e293.	1.9	4

#	Article	IF	Citations
2012	EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States. JTO Clinical and Research Reports, 2022, 3, 100285.	0.6	7
2013	Evaluation of molecular methods for plasma detection of EGFR mutations in nonâ€small cell lung cancer. Asia-Pacific Journal of Clinical Oncology, 2022, , .	0.7	1
2014	Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors. Molecules, 2022, 27, 819.	1.7	32
2015	Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study. BMC Pulmonary Medicine, 2022, 22, 32.	0.8	5
2016	PTP-PEST Regulated Membranous/Cytoplasmic Translocation of p120ctn in the Lung Cancer Resistance to Tyrosine Kinase Inhibitor. Applied Immunohistochemistry and Molecular Morphology, 2022, Publish Ahead of Print, .	0.6	0
2017	Mutation patterns of epidermal growth factor receptor gene in non-small cell lung cancer among Egyptian patients. Egyptian Journal of Basic and Applied Sciences, 2022, 9, 77-90.	0.2	2
2018	Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. Journal of Clinical Oncology, 2022, 40, 611-625.	0.8	242
2019	Three-Dimensional Convolutional Neural Network-Based Prediction of Epidermal Growth Factor Receptor Expression Status in Patients With Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 772770.	1.3	8
2020	Extracellular domain of semaphorin 5A serves a tumorâ€suppressing role by activating interferon signaling pathways in lung adenocarcinoma cells. International Journal of Oncology, 2022, 60, .	1.4	0
2021	Insights into the negative regulation of EGFR upon the binding of an allosteric inhibitor. Chemical Biology and Drug Design, 2022, 99, 650-661.	1.5	3
2022	A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors. Lung Cancer, 2022, 166, 98-106.	0.9	1
2023	Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings From a Large Australian Cohort. Journal of Thoracic Oncology, 2022, 17, 688-699.	0.5	24
2024	The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors. Frontiers in Oncology, 2022, 12, 843299.	1.3	6
2026	Research progress in immunotherapy of NSCLC with EGFR sensitive mutations. Oncology Research, 2022, , .	0.6	0
2027	Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis. Targeted Oncology, 2022, 17, 153-166.	1.7	15
2028	Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis. Future Oncology, 2022, 18, 2007-2028.	1.1	3
2029	Case Report: Benefits of a NSCLC Patient With EGFR A289G/F287_G288insHA cis Mutations From Immunotherapy in Combination With Antiangiogenesis and Chemotherapy and Sequential Treatment of EGFR-TKI. Frontiers in Oncology, 2022, 12, 826938.	1.3	1
2030	Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 869672.	1.3	30

#	Article	IF	Citations
2031	Pretreatment <scp>HDLâ€C</scp> and <scp>ApoA1</scp> are predictive biomarkers of progressionâ€free survival in patients with EGFR mutated advanced nonâ€small cell lung cancer treated with <scp>TKI</scp>. Thoracic Cancer, 2022, 13, 1126-1135.	0.8	4
2032	<scp>PDâ€L1</scp> expressed from tumor cells promotes tumor growth and invasion in lung cancer via modulating <scp>TGF</scp>âÎ²1/<scp>SMAD4</scp> expression. Thoracic Cancer, 2022, 13, 1322-1332.	0.8	5
2033	RELAY+: Exploratory Study of Ramucirumab PlusÂGefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC. JTO Clinical and Research Reports, 2022, 3, 100303.	0.6	1
2034	Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials. Expert Opinion on Emerging Drugs, 2022, 27, 111-126.	1.0	2
2035	Harnessing Reversed Allosteric Communication: A Novel Strategy for Allosteric Drug Discovery. Journal of Medicinal Chemistry, 2021, 64, 17728-17743.	2.9	29
2036	Therapeutic advances in nonâ€small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. MedComm, 2021, 2, 692-729.	3.1	38
2037	The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management. Cancer Cell International, 2021, 21, 675.	1.8	9
2038	Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment. Biomedicines, 2022, 10, 52.	1.4	4
2039	EGFR signaling pathway as therapeutic target in human cancers. Seminars in Cancer Biology, 2022, 85, 253-275.	4.3	61
2040	A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and 18F-FDG Metabolic Activity in Non-Small Cell Lung Cancer. Frontiers in Oncology, 2022, 12, 780186.	1.3	8
2041	Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review. Cancers, 2022, 14, 1949.	1.7	2
2047	Epidermal Growth Factor Receptor Inhibitors. , 0, , 352-368.		0
2048	The Pathology and Pathogenesis of Peripheral Lung Adenocarcinoma Including Bronchioloalveolar Carcinoma. , 0, , 121-143.		0
2049	Analysis of the molecular expression profile of non small cell lung carcinoma associated to chronic obstructive pulmonary disease. Histology and Histopathology, 2009, 24, 417-23.	0.5	0
2072	Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing. Genes, 2022, 13, 799.	1.0	4
2073	Respiratory Tract and Mediastinum. , 2014, , 59-104.		3
2074	Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2023, 23, 124-141.	0.9	1
2075	Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma. Modern Pathology, 2022, 35, 1181-1192.	2.9	11

#	Article	IF	Citations
2076	Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study. Respiratory Research, 2022, 23, .	1.4	7
2078	Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations. Molecules, 2022, 27, 3844.	1.7	4
2079	MERTK activation drives osimertinib resistance in EGFR-mutant nonâ€“small cell lung cancer. Journal of Clinical Investigation, 2022, 132, .	3.9	12
2080	Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. Journal of Clinical Oncology, 2022, 40, 3709-3718.	0.8	9
2081	The High Proportion of Discordant EGFR Mutations among Multiple Lung Tumors. Cancers, 2022, 14, 3011.	1.7	1
2082	Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib. OncoTargets and Therapy, 0, Volume 15, 659-667.	1.0	2
2083	DUSP3 regulates phosphorylation-mediated degradation of occludin and is required for maintaining epithelial tight junction. Journal of Biomedical Science, 2022, 29, .	2.6	3
2084	Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Nonâ€“Small Cell Lung Cancer. Frontiers in Pharmacology, 0, 13, .	1.6	3
2085	Realâ€world treatment patterns of metastatic nonâ€small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Medicine, 2023, 12, 159-169.	1.3	8
2087	The Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Predicting Treatment Response Before EGFR TKI Treatment in Patients with Advanced Lung Adenocarcinoma. Molecular Imaging and Radionuclide Therapy, 2022, 31, 104-113.	0.3	1
2088	Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer. BMC Pulmonary Medicine, 2022, 22, .	0.8	0
2090	Two Distinct Primary EGFR-Mutated Lung Adenocarcinoma Within the Same Patient: A Case Report. International Journal of Cancer Care and Delivery, 2022, 2, .	0.0	0
2092	Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor. Cellular Oncology (Dordrecht), 2022, 45, 709-728.	2.1	12
2093	Non-small-cell lung cancer: how to manage EGFR-mutated disease. Drugs in Context, 0, 11, 1-17.	1.0	3
2094	Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report. Medicine (United States), 2022, 101, e30080.	0.4	3
2095	Prognostic evaluation of preoperative serum tumor markerâ€negative cases in nonâ€small cell lung cancer: A retrospective study. Cancer Reports, 0, , .	0.6	0
2096	Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma. Genes, 2022, 13, 1499.	1.0	1
2097	P21-activated kinase 2-mediated Î²-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer. Oncogene, 0, , .	2.6	5

#	Article	IF	Citations
2098	The Clinical Significance of Deglycosylated PD-L1 Level Detection Using 28-8 Monoclonal Antibody in Lung Adenocarcinoma. International Journal of General Medicine, 0, Volume 15, 7383-7393.	0.8	1
2099	EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil. Oncologist, 0, , .	1.9	1
2100	Understanding the Molecular Kinetics in NSCLC Through Computational Method. , 2022, , 129-163.		0
2101	Translational Research in Lung Cancer. Medical Radiology, 2022, , .	0.0	0
2102	Targeted Therapies in Non-small Cell Lung Cancer. Medical Radiology, 2022, , .	0.0	1
2103	Temporal Pattern of Cardiac Adverse Events Associated with EGFR-TKIs in Lung Cancer Patients: A Pharmacovigilance Analysis. SSRN Electronic Journal, 0, , .	0.4	0
2104	The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations. Nature Communications, 2022, 13, .	5.8	7
2105	Can EGFR be a therapeutic target in breast cancer?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188789.	3.3	14
2107	Identification of Activating Mutations in the Transmembrane and Extracellular Domains of EGFR. Biochemistry, 2022, 61, 2049-2062.	1.2	1
2108	Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer. Journal of Radiation Research, 2023, 64, 142-153.	0.8	8
2109	Genomic landscape of lung adenocarcinomas in different races. Frontiers in Oncology, 0, 12, .	1.3	6
2111	Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort. Cancer Discovery, 2022, 12, 2552-2565.	7.7	21
2112	Clinicopathologic characteristics and prognostic impact of atypical EGFR mutations in completely resected lung adenocarcinoma. European Journal of Cancer, 2022, 177, 53-62.	1.3	3
2113	Comparison of nextâ€generation sequencing and cobas <scp>EGFR</scp> mutation test v2 in detecting <scp>EGFR</scp> mutations. Thoracic Cancer, 2022, 13, 3217-3224.	0.8	6
2114	Nanoencapsulation of tyrosine kinase inhibitors for oncological therapeutics. , 2022, , 251-267.		0
2115	Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue. , 2022, , .		0
2116	<scp>ERBB2</scp> exon 20 insertions are rare in Brazilian nonâ€small cell lung cancer. Thoracic Cancer, 2022, 13, 3402-3407.	0.8	3
2117	Integrated Tissue and Blood miRNA Expression Profiles Identify Novel Biomarkers for Accurate Non-Invasive Diagnosis of Breast Cancer: Preliminary Results and Future Clinical Implications. Genes, 2022, 13, 1931.	1.0	1

#	Article	IF	Citations
2118	<scp>TAS2940</scp>, a novel <scp>brainâ€penetrable panâ€ERBB</scp> inhibitor, for tumors with HER2 and EGFR aberrations. Cancer Science, 2023, 114, 654-664.	1.7	3
2119	Immunotherapeutic progress and application of bispecific antibody in cancer. Frontiers in Immunology, 0, 13, .	2.2	9
2120	Prognostic Impact of EBUS TBNA for Lung Adenocarcinoma Patients with Postoperative Recurrences. Diagnostics, 2022, 12, 2547.	1.3	1
2121	Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation. Frontiers in Immunology, 0, 13, .	2.2	3
2122	Prediction of the Presence of Targetable Molecular Alteration(s) with Clinico-Metabolic 18 F-FDG PET Radiomics in Non-Asian Lung Adenocarcinoma Patients. Diagnostics, 2022, 12, 2448.	1.3	2
2123	Multiple mutations in the EGFR gene in lung cancer: a systematic review. Translational Lung Cancer Research, 2022, 11, 2148-2163.	1.3	6
2125	Exploring the Next Frontier in Nonâ€“Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor. Journal of Clinical Oncology, 0, , .	0.8	0
2126	Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors. European Journal of Medicinal Chemistry, 2022, 244, 114856.	2.6	5
2127	Targeting the epidermal growth factor receptor (EGFR) - a new therapeutic option in oncology?. Swiss Medical Weekly, 0, , .	0.8	6
2128	Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases. Frontiers in Oncology, 0, 12, .	1.3	3
2129	Changes in survival of patients with nonâ€“small cell lung cancer in Japan: An interrupted time series study. Cancer Science, 2023, 114, 1154-1164.	1.7	3
2130	Targeting exon 20 insertion mutations in lung cancer. Current Opinion in Oncology, 0, Publish Ahead of Print, .	1.1	1
2131	Nuclear factor erythroid-2-related factor 2 (Nrf2) is a potential prognostic factor in patients with gastric adenocarcinoma. Arab Journal of Gastroenterology, 2022, , .	0.4	0
2132	Economic Burden of Recurrence in Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer: A Retrospective Study Using Nationwide Claims Data of South Korea. Advances in Therapy, 0, , .	1.3	0
2133	Therapeutic targets and signaling mechanisms of dasatinib activity against radiation skin ulcer. Frontiers in Public Health, 0, 10, .	1.3	1
2134	The coming decade in precision oncology: six riddles. Nature Reviews Cancer, 2023, 23, 43-54.	12.8	52
2136	Immunoregulatory framework and the role of miRNA in the pathogenesis of NSCLC â€“ A systematic review. Frontiers in Oncology, 0, 12, .	1.3	2
2137	Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. Molecular Biomedicine, 2022, 3, .	1.7	8

#	Article	IF	Citations
2138	Disparate Time-to-Treatment and Varied Incidence of Actionable Non-Small Cell Lung Cancer Molecular Alterations in British Columbia: A Historical Cohort Study. Current Oncology, 2023, 30, 145-156.	0.9	0
2139	Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study. JTO Clinical and Research Reports, 2023, 4, 100459.	0.6	4
2140	Inter-Ethnic Differencesâ€"How Important is it in Cancer Treatment?. Annals of the Academy of Medicine, Singapore, 2011, 40, 356-361.	0.2	20
2141	Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis. BMC Pulmonary Medicine, 2022, 22, .	0.8	0
2142	Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. Cancers, 2023, 15, 1433.	1.7	3
2143	Chronic Inhalation Exposure to Antimony Trioxide Exacerbates the MAPK Signaling in Alveolar Bronchiolar Carcinomas in B6C3F1/N Mice. Toxicologic Pathology, 2023, 51, 39-55.	0.9	1
2144	Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma. Biomedicine and Pharmacotherapy, 2023, 161, 114452.	2.5	5
2145	Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Nonâ€"Small Cell Lung Cancer. Biomolecules, 2023, 13, 210.	1.8	2
2146	The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics. Experimental Cell Research, 2023, 424, 113503.	1.2	2
2147	CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Cancer Cell, 2023, 41, 340-355.e6.	7.7	23
2148	Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence. Cancers, 2023, 15, 1314.	1.7	2
2149	A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine. Journal of Clinical Medicine, 2023, 12, 1936.	1.0	3
2150	TRIP13 overexpression promotes gefitinib resistance in nonâ€'small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway. Oncology Reports, 2023, 49, .	1.2	4
2151	Mutant K-Ras in Pancreatic Cancer: An Insight on the Role of Wild-Type N-Ras and K-Ras-Dependent Cell Cycle Regulation. Current Issues in Molecular Biology, 2023, 45, 2505-2520.	1.0	2
2152	Molecular Pathology of Lung Cancer. , 0, , .		0
2153	Polygenic risk scores for the prediction of common cancers in East Asians: A population-based prospective cohort study. ELife, 0, 12, .	2.8	3
2154	Global burden and trends of lung cancer incidence and mortality. Chinese Medical Journal, 2023, 136, 1583-1590.	0.9	11
2155	Correlation between gene mutation status and clinicopathologic features in early multiple primary lung cancer. Frontiers in Oncology, 0, 13, .	1.3	0

#	Article	IF	Citations
2156	Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation. Cancer Discovery, 2023, 13, 1572-1591.	7.7	13
2159	Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation. Frontiers in Oncology, 0, 13, .	1.3	1
2169	EGFR Mutations Are Not All the Same: the Importance of Biomarker Testing in Non-small Cell Lung Cancer (NSCLC)â€"A Podcast Discussion Between Patients and Oncologists. Oncology and Therapy, 0, , .	1.0	0